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Abstract 
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Abstract 
The genetic information of all life is encoded within DNA molecules that are translated into 
functional entities, so-called proteins. They are responsible for operating and controlling a 
vast array of molecular mechanisms in any biological system and ubiquitous in 
(patho)physiology as a result. Besides, proteins are the primary target of drugs and can 
have a central role as biomarkers for diagnostic, prognostic, or predictive purposes. Here, 
many regulatory mechanisms and spatiotemporal influences prevent an accurate 
prediction of a proteins’ abundance and its associated functionality based on the genome 
information alone. Nowadays, it has become possible to measure and quantify thousands 
of proteins simultaneously, however, involving comprehensive sample preparation 
procedures. Currently, no universally standardized method enables a routine application of 
proteome profiling in a clinical environment. 
In this thesis, an automated workflow for the efficient processing of the most common and 
quantity-limited specimens is described. In order to demonstrate the usefulness of the end-
to-end pipeline, which was termed autoSP3, it was applied to the proteome profiling of 
histologically defined and WHO recognized growth patterns of pulmonary adenocarcinoma 
(ADC) that currently have a limited clinical implication. Secondly, we investigated the 
proteome composition of a molecularly well-defined cohort of Ependymoma (EPN) 
pediatric brain tumors. Despite the availability of substantial NGS data and their ability to 
differentiate nine distinct subgroups, the majority of tumors remained without a functional 
insight. Here, the proteome profiling could provide a missing link and emphasize several 
subgroup-specific protein targets. 
In summary, this thesis describes the optimization of SP3 and its automation into a robust 
and cost-efficient pipeline for quantity-limited sample preparation and biological insight 
into the proteome composition of ADC growth patterns and EPN tumor subgroups. 
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V 
Zusammenfassung 
Die genetische Information, welche in der DNS eines jeden Lebewesen’s codiert ist, wird 
übertragen in funktionellen Einheiten, so genannte Proteine. Diese sind verantwortlich fuer 
den Betrieb und die Kontrolle zahlreicher molekularer Mechanismen in jedem biologischen 
System. Dadurch sind Proteine allgegenwärtig in der (Patho)-physiologie. Zusätzlich sind 
Proteine der Hauptangriffspunkt der meisten klinischen Arzneimittel und sie können eine 
zentrale Rolle als Biomarker fuer diagnostische, prognostische oder prädiktive Zwecke 
einnehmen. Da die Abundanz eines jeden Proteins und die damit zusammenhängende 
Funktion von zahlreichen regulatorischen Mechanisms sowie räumlichen und zeitlichen 
Faktoren abhängt, ist es kaum möglich diese allein anhand der genetischen Information 
vorherzusagen. Heutzutage ist es möglich tausende von Proteinen gleichzeitig zu messen 
und zu quantifizieren. Bisher gibt es allerdings keine universelle und standardisierte 
Methode, welche eine routinierte Anwendung in einem klinischen Umfeld ermöglichen 
würde. 
In dieser Doktorarbeit wird eine automatisierte Methode zur effizienten Prozessierung der 
am häufigsten verwendeten und mengenlimitierten Probentypen beschrieben. Um die 
allgemeine Nützlichkeit dieser Methode zu demonstrieren, welche autoSP3 genannt 
wurde, wurde sie in zwei realistischen Szenarios angewendet. Zunächst wurde sie 
verwendet um Unterschiede in der Proteinzusammensetzung von Lungenkarzinomen mit 
verschiedenen Wachstumsmustern zu untersuchen, welche nach WHO Richtlinien 
histologisch klassifiziert wurden. Darüber hinaus wurde eine Kohorte von Ependymoma 
(EPN) Gehirntumoren, welche bei Kindern und Jugendlichen vorkommen, auf Ihre 
Proteinzusammensetzung untersucht. Bisher konnten diese basierend auf NGS Daten in 
neun individuelle Untergruppen klassifiziert werden, aber für die Mehrheit exisitiert bisher 
keine funktionelle Erklärung. Die tumorspezifischen Proteinprofile bieten die Möglichkeit 
potentielle Ursachen, Mechanismen oder Angriffspunkte für Therapien aufzudecken. 
Zusammenfassend beschreibt diese Doktorarbeit die Optimierung und Automatisierung 
von SP3 zu einem robusten und kosteneffizienten Prozess sowie dessen Anwendung und 
daraus folgende biologische Erkenntnisse zu Lungenkarzinom-Wachstumsmustern und 
EPN-Gehirntumoren. 
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1. Introduction 
1.1. Systems Medicine 
1.1.1. Definition and emergence 
The interdisciplinary field of systems medicine emanates from the translation of systems 
biology to medical research and routine clinical practice1,2. It is a systems-oriented 
approach that aims to combine the multifaceted network of factors (e.g., genes, transcripts, 
proteins, metabolites, family history, and environmental factors) that define and influence 
the function and development of the human body to improve disease diagnostics, 
prognostics, and to develop innovative therapies3,4. 
Early phases of most scientific fields were coined mainly by the concept of reductionism, in 
which one attempts to reduce every instance of a system to its individual, constituent 
parts5,6. It hypothesizes that understanding the simple parts suffices to draw upward 
causation to explain all overarching phenomena or mechanisms that are crucial for 
understanding the whole system itself5,6. This method has been successful in physics and 
chemistry because physicochemical properties and resulting physical laws down to the 
atomic level can explain most problems or questions. Then and now, reductionism models 
were also used to explain many fundamentals in biology to understand living processes, 
and it remains to be the predominant concept in classical medicine approaches7–9. Here, 
clinicians aim to break down a problem or disease phenotype to its single-cause, which has 
proven utility in cases were an individual factor, such as a bacterial infection, is responsible 
for the disease. However, this concept quickly becomes challenged by I) the heterogeneity 
of most diseases10, such as cancer, with a complex patho-phenotype and without a single 
causative factor, II) the sheer complexity of biological systems, organisms or patients, being 
comprised of several networks of factors, signaling pathways, multi-layer interaction, and 
dynamic spatiotemporal features, and III) the variable influence of environmental 
factors7,11. Taken together, this complex and dynamic interaction of multi-layer factors 
within a system and with its environment leads to a yet non-predictable behavior that 
cannot be explained by the individual parts of a system7,12. 
The foresight about the importance of a systems-oriented approach dates back to Aristotle, 
one of the first inquiring minds in philosophical and scientific history, who wrote: “The 
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totality is not, as it were, a mere heap, but the whole is something besides the parts.” 
(Aristotle’s Metaphysics: Book VIII, 1045a.8–10)13. His primal understanding of the essential 
complexity of biological systems can be seen as the philosophical foundation of modern 
systems biology as it emerged throughout the 20th century9. In 1926, Jan Christian Smuts, 
a South African statesman and philosopher, introduced the concept of holism antithetic to 
reductionism, which in a broader sense of Aristotle’s words states that a system is more 
than the sum of its parts14,15. The theory was further extended at the end of the 1960s by 
Ludwig von Bertalanffy, who is thought to have created the term of systems biology by 
introducing his general systems theory (GST)9,16. In its essence, he describes that every 
system is composed of the sum of its structure and functional purpose, the environmental 
and temporal influences, and its spacial boundaries9,16. This steady change to a systems-
oriented mindset was manifested and driven by numerous breakthrough discoveries 
throughout the 20th century, including the discovery that DNA makes up the genetic 
material of the chromosome in 1944 (Oswald Avery)17, the finding of the structure of DNA 
in 1953 (James Watson, Francis Crick, and Rosalind Franklin)18–20, and the Sanger 
sequencing technology providing the first DNA genome of an entire organism in 1977 
(Frederick Sanger)21. 
Nowadays, systems biology has matured into its own independent, inter-disciplinary 
field22–24. It involves not only modern analytical technologies to generate comprehensive 
data but also gained momentum through the rapid development of computational 
hardware and software, providing the performance capacity and mathematical models to 
store, handle, and analyze the data24. This advanced technological toolbox of systems 
biology approaches enables the study of (patho)physiological processes on a complex 
molecular level beyond single, linear parameters22. Thus, the complexity of biological 
systems and the sheer amount of qualitative and quantitative data became impossible to 
handle without a systems biology-based approach22–24. In a clinical context, the integration 
of systems biology marks the beginning of systems medicine as a new discipline10. Since 
then, it is rapidly evolving and growing to an integration of all fields of expertise from 
bioinformatics- and statistics to basic biology research, mathematics, and classical medicine 
to generate, collect, and interpret data comprising molecular, behavioral (lifestyle), 
environmental, as well as family data. 
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Systems medicine, first introduced by B.Z. Zeng25 and T. Kamada26 in 1992, promises to 
surpass the limits of reductionism and leverages our understanding of (patho)physiological 
processes to positively impact therapy development and decision making, diagnostics, and 
prognostics7,27. It was Hippocrates of Kos (460-377 B.C.) who said: “It is more important to 
know what sort of person has a disease than to know what sort of disease a person has”28. 
Thus, he recognized early on the importance of the individual and the necessity of a 
personalized medicine approach, including tailored diagnostics and treatment29. To achieve 
this, the translation of modern technologies towards clinics and tackling remaining 
bottlenecks are gaining momentum since the beginning of the new century27,30. Systems 
medicine promises to not only measurably improve patients’ health and treatment 
outcomes but also offers aid in improving the efficacy of drug discovery and development 
through better disease and patient characterization27,30,31. The future of medicine is at a 
tipping point. 
1.1.2. Next-generation sequencing (NGS): status quo in the clinic 
After the discovery of the DNA structure in 195318–20, it took more than two decades, until 
1977, for the development of first sequencing methods, namely the Maxam & Gilbert 
sequencing32 and the Sanger sequencing21. The latter of the two became the predominant 
method for the following years up until today, because of less handling requirements of 
toxic chemicals and radioisotopes33. Since then, Sanger sequencing technologies have 
rapidly evolved at an unprecedent speed with the immense support of the Human Genome 
Project, which initiated in 199033. As the largest collaborative biological project, it resulted 
in the completion of the first human genome sequence in 2004, a significant milestone for 
the field of systems biology34,35. However, the sequencing of an entire genome required 
extensive amounts of time and resources, which lead to a new funding initiative by the 
National Human Genome Research Institute (NHGRI) aiming to reduce the human genome 
sequencing cost to about 1000 US-Dollar within the next ten years36. This call has led to an 
explosion of “next-generation” sequencing (NGS) methods, including faster instruments, 
chemicals, tools, bioinformatics data analysis, and protocols within the last 15 years that 
enable scientists to address all sorts of basic genetics or clinically relevant questions37–44. 
NGS has become the mainstream acronym for essentially every very-high-throughput 
sequencing technique or methods involving sequencing, that allow millions of observations 
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in a single run at significantly reduced costs as compared to 200433. In more recent years, 
third-generation instruments and methods (also considered NGS) were commercialized 
that are even faster and more accurate, that require less DNA or RNA input material, 
generate lower error rates and fewer artifacts, at lower costs45–47. A higher standardization 
and automated sample handling, as well as improved bioinformatic tools and pipelines, 
continuously support these developments33,45. Taken together, scientists nowadays have a 
vast toolbox of NGS applications that enable the study of entire genomes (DNA-seq)34,35, 
the transcriptome (RNA-seq)48, and targeted fractions of both beyond the determination 
of a nucleotide sequence40,47,49,50. 
In 2010, the first large-scale study of human genetic variation was published, providing 
evolutionary insights at a population scale to understand the impact of genetic differences 
on our (patho)physiology51. This massive sequencing effort extends our knowledge of the 
functional consequences of mutations, providing a link between genotype and phenotype 
concerning health and disease. This type of study has the potential to improve the precision 
of diagnosis, the classification of a disease state or subtype, and to provide accurate 
prognosis or even identify potentially druggable mutations for individual patients51. In a 
study by Ashley, E.A. et al. in 2010, for example, the genome of a patient with a family 
history of vascular disease and sudden early death was assessed52. The whole-genome 
sequencing (WGS) analysis and integration with clinical features pointed to an increased 
genetic risk for myocardial infarction and discovered three rare gene variants that are 
clinically associated with sudden cardiac death. Thus, relevant and personalized 
information could be retrieved using WGS analysis52. 
In practice, genetic disease diagnostics is focused on panels of genes that are sequenced, 
which are associated with a clinical phenotype53,54. This approach is limited to well-
characterized monogenic illnesses in which a single mutation can explain the disease55–58. 
For less straight-forward applications, the WGS52–54 or targeted approach55–58 is neither 
necessary nor beneficial and replaced by whole-exome sequencing (WES)59,60, in which 
solely the coding regions of the genome are sequenced. The human exome represents a 
small fraction of the entire genome but comprises >85% of disease-causing gene 
variants61,62. In 2011, Worthey E.A. et al. used WES to identify a causative mutation in a 
male child with Crohn disease-like illness were comprehensive clinical evaluation did not 
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yield in a definitive diagnosis63. The sequencing analysis identified a novel missense 
mutation in the X-linked inhibitor of apoptosis gene, which was previously not correlated 
to Crohn disease. That followed, the child was diagnosed with an X-linked inhibitor of 
apoptosis deficiency and treated in concordance with the respective recommendation 
guidelines63. Thus, the exome sequencing led to a valuable, life-saving therapeutic decision, 
highlighting the potential of NGS approaches in a clinical setup beyond standard 
diagnostics. 
Furthermore, NGS enables the identification of single nucleotide variants64, for example, 
somatic or germline mutations and structural variants65–68, such as inversions, 
translocations, or gene copy number alterations. Other sequencing-based gene expression 
analysis (RNA-seq) enable the identification and quantification of rare transcripts, 
alternative splicing variants, or newly synthesized (nascent) transcripts48,69. Techniques to 
profile protein-DNA interactions, using chromatin immunoprecipitation followed by 
sequencing (ChIP-seq)70,71, and epigenetic marks72,73, have been developed driven by the 
continuous evolution of the NGS field33. The latter, epigenetics, defines functionally 
relevant changes to the genome without an alteration in the nucleotide sequence74. In 
particular, the epigenome of DNA methylation, a mark for silencing of transcription, has 
been extensively studied using methods such as bisulfite sequencing73,75. Here, the DNA is 
treated with bisulfite before routine sequencing, which leads to a conversion of the base 
cytosine to uracil. The majority of DNA methylation events occur at cytosine and remain 
unaffected during the bisulfite treatment, leading to methylation status dependent 
alterations of the nucleotide sequence that can be readout50,76. 
The impressive developments in NGS technologies and the ever-increasing number of 
applications and molecular profiling studies highlight the potential impact in improving a 
patient’s health38,40,42. The analysis of cell-free, circulating DNA isolated from liquid 
biopsies, for example, offers an attractive, low-invasive approach for the discovery of 
disease biomarkers77,78. The genetic information contained in circulating tumor DNA 
(ctDNA) might be relevant for cancer diagnostics, progression or relapse monitoring, and 
guiding therapy decisions78. Altogether, NGS promises improvements in patient 
stratification, risk assessment for genetic diseases, and the capability to identify multiple 
mutations in a variety of cases, such as oncology38,42. This holds for the broad field of 
Introduction 
6 
oncology79, but also other diseases, such as Parkinson’s disease80, Alzheimer’s disease81, 
and cardiovascular diseases82. 
Nevertheless, neither WGS nor WES or RNA-seq is currently established in routine 
diagnostics, and the implementation is only slowly progressing with a few examples of 
clinical translation83,84. Known obstacles for clinical translation are false positive and false 
negative results as well as low sensitivity in the detection of early-stage cancer84. Other 
limitations are practical demands, such as fast turn-around times from receiving patient 
samples to providing analyzed data, the establishment of necessary infrastructure, and the 
overall costs84. Besides, the sheer amount of data, the requirements to ensure high data 
quality and reproducibility, the associated bioinformatic analysis, the handling and storing 
of data, the medically relevant interpretation, and the clarification of ethical concerns are 
significant challenges for a successful implementation of any systems medicine approach 
that need systematic problem-solving85,86. Other obvious bottlenecks of NGS profiling are 
I) the challenges in distinguishing between a driver and a passenger mutation (explained in 
chapter 1.3.2.)87, or II) the low correlation of gene expression and protein expression and 
the consequential phenotype88–90. This is because proteins are dynamically regulated by 
numerous post-transcriptional mechanisms and post-translational modifications (PTMs), 
such as phosphorylation88–90. The function of a protein additionally depends on its 
subcellular localization91, the interaction of proteins in complexes92, or their half-life’s93, 
which explains why transcript abundance does not need to correlate with a protein’s 
abundance and activity90. Knowing that proteins are responsible for a vast number of 
biological functions, this makes them an essential factor for understanding a biological 
system and its phenotype94,95. The function of proteins and their behavior, however, 
remain invisible for the NGS technology, leading to an incomplete molecular picture 
without the proteome96. 
1.2. Mass spectrometry-based proteome profiling 
1.2.1. Definition and emergence 
The field of proteomics, termed by Marc Wilkins in 1996, describes the large-scale study of 
proteins, the functional workhorses of any living system, cells or whole organisms97. In 
particular, proteins are the molecular entities or biomolecules encoded in the genome that 
operate and control a vast array of processes from replication of DNA and cell cycle, to 
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signaling tasks, immune response, and cell differentiation94,95. In the form of the 
cytoskeleton, proteins provide the mechanical stability of cells, support the information 
and molecule transport, lead responses to internal and external stimuli, and catalyze 
biochemical reactions94,95. 
The existence of proteins as distinct biomolecules is recognized since the mid-18th century, 
described by the Dutch chemist Gerardus Johannes Mulder and named by the Swedish 
chemist Jöns Jacob Berzelius98. Since then, it took years of research to understand the 
structure, function, and complexity of proteins. In 1951, Linus Pauling et al., for example, 
described the helices structure with indirect evidence in particular proteins99, whereas in 
1956, Walter Kauzmann significantly contributed to the understanding of protein folding 
with his work about structural factors in protein denaturation100. Just before, in 1949, it 
was Frederick Sanger, who sequenced the first protein, namely insulin, and established the 
link of proteins being amino acid sequences101,102. The first complete structure was 
unraveled for the myoglobin protein molecule by Sir John Cowdery Kendrew in 1958103. 
These and numerous other discoveries throughout the 20th century have significantly 
enhanced our knowledge about proteins, the 3rd downstream layer of the genetically 
encoded information following DNA and RNA, as explained within the central dogma of 
biological systems. Studying the entire set of proteins, however, remains a challenging task 
owing to technical difficulties to measure proteins and the highly variable and complex 
environment of protein expression, its regulation, and their interaction94,95,104. 
The framework for large-scale protein measurements, as we know it today, was set by 
crucial developments in the field of mass spectrometry, a technique to determine the mass-
to-charge ratio of ions105. Besides others, this includes the development of quadrupole ions 
traps, so-called Paul traps, in the 1950s by Wolfgang Paul and Hans Georg Dehmelt to trap 
charged particles in electric fields106. Therefore, they were later recognized with the Nobel 
Prize in Physics in 1989 (shared with Norman Foster Ramsey, Jr. for the invention of the 
separated oscillatory field method to precisely measure time and frequency)106. In the same 
year, Prestage J.D. et al. described the linear ion trap providing higher ion storage capacity 
and faster scan rates107. Another significant milestone was the employment of electrospray 
as a soft ionization method to produce ions from large molecules, such as proteins or 
peptides, with minimal fragmentation or degradation during the liquid-to-gas-phase 
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transition108. Electrospray ionization (ESI)108 was developed in 1984 by John Bennett Fenn. 
He was awarded the Nobel Prize in Chemistry in 2002 (shared with Koichi Tanaka for the 
development of MALDI - matrix-assisted laser desorption ionization109, another soft 
ionization technique, and Kurt Wüthrich for the development of NMR - nuclear magnetic 
resonance spectroscopy to identify 3D structures of biological macromolecules110). In 1999, 
Alexander Makarov presented his proof-of-principle for the first orbital ion trap mass 
analyzer, the Orbitrap, a derivative of the earlier Kingdon trap (1923) or the modified Knight 
configuration (1981)111. The Orbitrap provided unprecedented, sensitive, and robust mass 
accuracy and high resolution. Then and nowadays, this marks a kick-off for continuous 
technological improvements that pave the way for modern analytical mass-spectrometry 
(MS)-based proteomics. The first Orbitrap mass spectrometer became commercially 
available in 2005 and has since remained the chief MS technology in proteomics112. 
In the last 15 years, MS-based proteomic technologies have matured into a powerful tool 
allowing robust, reliable, and comprehensive proteome profiling in cells and tissues94,95. 
This is the result of parallel developments in mass spectrometric instrumentation that 
continues to gain speed and sensitivity113–116, in liquid chromatographic technology to 
separate proteins and peptides directly interfaced with MS117,118, and in data analysis 
pipelines for reliable protein identification and quantification119,120. Various workflows have 
been developed for comparative analyses across many samples using, for example, isobaric 
labels allowing sample multiplexing, or label-free approaches and short liquid 
chromatography (LC) gradients118,121,122. Collectively this has propelled proteomic studies 
in multiple areas of basic, mechanistic, and systems biology, using in-depth and 
quantitative proteomic profiles to understand spatial and temporal aspects of proteome 
organization and dynamics in a wide variety of conditions123. In 2014, Mathias Wilhelm et 
al. and Min-Sik Kim et al., released the first drafts of the human proteome124,125. 
1.2.2. Status quo: proteomics in systems medicine 
The speed, sensitivity, robustness, and general accessibility of present-day proteomic 
technologies have an increasing appeal for clinical applications, for various reasons: I) 
underlying mechanisms of many diseases are still unclear, where proteome-level 
information will increase the mechanistic insight of (patho)physiological processes94,126,127; 
II) proteins are the primary targets of almost all current drugs, and insight in their function 
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will help to understand how drugs impact on cellular processes. Many drugs act 
unspecifically on multiple rather than a single protein target, thus making it a crucial factor 
to deconvolute the mechanism of action to gain confidence and improve drug discovery128; 
III) for many diseases there is a persistent lack of robust protein biomarkers for diagnostic, 
prognostic, or predictive purposes1,3. Liquid biopsies, such as blood or urine, are again 
particularly promising for protein-based biomarker discovery due to their non-invasiveness 
as compared to tissue biopsies obtained through surgery77,78. The proteome provides a 
unique insight that can also complement NGS-derived data, and with the current state of 
development, it is the consequential next step in studying biological systems, animal or cell 
models, and patient specimens126,129. 
Despite the demand for in-depth proteome-level information, its value, and promise to 
bridge the blind spot between DNA/RNA and phenotype126,127, most recent applications in 
a clinical context have been limited to highly specialized workflows or individual 
proteins130,131. Many routine laboratory tests for diagnostics and therapy decision-making 
are based on proteins132,133. Immunohistochemistry, for example, is the main procedure in 
pathology for disease entity classification through staining of individual proteins, which in 
turn highlights their role in clinical practice133,134. In contrast, MS-based proteomics enables 
the global identification and quantification of thousands of proteins simultaneously94. Here, 
the proteomic field benefits from the head start of NGS technologies, in which it has already 
become clear that complex biological disease entities cannot be explained simply by their 
genetic alterations and transcriptional response alone1,33,127. Instead, an integration of 
multiple “omics” layers, including clinical data and proteomics, holds promise to extend our 
understanding of (patho)physiological processes and to gain insight into its clinical 
utility1,33,127,135. Latest systems medicine programs, such as the “Obama Precision 
Medicine” initiative, clearly propose an incentive to establish MS-based profiling of 
proteins and other biomolecules and to integrate with NGS-based and clinical data136. 
Several promising case studies utilizing global proteome or phosphoproteome profiling and 
data integration in a clinical context are available137, which guided a therapy decision or 
helped subclassify a specific disease entity. In 2018, for example, Doll S. et al. have applied 
proteomic profiling to a chemorefractory patient with a rare urachal carcinoma for whom 
all previous treatment options failed130. Comparing the protein profiles in tumor tissue to 
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its surrounding, they identified differentially expressed candidates, of which one, namely 
lysine-specific histone demethylase 1 (LSD1), an epigenetic regulator, was in focus as a 
potential target in ongoing drug development attempts. Backed up with NGS and clinical 
data, their finding sufficiently convinced the tumor board to propose a personalized 
treatment with an LSD1 targeting drug. In another example, in 2018, Archer T.C. et al. 
applied quantitative proteome and phosphoproteome profiling to a cohort of 45 primary 
medulloblastoma specimens, a common pediatric brain tumor, to identify potential 
therapeutic targets131. Despite the low mutation rates in pediatric tumors and highly similar 
RNA expression, they identified extensive heterogeneity in molecular mechanisms, 
representing the functional state of the cancer cells, within the World Health Organization 
(WHO)-accepted subgroups for medulloblastoma. The membrane protein CD47, for 
example, was significantly enriched, suggesting that anti-CD47 therapies might be 
particularly successful within the respective subgroup. Furthermore, the PTM readout of 
phosphorylation status in MYC revealed its distinct activity in certain tumors irrespective of 
the expression level. The activity of MYC upregulates many genes, some of which are 
involved in cancer formation and cell proliferation. The utility for a clinical implication 
remains to be shown, but the integrative data promise a new perspective for understanding 
tumor biology and guiding therapy. 
MS-based proteomics in clinical systems medicine is a promising trend, yet remains 
challenging to implement as a routine application126–129. Considering recent pioneering 
measures and technological maturation, it seems to be a question of time until robust 
instrumentation, broad training, computational efforts, and standardization will facilitate 
the day-to-day molecular proteome profiling of individual patients. 
1.2.3. Clinical translation: bottlenecks and requirements 
The field of proteomics is faced with significant analytical challenges due to the sheer 
complexity of protein expression, their interaction, and regulation94. They can be highly 
variable in their spatiotemporal expression across different tissue or cell types and an 
organism's lifetime138–140. The expression of proteins varies tremendously during cell 
differentiation141, early development142, during cell cycle phases143,144, or in a disease, such 
as cancer145. Unlike the proteome, the nucleotide sequence of the genome stays constant 
and static over time, whereas individual genes or genomic regions can be more actively 
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transcribed or repressed146. Proteins can differ in their abundance by several orders of 
magnitude, complicating the identification and quantification of low abundant proteins in 
the presence of high abundant proteins104. The broad dynamic range constitutes a 
sensitivity issue for sample preparation as well as MS instrumentation, lacking a 
methodology to amplify protein samples similar to the polymerase chain reaction (1983 by 
Kary Mullis) for nucleotide sequences104,147. The transcription of a gene to mRNA does not 
allow a sufficient prediction of protein expression and the underlying phenotype90. 
Transcripts might be inefficiently translated or quickly degraded by other post-
transcriptional regulatory mechanisms. On top of differential synthesis rates of individual 
transcripts, proteins vary significantly in their half-life or become stabilized through 
functional interaction in protein complexes. As previously mentioned, some proteins can 
be post-translationally modified by, for example, phosphorylation, which determines their 
activity and might be crucial for oncogenic drivers. All of the above contribute to the 
technical and functional complexity of proteomics, presenting both challenges and 
promises for systematic proteome profiling. 
The successful implementation of MS-based proteomics in a clinical environment has not 
materialized yet, primarily because of additional requirements that need to be met on top 
of those in a research environment alluded to above (e.g., proteome coverage, 
sensitivity)126–129. This mostly pertains to I) the ability to analyze many (possibly hundreds) 
samples uninterruptedly and robustly in order to achieve sufficient statistical power in 
patient cohorts117,118, II) simplify the workflow, thereby removing the need for personnel 
with cutting-edge expertise and technical skills in proteomics148,149, III) achieving an 
adequate turn-around time from receiving samples to the generation of a complete 
proteome profile analysis126,129, and IV) cost-effectiveness of the workflow128. Most of these 
bottlenecks can be resolved simultaneously by automation, avoiding manual handling and 
thereby eliminating the risk of error and variability, while at the same time enabling 
longitudinal standardization irrespective of the number of samples. Although liquid 
chromatography coupled to mass spectrometry (LC-MS) has nowadays been sufficiently 
standardized to achieve excellent performance across hundreds of samples150, preceding 
sample preparation is often still highly cumbersome, involving multiple steps to extract, 
purify, and digest proteins before subsequent LC-MS94,104. In an ideal scenario, this 
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procedure should be streamlined into an automated pipeline that accepts processing 
conditions for any sample type, thereby facilitating universal applicability. Despite the 
range of existing sample preparation methods151–158, very few satisfy these demands to 
universally accommodate the different requirements imposed by various clinical tissue 
types. For instance, blood cells can be lysed under more mild conditions than fresh frozen 
tissue, while formalin-fixed and paraffin-embedded (FFPE) tissue requires harsh detergent-
based methods to extract proteins efficiently159. Many currently available sample 
preparation methods have demonstrated their great utility in many application areas of 
proteomics92,139,160–167. However, they also come with some drawbacks. For instance, stage 
tips154, and its derivative iST156, do not tolerate detergents commonly used in proteomics, 
thereby restricting their generic use. Other approaches involve extensive handling 
procedures such as filtration151,156,158, centrifugation151,156,158, precipitation153, and 
electrophoresis152 that are difficult to standardize or scale-up, or that lead to undesirable 
sample losses. The latter is especially important because the majority of realistic clinical 
scenarios are limited to minute amounts of an available specimen, highlighting the demand 
for universal and sensitive methods149,168. 
With large-scale, multi-omics molecular profiling comes a considerable time and resource 
investment in computational data handling, storing, and integration135,169,170. Clinicians 
need to be aware and willing to utilize comprehensive data for therapeutic decision making. 
This, however, requires bioinformatic analysis due to the immense amount of data, which 
practically cannot easily be interpreted by a single person169. Therefore, clinical 
implementation of a systems medicine approach, including proteomics, needs to be an 
inter-disciplinary coordination between scientists, medical doctors, bioinformaticians, and 
others. Logistical challenges for dedicated instruments, working space, personnel, and 
others add up to the list of requirements128,129. Ethical issues concerning the collection and 
interpretation of ‘big data’ are another critical aspect that needs to be discussed to find 
binding agreements1,171,172. Insurance companies and health care providers need to be 
involved in order to ease the translation of clinical decisions and tumor boards to approved 
cost reimbursements. 
We are still far from decoding the full complexity of biological systems, and many diseases, 
such as cancer, remain poorly understood. Each tumor is unique, and most exhibit a diverse 
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cellular and molecular heterogeneity, illustrating the need for systematic profiling. Here, 
MS-based proteomics will provide a crucial, thus far missing, bridge between genome, 
transcriptome, and phenotype. 
1.3. Oncology 
In this thesis, two specific cancer entities, namely lung cancer and ependymoma (EPN) 
pediatric brain cancer, were used to showcase the applicability of our workflow and to 
illustrate the added value of proteome profiling. Both are introduced in the following 
chapters among a general framework of cancer, its epidemiology and emergence. 
1.3.1. Cancer: definition and epidemiology 
Neoplasia defines the uncontrolled and excessive growth of cells and tissue. The abnormal 
proliferation of cells typically leads to the formation of a tumor173. Neoplasms can be 
described in four main classes that are defined and recognized by the WHO international 
classification of diseases (ICD-11), namely: benign, in-situ, malignant, and of unknown 
behavior174,175. Malignant neoplasms are more commonly known as cancer and the focus 
of oncology (ICD-O), the medical branch dealing with its prevention, diagnosis, and 
treatment176. Cancer cells can invade surrounding tissue or organs and spread to distant 
parts of the body via the blood and lymph system177,178. This process is called metastasis 
and denotes a significant cause of cancer-related death. Several main types of cancer can 
be distinguished based on their cells of origin; for example, I) carcinomas emerge from 
epithelial cells in the skin or within tissue covering internal organs; II) sarcoma describes 
cancer beginning in the bone, fat, muscle, blood vessels, or connective tissue; III) multiple 
myeloma and lymphoma define cancer types beginning in cells of the immune system, and 
IV) leukemia originates from bone marrow and causes abnormal blood cells173,175,176. 
Besides cardiovascular diseases, cancer is the second most prevalent cause of death 
worldwide, with approximately 9.6 million cases of deaths and a total burden of 18.1 million 
new cases in 2018 (according to the WHO)179,180. It is estimated that 38.4% of men and 
women will be diagnosed with cancer during their lifetime, while the prevalence 
significantly increases with age181. Children and young adults under 14 years of age account 
for roughly 1% of cancer deaths worldwide181,182. Men have a 20% higher chance than 
women to develop cancer179. The 5-year relative survival across all cancer types in adults 
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has increased from 50.3% between 1970 and 1977 to 67% between 2007 and 2013183–185. 
Improved early diagnosis and better treatment options are positively contributing factors 
to this development. 
The most common types of cancer in both males and females are lung cancer and breast 
cancer, with approximately 2.09 million cases in 2018, respectively. That followed are 
colorectal cancer and prostate cancer with 1.8 million and 1.28 million annual cases in 2018 
(according to the WHO). Lung cancer was the leading cause of cancer-related death, with 
approximately 1.76 million cases in 2018, followed by colorectal cancer (~862.000 cases), 
stomach cancer (~783.000 cases), liver cancer (~782.00 cases), and breast cancer (~627.000 
cases). The highest mortality rate for either male or female prevails from lung cancer (22%) 
and breast cancer (15%), respectively173,179. In children, brain tumors, lymphomas, and 
leukemia are the most commonly diagnosed types of cancer. Brain tumors remain the 
leading cause of cancer-related death in children186. 
1.3.2. Carcinogenesis 
Carcinogenesis describes the transition from a normal cell into a cancer cell177,178. This 
process is characterized by cellular, genetic, and epigenetic changes and consequential 
abnormal cell proliferation and division. Homeostatic cells exhibit a fine regulation of 
growth and programmed cell death (apoptosis). During carcinogenesis, this order is 
disrupted in a stepwise process during which a cell acquires distinct traits enabling a 
continuous, abnormal proliferation. Initially proposed by Douglas Hanahan and Robert A. 
Weinberg in 2000, these traits are widely accepted as the “hallmarks of cancer”177,178. They 
encompass the following eight essential alterations to a cell's physiology that are necessary 
to breach the anti-cancer defense mechanisms and shared among all types of cancer: I) 
self-sufficient in growth signals, II) insensitive to growth-inhibitory signals, III) ability to 
evade apoptosis, IV) limitless replicative potential, V) sustained angiogenesis, the process 
of blood vessel formation, VI) metastasizing capabilities, VII) the reprogramming of a cell’s 
energy metabolism, and VIII) the ability to avoid immune destruction. Hanahan and 
Weinberg suggest that these hallmarks are individually acquired during tumor 
development and only collectively cause cancer. Further, they define genomic instability, 
tumor-promoting inflammation, and the tumor microenvironment as “enabling 
characteristics” that contribute to genetic diversity and the acquisition of all hallmark traits. 
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This framework illustrates that carcinogenesis is a multi-step transition of distinct cellular 
mechanisms and pathways from their physiological conditions to deregulation, upsetting 
the integrity between proliferation and cell death177,178. 
The accumulation of mutations in the genome is an evolutionary process that likely leads 
to carcinogenesis187. Several types of mutations exist ranging from single nucleotide 
variations (SNVs), large structural variations (SVs), such as copy-number variations (CNVs), 
and small insertions and deletions of nucleotide sequences (InDels)188,189. Most of them 
occurring in human cancer are so-called “passenger mutations” because they do not trigger 
a disease phenotype190. The role of these uninvolved mutations remains poorly 
understood, whereas an increasing body of scientists suspect that they might have a crucial 
involvement in pathophysiology. In contrast, mutations that cause a selective growth 
advantage or increased survival for the cell are called “driver mutation”190. Genes that carry 
a driver mutation are grouped into two classes, namely oncogenes and tumor suppressor 
genes191. Both play a crucial role in carcinogenesis. 
Oncogenes typically upregulate cell proliferation and survival191. They are characterized by 
a dominant gain-of-function mutation that leads to its constant activation or 
overexpression192,193. In some cases, mutations in oncogenes result in altered proteins with 
a novel, tumor-promoting property194–196. A prominent example is an amplifying point 
mutation in the gene coding for the AKT protein, a serine/threonine-protein kinase (AKT1, 
AKT2, and AKT3)197. Under physiological conditions, it is involved in an array of different 
processes from metabolism, proliferation, to angiogenesis. It contributes to the regulation 
of cell survival via the phosphorylation of MAP3K5, an apoptosis signal-related kinase, 
which is activated upon oxidative stress. Its decreasing activity triggered by the AKT 
overexpression prevents apoptosis, one of the acquired hallmark traits. On the other hand, 
tumor suppressor genes are characterized by a repressive loss-of-function mutation191. 
They are often involved in maintaining the integrity of cell proliferation or protection 
against genomic instability. During carcinogenesis, they are often disabled by cancer-
promoting genetic alterations leading to an inactivation of their regulatory impact. The 
cellular tumor antigen p53 (TP53), for example, acts as a tumor suppressor in many cancer 
types as it is involved in growth arrest, apoptosis, or cell cycle regulation191. Its inactivation 
causes insensitivity to anti-growth signals and the ability to evade apoptosis. 
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Despite the theoretical understanding of carcinogenesis, the coherence between a 
genotype, its influencing environmental factors, and corresponding cancer or disease states 
often remain unclear177,178. Here, the proteome composition has the potential to provide 
the missing link to understand the impact of mutations, the mechanisms of hallmark trait 
acquisition, and the breaching of anti-cancer defenses as a result. 
1.3.3. Lung cancer 
Primary lung cancer arises from respiratory epithelial cells and thereby classifies as 
carcinoma with uncontrolled growth in the lung175,198. Metastasis that spread to the lung 
from other parts of the body are considered as secondary lung cancer. The most common 
age of diagnosis is 65 years or older, with an average of around 70 years181,199,200. A small 
number of cases are diagnosed per year at an age younger than 45 years. About 85%, the 
vast majority of cases of lung cancer are caused by long-term tobacco smoking181,200. The 
number of diagnosed cases per year is continuously declining, together with the increasing 
trend of non-smokers. Other causes are frequent exposure to dust, asbestos, paint, or 
general air pollution. On average, lung cancer has a 5-year survival rate of approximately 
18.6% (>55% at early detection). The occurrence of lung cancer is categorized based on the 
size and appearance of the tumor mass and the malignant cells’ morphology. The WHO 
classification of lung cancer comprises two main types, namely small-cell lung carcinoma 
(SCLC) and non-small-cell lung carcinoma (NSCLC), based on the cell type of cancer 
origin175,176. In comparison, SCLC comprises significantly smaller cells and features the 
ability to metastasize, making it a highly malignant tumor rapidly. SCLC is rarely seen in non-
smokers and accounts for roughly 13% of lung cancer cases worldwide181,200. On the other 
hand, NSCLC represents roughly 87% of all cases201. 
NSCLC can be sub-divided into three major pathologic subtypes: I) squamous cell 
carcinoma, II) large cell carcinoma, and III) adenocarcinoma (ADCs)175. The latter is the most 
common histological lung cancer subtype accounting for roughly 60% of all NSCLC (~38% of 
all lung cancer cases). They are known for their heterogeneous clinical, radiologic162, 
molecular202–204, and morphological205 features. Thus far, five distinct histological growth 
patterns have been recognized by the 2015 WHO Classification of Lung Tumors206. These 
growth patterns, which are reported in any pathology report, have been proposed for 
tumor grading according to the predominant pattern of a tumor: lepidic (low grade; group 
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1), acinar and papillary (intermediate grade; group 2), and solid and micropapillary (high 
grade; group 3)198,201. Applying this grading system led to the observation of significant 
differences regarding prognosis207 and prediction of benefit from adjuvant 
chemotherapy208, where patients with lepidic ADC or micropapillary ADC were associated 
with the most favorable or worst prognosis, respectively. 
The current standard of care for lung cancer is highly dependent on the stage of diagnosis, 
the type of mutation, and the potential spread of metastasis198,201. In an early stage, for 
example, a maximal-safe surgical resection can be facilitated by a still confined area of 
cancerous cells (a localized disease has a 5-year survival rate of approximately 52%). In 
severe cases that do not allow surgery, cancerous cells might be targeted by radiotherapy 
if it is tolerable considering the patients’ health201,209. Platinum-based chemotherapy is 
likely the next stage of treatment in cases that already developed metastasis. The spreading 
and growth of cancer cells might be slowed down by drug therapies that target specific 
changes in the cancer cell microenvironment210. Unfortunately, lung cancer frequently does 
not cause symptoms until cancerous cells have spread to other parts of the body, leading 
to an overall bad prognosis. 
A vast number of studies aimed to bring genetic factors associated with lung cancer to light. 
These efforts have led to several different discoveries. In 2006, for example, Lu Y. et al. 
performed a meta-analysis of seven microarray studies and identified a 64-gene signature, 
which is predictive for lung cancer reoccurrence in stage I NSCLC patients211. In other 
genomic studies, a tumors’ responsiveness to chemotherapies could be predicted, or the 
association between genomic alterations and distinct growth advantages was 
elucidated189. Further, the risk of developing lung cancer correlates to frequently observed 
polymorphisms on chromosome 5, 6, and 15212–214. Increasing mutations rates in epidermal 
growth factor receptor (EGFR) were linked to NSCLC ADC of patients215. Supported by 
molecular characterization, treatment plans using EGFR tyrosine kinase inhibitors (gefitinib 
and erlotinib) have demonstrated improved clinical outcomes by slowing down disease 
progression215. In another study in 2009, Boutros PC. et al. identified a six-gene expression 
signature (STX1A, HIF1A, CCT3, HLA-DPB1, RNF5, and MAFK) with prognostic value for 
NSCLC patients, which could be validated in four distinct testing datasets216. They propose 
that a clinical implementation using RT-PCR analysis of the six genes can provide a quick 
Introduction 
18 
readout about good or poor prognosis. However, they observed that many proposed gene 
signatures from immense efforts in lung cancer research appear to have a lack of overlap, 
illustrating the need for an improved molecular characterization. Additional proteome 
profiling efforts may achieve a complementary or improved insight. 
To this end, there were no efforts to perform a molecular classification and characterization 
of growth patterns of ADCs (NSCLC), the most common lung cancer type, on the proteome 
level. In most invasive ADCs, more than one of the previously mentioned growth patterns 
can coincide204,217, which further highlights the need to understand functional differences 
and clinical implications of histological heterogeneity better. In this thesis, proteome 
profiling of ADC growth patterns was performed for the first time. 
1.3.4. Pediatric brain tumor: ependymoma 
1.3.4.1. Definition and epidemiology 
The majority of pediatric brain tumors are classified as gliomas accounting for roughly 
52.9% of all cases218. Brain tumors are the second most common type of tumor occurring 
in children219. Other types of pediatric brain tumors are medulloblastomas (15-20%), 
originating from immature or embryonal cells, choroid plexus tumors (10-20%), germ cell 
brain tumors (4%) or atypical teratoid rhabdoid tumors (ATRTs; 1-2%)218. Gliomas are 
primary tumors that arise from glial cells220,221. Oligodendrocytes, astrocytes, ependymal 
cells, and microglia comprise the four types of glial cells in the central nervous system (CNS). 
The majority of gliomas are typically named corresponding to the glial cell type that is 
histologically most similar but which not necessarily reflect the tumor origin. The main 
types include astrocytomas, ependymomas, oligodendrogliomas, brainstem gliomas, and 
mixed gliomas that are comprised of several types of glial cells. They are further categorized 
by four different tumor grades, from least severe (low-grade: grade I and II) to highly 
malignant (high-grade gliomas: grade III and IV), and by their anatomical location within the 
CNS175,176. Astrocytomas are the most common glioma tumor in children, accounting for 
33.2% of all pediatric cases218. 
Ependymomas are the third most common type of glioma tumor in the CNS in children222. 
They account for 10.4% of all pediatric glioma cases and arise from ependymal cells or so-
called radial glial cells. They constitute a specialized type of epithelium to line the 
ventricular system of the brain and the spinal cords’ central canal, allowing a continuous 
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flow of cerebrospinal fluid (CSF)223,224. Ependymal cells are further involved in CSF 
production and secretion. Ependymomas most frequently occur at an average age of 5 
years and 35 years, in children and adults, respectively225. In adults, they are rarely 
diagnosed and only account for 1.9% of all primary brain tumors226. While the majority of 
incidences in children occur intracranially (90% within the brain), most ependymal tumors 
in adults arise in the spine227,228. The clinical outcome for ependymoma patients also varies 
between children and adults with a 10-year survival of 64% and >80%229. Despite the ability 
of ependymomas to spread, they are rarely observed to metastasize beyond the CNS230. 
Following the glioma-related grading system, the most recent WHO classification 
distinguishes ependymomas into main categories of subependymoma (grade I), 
myxopapillary ependymoma (grade II), anaplastic ependymoma (grade III), and 
ependymoma, RELA-fusion positive (grade II and III)231,232. The tumor cells can be well 
separated from the surrounding healthy cells by histological examination and exhibit 
features of true ependymal rosettes and perivascular pseudorosettes233. Most tumors are 
low-grade (grade II), while anaplastic ependymoma (grade III) are often additionally 
characterized by an increased cellular density, necrosis, and microvascular proliferation, 
without compromising the typical tissue pattern233. Myxopapillary ependymomas are 
further characterized by papillary formation with a mucinous core and most commonly 
arise in the spine. Low-grade subependymomas have a spherical phenotype and consist of 
uniform cells in a fibrillary stroma with cystic degeneration226. 
The standard of care for ependymal tumors is a gross total resection (GTR) via surgery 
followed by optional chemotherapy and focal radiotherapy234–238. The latter has been 
linked to reduced tumor mass, increased overall survival rates, and benefits in the 
prevention of ependymoma recurrence235,239. The complete removal of the tumor mass is 
typically confirmed using postoperative magnetic resonance imaging (MRI)240. In many 
cases, GRT surgery in the brain or spine of children remains challenging, with a high risk of 
side effects or damaging healthy tissue241–243. This may be due to the tumor location, or a 
not well-differentiated growth and infiltration into healthy parenchyma. Some highly 
malignant ependymoma types may spread through the CSF to other parts of the CNS and 
typically require radiation therapy. Here, the surgeon aims for a maximal safe surgical 
resection (subtotal resection, STR), which can still significantly reduce the tumor mass to 
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increase the efficacy of the subsequent radiotherapy241,242. The degree of tumor resection 
via GTR or STR has been shown as the main prognostic factor in children and adults234–
236,238. 
Not every incidence of ependymoma can be treated easily, especially children younger than 
three years of age have shown severe side-effects upon focal radiotherapy, resulting in 
neurocognitive deficiencies, surrounding tissue abnormalities, or increased likelihood of 
secondary cancer development244–246. For highly malignant, anaplastic ependymomas, the 
overall recurrence rate remains high, showing a median progression-free survival (PFS) of 
only 2.3 years247. This further highlights an obvious need for novel treatment strategies and 
a better understanding of the ependymoma-related pathophysiology. Both are addressed 
by molecular characterization, including insight into the proteome composition. 
1.3.4.2. Molecular classification 
The molecular characterization of brain tumors248,249 has an increasing appeal to improve 
diagnosis and the WHO classification, which conventionally relies mostly on 
histopathological examination and staging into grade I to IV175,231,232. While routinely 
applied for many diseases, this histological grading presents a common problem for many 
brain tumors250–252. Low inter-observer reproducibility and ambiguous results are frequent 
in ependymomas, due to their diverse clinical behavior and highly challenging 
histopathological features250–252. Increasing numbers of studies additionally rely on 
molecular characterization, such as gene expression profiling or DNA methylation profiling 
(e.g., CNS-PNET)253,254. The latter has been established to enable robust and reproducible 
evaluation of brain tumors beyond the hitherto existing classification. Capper D. et al. 
recently implemented a DNA methylation-based classifier with which a brain tumor can be 
assigned to a distinct methylation class by comparison to a reference cohort of 2801 brain 
tumors255. In their validation cohort of 1104 tumors, the initial histopathological diagnosis 
was changed in 12% of all cases based on the assigned methylation class, thereby improving 
the diagnostic accuracy. Despite a few examples in which the WHO accredited the 
incorporation of molecular features to extend the conventional classification, 
histopathology remains the established standard of diagnostics231,232. In 2015, Kristian 
Pajtler et al. revealed that ependymal tumors are comprised of at least nine molecular 
subgroups utilizing DNA methylation profiling and additional gene expression data73. The 
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subgroups are equally distributed among the compartments of the CNS (ST: supratentorial, 
PF: posterior fossa, and SP: Spine) and named accordingly: SP-EPN, SP-MPE, SP-SE, PF-EPN-
A, PF-EPN-B, PF-SE, as well as ST-EPN-RELA, ST-EPN-YAP1, and ST-SE. Despite these 
immense efforts, the subgroup-specific oncogenic driver and functional background remain 
largely unknown and only few or no recurrent genetic events were observed72,73,227,256–259. 
This highlights the potential for complementary proteome profiling to shed light on 
currently unknown EPN subgroup-specific biology. 
The SP-SE group predominantly encompasses low-grade I subependymomas (SE) with most 
incidences in adults226,260. They exhibit a characteristic deletion of chromosome arm 6q 
with an otherwise stable genome73. Nevertheless, they usually have an excellent prognosis 
and outcome, even in highly malignant grade III anaplastic EPNs. SP-MPE ependymal 
tumors are mostly grade I myxopapillary ependymomas, which also primarily occur in 
adults. Despite a vast number of chromosomal instabilities, including gains and losses of 
entire arms, they instead display a favorable clinical outcome. Most grade II and III 
ependymal tumors in the spine are classified as SP-EPN. They typically feature a deletion of 
chromosome arm 22q, harboring the tumor suppressor gene NF2 that is frequently 
mutated or lost in spine ependymal tumors261. NF2 codes for the Merlin protein and is 
involved in tumor suppression by restricting proliferation and promoting apoptosis. 
The second anatomical region with the occurrence of ependymomas is the posterior fossa. 
It is part of the intracranial space and contains the brainstem (medulla oblongata, pons, 
mid- and hindbrain) and cerebellum262. Subependymomas within the posterior fossa (PF-
SE) again have a distinctive methylation pattern, showcasing similar prevalence and clinical 
characteristics as SP-SE tumors without the deletion of chromosome arm 6q73. PF-EPN-A 
and PF-EPN-B subgroups are comprised of grade II and III tumors with vast molecular and 
clinical differences263–265. PF-EPN-A tumors predominantly occur in children with high 
reoccurrence and invasive growth patterns. On the other hand, PF-EPN-B tumors display a 
more benign phenotype with antithetic characteristics occurring mostly in adults, low rate 
of recurrence, non-invasive growth, and a resulting reasonable 10-year survival rate of 
88%73,260,263. Molecularly, PF-EPN-A tumors present a balanced genome besides a 
prominent gain of chromosome arm 1q260,266. This gain has been linked to poor prognosis 
in some independent studies266–269. Another unique characteristic of PF-EPN-A tumors is 
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the lack of the repressive histone mark H3K27me3265,270–272. Correspondingly, these tumors 
show increased expression of several genes involved in various carcinogenic processes, 
such as angiogenesis, growth-factor pathways, and receptor tyrosine kinase signaling. In 
comparison, PF-EPN-B tumors neither lack the H3K27me3 mark nor do they show the 
associated genes upregulated265,270,272. Further, PF-EPN-A tumors display an increased CpG 
methylation pattern (CpG island methylator phenotype: CIMP-positive) of promoter 
regions of polycomb repressive complex 2 (PRC2) target genes. CIMP-positive cancer types 
are often associated with worst disease-free survival after primary treatment and worse 
overall survival273. The PRC2 complex has histone methyltransferase activity and primarily 
functions to trimethylate the H3K27 for the silencing of genomic regions274,275. 
The remaining site of ependymal tumor occurrence is the supratentorial region of the brain. 
The reasonably large area contains the cerebrum, which consists of both hemispheres of 
the cerebral cortex, the hippocampus, basal ganglia, and the olfactory bulb262. The cerebral 
cortex is the most prominent site of neural integration in the CNS and has a pivotal role in 
consciousness, awareness, memory, language, and other crucial functions262. The ST 
regions again present a grade I subependymoma (ST-SE) molecular subgroup with an 
overall good outcome, the highest prevalence in adults, and otherwise similar 
characteristics to the SP- and PF-SE tumors73. A similar good outcome is observed in ST-
EPN-YAP1 tumors that are predominantly comprised of grade II and III tumors73. They are 
characterized by focal aberrations on chromosome 11, resulting in the dominating and the 
less recurrent fusion genes, YAP1-MAMLD1 and YAP1-FAM118873,276. YAP1 is a 
transcriptional regulator taking part in proliferation and suppression of apoptotic genes. 
The Hippo signaling pathway is known to inhibit YAP1 to allow cellular control of organ size 
and tumor suppression277,278. ST-EPN-RELA tumors are driven by other distinct gene fusions 
involving C11orf95 and RELA, an effector of the NF-kappa-B transcription factor 
complex73,259. The complex is involved in a vast number of cellular processes and 
metabolism279. The NF-kappa-B/RELA activation has been associated with carcinogenesis 
and a negative correlation with patient survival in a series of different tumor entities279–282, 
such as breast cancer283, prostate cancer284, and leukemia285. The fusion is thought to result 
from a local chromothripsis on chromosome 11, a single, massive mutational 
rearrangement in a confined genomic region259,265. ST-EPN-RELA tumors encompass grade 
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II and III ependymomas and mostly occur in children. Together with PF-EPN-A, they show 
the worst overall prognosis with a 10-year survival rate of 50%, while accounting for the 
majority of ST ependymal tumors (70%)73,260,286. Importantly, ST-EPN-RELA constitutes the 
only molecular subgroup that is already accredited and included in the latest WHO 
classification of tumors in the CNS231,232. 
Although, in the past and present, extensive efforts are undertaken to elucidate the biology 
of EPNs and to find potential therapeutic implications, the majority of subgroups are still 
poorly understood and without a specific treatment possibility73,260. Here, proteomic 
profiling has the potential to enhance our insight into unknown biological functions on the 
level of molecular mechanisms that drive pathophysiologic conditions. Ensuing, the 
proteome composition may facilitate the discovery of new drug targets, subgroup-specific 
biomarkers, or provide an extension of the current classification system for EPNs. 
Collectively, the proteome holds promise to complement the yet incomplete molecular 
picture along with previous molecular characterization efforts. 
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1.4. Aim of this study 
Mass spectrometry (MS)-based proteomic technologies have evolved to allow global 
profiling across thousands of proteins. Due to previously mentioned bottlenecks in 
proteomics workflows, the routine application of proteome profiling has not yet been 
implemented in a clinical context complementary to other next-generation sequencing 
techniques. The aim of this study was 2-fold: 
I) the technical establishment and implementation of an automated, universal workflow for 
routine protein sample preparation from a wide range of clinically relevant input material. 
Specifically, we aimed to include challenging to handle sample types, such as FFPE tissue, 
or quantity-limited samples. The workflow’s performance was demonstrated by assessing 
the precision, longitudinal robustness, and sensitivity. We further aimed to evaluated and 
optimized all relevant parameters to allow a deep proteome profiling with optimal 
quantification and rapid turn-around times. 
II) the applicability of our workflow to a clinical question: we used our automated workflow 
to process a pulmonary ADC (FFPE) cohort, comprising all histologically defined growth 
patterns that are accredited by the WHO. Currently, these growth patterns have a limited 
clinical implication. To the best of our knowledge, a proteomic characterization, including 
the functional assessment of molecular mechanisms between different ADC growth 
patterns, did not exist until now. Simultaneously, we aimed to illustrate the potential of 
proteome profiling in another realistic scenario. Specifically, we utilized a cohort of EPN 
pediatric brain tumors, an entity of primary tumors within the CNS of children and young 
adults. Recently, the existence of nine distinct molecular subgroups has been shown, 
whereas, for the majority of subgroups, a functional explanation is still lacking. In this study, 
we used a subset of an EPN cohort (Pajtler et al., 2015)73 to investigate the proteome 
composition across all nine molecular subgroups. Altogether, this provides a rich molecular 
dataset to explore the utility of proteomic data in combination with other NGS data to 
enhance our understanding of EPN biology and potential clinical implications. 
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2. Materials 
2.1. Chemicals and other materials 
Here, all used chemicals, reagents, equipment, and consumables are listed in alphabetically 
ordered groups. The materials used solely by collaborators are not explicitly listed: 
Reagent/Resource RReference or Source Identifier or Catalog Number 
Experimental Models    
HeLa cells (H. sapiens) ATCC (Wesel, Germany) ATCC CCL-2 
MCF7 cells (H. sapiens) ATCC (Wesel, Germany) ATCC 
HEK-293 (H. sapiens) ATCC (Wesel, Germany) ATCC 
ISTMEL-1 (H. sapiens) Obtained from colleagues for protein 
quantification 
N/A 
UACC-62 (H. sapiens) Obtained from colleagues for protein 
quantification 
N/A 
RPMI-7951 (H. sapiens) Obtained from colleagues for protein 
quantification 
N/A 
A375 (H. sapiens) Obtained from colleagues for protein 
quantification 
N/A 
Patient-derived EPN cell lines (H. 
sapiens) 
Obtained from collaborator N/A 
Pulmonary adenocarcinoma (ADC) FFPE 
specimens (H. sapiens) 
Thoraxklinik at Heidelberg University 
(NCT; project: # 1746; # 2818) 
N/A 
Ependymoma patient fresh-frozen 
tissue (H. sapiens) 
N/A N/A 
Chemicals, Enzymes and other 
reagents  
  
1,2- Cyclohexanedione Sigma-Aldrich (Steinheim, Germany) Ref: C101400; Lot: STBF6948V 
100 x glutamine stock solution 
Life Technologies (Darmstadt, 
Germany) 
25030081 
2-Chloroacetamide (CAA) Sigma-Aldrich (Steinheim, Germany) 22790; Lot: BCBN8771V 
4x Laemmli Buffer 
Bio-Rad Laboratories GmbH 
(Feldkirchen, Germany) 
Ref: 1610747; Lot: 64261673 
6x DNA loading dye 
Thermo Scientific (Schwerte, 
Germany) 
Ref: R0611; Lot: 00652028 
Acetic acid glacial Biosolve Chemicals (Dieuze, France) 000107413185; Lot: 1061651 
Acetic acid glacial Fisher Scientific (Schwerte, Germany) UN2789; Lot: 1679445 
Acetonitrile (ACN) Biosolve Chemicals (Dieuze, France) 0001204101BS; Lot: 1274241 
Agarose Sigma-Aldrich (Steinheim, Germany) Ref: A9539; Lot: SLBT5972 
Ammonium bicarbonate (ABC) Fluka Analytical (Munich, Germany) Ref: 40867; Lot: I1620 
Ammonium formate Sigma-Aldrich (Steinheim, Germany) 
Ref: 70221-25G, Lot: 
BCBV1667 
Ammonium formate Biosolve Chemicals (Dieuze, France) 
Ref: 0001904153BS; Lot: 
1323041 
Ammonium hydroxide solution Fluka Analytical (Munich, Germany) 
Ref: 44273-100ML-F, Lot: 
BCBQ0888V 
Aniline Sigma-Aldrich (Steinheim, Germany) Ref: 242284; Lot: STBH5612 
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Benzonase Merck (Darmstadt, Germany) 71206-3; Lot: 3271105 
Bovine Serium Albumin (BSA) Fisher Scientific (Schwerte, Germany) BP9702; Lot: 190211-0662 
cOmplete, EDTA-free Protease Inhibitor 
Cocktail 
Roche Diagnostics (Mannheim, 
Germany) 
40694200; Lot: 05056489001 
Dithiothreitol (DTT) Biomol GmbH (Hamburg, Germany) 04010.25; Lot: 4001 
Dulbecco’s Modified Eagle Medium 
(DMEM) with high glucose and no 
glutamine 
Life Technologies (Darmstadt, 
Germany) 
11960085 
E. coli standard 
Bio-Rad Laboratories GmbH 
(Feldkirchen, Germany) 
1632110 
Ethanol (EtOH) Merck (Darmstadt, Germany) 34852 
Ethanol (EtOH) absolute 
VWR International GmbH (Darmstadt, 
Germany) 
20821.310; Lot: 18K144019 
Ethylenediaminetetraacetic acid (EDTA) Sigma-Aldrich (Steinheim, Germany) Ref: E9884; Lot: BCBZ8264 
EZ-Link Alkoxyamine-PEG4-Biotin 
Thermo Scientific (Schwerte, 
Germany) 
Ref: 26137 
Fetal Bovine Serum (FBS) 
Life Technologies (Darmstadt, 
Germany) 
10270106 
Formaldehyde solution (37%) Merck (Darmstadt, Germany) K46701403519; 1.04003.1000 
Formaldehyde solution (w/v) (16%) 
Methanol-free 
Thermo Scientific (Schwerte, 
Germany) 
Ref: 28908; Lot: TL2688131 
Formic acid (FA) Biosolve Chemicals (Dieuze, France) 0006914143BS; Lot: 1297891 
Gene Ruler 1kb DNA Ladder 
Thermo Scientific (Schwerte, 
Germany) 
Ref: SM1331; Lot: 00663462 
GeneRuler 100 bp Plus DNA Ladder 
Thermo Scientific (Schwerte, 
Germany) 
Ref: SN0321; Lot: 00303113 
GlutaMAX HEPES supplement 
Thermo Fisher Scientific 
(Braunschweig, Germany) 
10564011 
High Capacity Neutravidin Agarose 
Resin 
Thermo Scientific (Schwerte, 
Germany) 
Ref: 29204; Lot: TE269779 
Hydrochloric acid (37%) Merck (Darmstadt, Germany) K51884217943; 1.00317.1011 
LCMS-grade water Biosolve Chemicals (Dieuze, France) 00232141B1BS 
MagReSyn Amine Beads 
ReSyn Biosciences (Edenvale, South 
Africa) 
NA 
MagReSyn HILIC Beads 
ReSyn Biosciences (Edenvale, South 
Africa) 
NA  
Methanol (MeOH) Biosolve Chemicals (Dieuze, France) 0013684101BS; Lot: 1277161 
Paramagnetic beads for SP3 (Sera-Mag 
Speed Beads A and B) 
Fisher Scientific (Schwerte, Germany) 
24152105050250 & 
44152105050250 
Penicillin-Streptomycin (P&S) mix 
Life Technologies (Darmstadt, 
Germany) 
15140122 
Phosphate buffered saline (PBS) 
Life Technologies (Darmstadt, 
Germany) 
70011051 
Pierce HeLa standard 
Thermo Fisher Scientific 
(Braunschweig, Germany) 
88328 
Pierce LTQ Velos ESI Positive Ion 
Calibration Solution 
Thermo Scientific (Schwerte, 
Germany) 
Ref: 88323; Lot: UE283806 
Precision Plus Protein Dual Color 
Standard 
Bio-Rad Laboratories GmbH 
(Feldkirchen, Germany) 
Ref: 61-0374; Lot: 004030A 
Precision Plus Protein standard 
Bio-Rad Laboratories GmbH 
(Feldkirchen, Germany) 
161-0374 
Protease inhibitor cocktail (PIC) Sigma-Aldrich (Steinheim, Germany) 5056489001 
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ProteaseMax Surfactant, Trypsin 
Enhancer 
Promega (Madison, WI, USA) Ref: V2072; Lot: 000340968 
Proteinase K 
Thermo Scientific (Schwerte, 
Germany) 
Ref: EO0491, Lot: 00521266 
RapiGest SF Surfactant Waters Corporation (Milford, USA) Ref:186001861; Lot: 190231 
Sequencing grade modified trypsin Promega (Madison, WI, USA) V5111; Lot: 0000379610 
Silver nitrate Sigma-Aldrich (Steinheim, Germany) S8157; Lot: MKBZ5510V 
Sodium carbonate Sigma-Aldrich (Steinheim, Germany) Ref: S7795; Lot: BCBT4969 
Sodium Chloride Sigma-Aldrich (Steinheim, Germany) Ref: S1679; Lot: SLBN3273V 
Sodium Cyanoborohybride Sigma-Aldrich (Steinheim, Germany) Ref: 156159; Lot: SHBH1335V 
Sodium meta-Periodate 
Thermo Scientific (Schwerte, 
Germany) 
Ref: 20504, Lot: TI273898 
Sodium pyruvate 
Thermo Fisher Scientific 
(Braunschweig, Germany) 
11360070 
Sodium thiosulfate anhydrous Merck (Darmstadt, Germany) K48623312707; 1.06512.0250 
Sodium-dodecylsulfate (SDS) Applichem (Darmstadt, Germany) A0675 
Sodium-dodecylsulfate (SDS) 20% 
Bio-Rad Laboratories GmbH 
(Feldkirchen, Germany) 
Ref: 1610418; Lot: 64245485 
SYBR Safe DNA Gel Stain Invitrogen (Carlsbad, USA) Ref: S33102; Lot: 2053914 
TAE buffer (50 mM EDTA, 2 M Tris, 1 M 
glacial acetic acid) 
Self-made (chemicals listed 
separately) 
  
Tartrazine Sigma-Aldrich (Steinheim, Germany) T0388; Lot: MKCB1542V 
Tissue Lysis Buffer Covaris, Inc. (Woburn, USA) Lot: R001595 
Triethylammonium bicarbonate Sigma-Aldrich (Steinheim, Germany) T7408; Lot: BCBX6381 
Trifluoroacetic acid (TFA) Biosolve Chemicals (Dieuze, France) 0020234131BS; Lot: 1273961 
Tris(2-carboxyethyl)phosphine (TCEP) Sigma-Aldrich (Steinheim, Germany) C4706 
Triton X-100 Sigma-Aldrich (Steinheim, Germany) 
Ref: T8787-250ML, Lot: 
SLBW7103 
Trypsin/Lys-C Mix, Mass Spec grade Promega (Madison, WI, USA) V5073; Lot: 0000351191 
Trypsin-EDTA (0.25%) 
Life Technologies (Darmstadt, 
Germany) 
25200056 
TWEEN20 Sigma-Aldrich (Steinheim, Germany) 
Ref: P9416-100ML, Lot: 
SLBS9921 
UltraPure Tris Invitrogen (Carlsbad, USA) Ref: 15504-020; Lot:8309093 
Urea 
Bio-Rad Laboratories GmbH 
(Feldkirchen, Germany) 
161-0731 
Software    
Limma moderated t-statistics (R 
package version 3.36.3) 
https://support.bioconductor.org/p/6
124/ 
 
MaxQuant (version 1.5.1.2) https://www.maxquant.org/  
MOFA 
https://rdrr.io/bioc/MOFA/man/MOF
A.html 
 
Perseus (version 1.6.1.3) https://maxquant.net/perseus/  
R (version 3.5.1) https://www.r-project.org/  
R package fgsea (version 1.6.0 
Sergushichev, A. A. An algorithm for 
fast pre-ranked gene set enrichment 
analysis using cumulative statistic 
calculation. bioRxiv 60012 (2016). 
doi:10.1101/060012 
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REACTOME pathway database Gene 
sets using ReactomePA R package 
(version 1.24.0) 
Yu, G. & He, Q. Y. ReactomePA: An 
R/Bioconductor package for reactome 
pathway analysis and visualization. 
Mol. Biosyst. 12, 477–479 (2016). 
 
t-SNE analyses were performed using R 
package tsne (version 0.1-3) 
van der Maaten, Laurens, Hinton E., G. 
Visualizing Data using t-SNE. J. Mach. 
Learn. Res. 164, 10 (2008). 
 
vworks automation control software 
https://www.agilent.com/en/product
s/software-informatics/automation-
solutions/vworks-automation-
control-software 
 
Instrumentation/ Equipment   
1 mL tissue dounce homogenizer Wheaton (DWK Life Science Inc.) N/A 
-80°C Freezer 
Eppendorf - New Brunswick (Edison, 
USA) 
U725-G Innova 
Agarose-Gel running chamber 
Biostep GmbH (Burkhardtsdorf, 
Germany) 
GH140318005 
Aspiration System Integra Bioscience GmbH Integra Vacusafe 
Automated Cell Counter 
Bio-Rad Laboratories GmbH 
(Feldkirchen, Germany) 
TC20 
Bioruptor Pico Diagenode SA (Seraing, Belgium) SN:P-152703 
Branson Digital Sonifier Branson Ultrasonic Corporation (USA) NA 
Bravo liquid handling system 
Agilent Technologies (Santa Clara, 
USA) 
https://www.agilent.com/en/
products/automated-liquid-
handling/automated-liquid-
handling-platforms/bravo-
automated-liquid-handling-
platform 
Cell Culture Centrifuge 
Thermo Scientific (Schwerte, 
Germany) 
Heraeus MegaFuge 40 
Cell Culture Laminar Flow Hood 
Thermo Scientific (Schwerte, 
Germany) 
MaxiSafe 2020 
Centrifuge Eppendorf (Hamburg, Germany) Centrifuge 5424 
Centrifuge 5424 Rotor Eppendorf (Hamburg, Germany) F-45-32-5-PCR 
Centrifuge 5424 Rotor Eppendorf (Hamburg, Germany) FA-45-24-11 (Eppi’s) 
Centrifuge 5430R Rotor Eppendorf (Hamburg, Germany) FA-45-48-11 (Eppi’s) 
Centrifuge 5430R Rotor Eppendorf (Hamburg, Germany) A-2-MTP (Plates) 
CO2 Incubator 
Thermo Scientific (Schwerte, 
Germany) 
HeraCell Vios 160i 
Cooling Centrifuge Eppendorf (Hamburg, Germany) Centrifuge 5430R 
Covaris Cap Strip Seal holder Covaris, Inc. (Woburn, USA) 500608 (Strip Caps) 
Covaris Foil Seal holder Covaris, Inc. (Woburn, USA) 500608 (Foil) 
Custom-made SP3 magnet EMBL, Heidelberg N/A 
DynaMag-2 magnetic stand 
Life Technologies (Darmstadt, 
Germany) 
N/A 
Easy NanoLC 1200 
Thermo Fisher Scientific 
(Braunschweig, Germany) 
NA 
Heraeus MegaFuge 40 Rotor 
Thermo Scientific (Schwerte, 
Germany) 
75003180 
High pH HPLC System (Infinity 1260) 
Agilent Technologies (Santa Clara, 
USA) 
1260/1290 Infinity 
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HotSleeve 25 cm Smart Column Heater 
Analytical Sales & Services, Inc. 
(Flanders, USA) 
Ref: HSI-25L 
Ice machine 
Ziegra Eismaschinen GmbH 
(Isernhagen, Germany) 
SN:151759 
Incubator 
Thermo Scientific (Schwerte, 
Germany) 
HeraTherm 
LE220R-plus Focused-ultrasonicator Covaris, Inc. (Woburn, USA) 500578 
MAGNUM FLX enhanced universal 
magnet 
ALPAQUA (Beverly, USA) 
https://www.alpaqua.com/Pr
oducts/Magnet-
Plates/Magnum-FLX 
Mastercylcer Eppendorf (Hamburg, Germany) Epgradient S 
Microscale 
Sartorius Lab Instruments (Göttingen, 
German) 
MSA125P-000-DA 
Minicentrifuge neoLab (Heidelberg, Germany) 3-1810 
MiniChiller (Picoruptor) 
Diagenode SA / Huber (Seraing, 
Belgium) 
NA 
MonoSleeve Column Heater 
Analytical Sales & Services, Inc. 
(Flanders, USA) 
NA 
Multi-image Light Cabinet 
Alpha Innotech Corporation (San 
Leandrio, USA) 
NA 
Multi-Rotator Grant-bio Instruments (Royston, UK) PTR-35 
Nanodrop 1000 Spectrophotometer 
Thermo Scientific (Schwerte, 
Germany) 
N/A 
NanoQuant Plate Reader Tecan (Männedorf, Switzerland) Infinite M200pro 
Orbital shaking station 
Agilent Technologies (Santa Clara, 
USA) 
Variomag Teleshake 
PCR cycler with lid heating (CHB-T2-D 
ThermoQ) 
Hangzhou BIOER Technologies 
(Binjiang, China) 
CHB-T2-D ThermoQ 
Polymax 2040 Platform shaker 
Heidolph Instruments GmbH & Co. KG 
(Schwabach, Germany) 
Polymax 2040 
Power Supply 
Bio-Rad Laboratories GmbH 
(Feldkirchen, Germany) 
PowerPac Universal 
Pressure Bomb 
Nanobaume-Western fluids 
(Wildomar, USA) 
N/A 
Primovert Microscope 
Carl Zeiss Microscopy GmbH 
(Oberkochen, Germany= 
N/A 
Probe Sonicator horn Branson Ultrasonic Corporation (USA) 102C, SN: OBU15091229G 
Q-Exactive HF Orbitrap mass 
spectrometer 
Thermo Fisher Scientific 
(Braunschweig, Germany) 
NA 
Scale 
Sartorius Lab Instruments (Göttingen, 
German) 
MSE2202S-000-D0 
SDS-Gel running chamber 
Bio-Rad Laboratories GmbH 
(Feldkirchen, Germany) 
Mini-Protean Tetra System 
Solid-state cooling systems, Thermo 
Cube 
Covaris, Inc. (Woburn, USA) SN005576 
SPD111V Rotor 
Thermo Scientific (Schwerte, 
Germany) 
RH40-11 (Eppi’s) 
SPD111V Rotor 
Thermo Scientific (Schwerte, 
Germany) 
(Plates) 
SpeedVac Concentrator 
Thermo Scientific (Schwerte, 
Germany) 
Savant SPD111V 
Stemi 305 Microscope 
Carl Zeiss Microscopy GmbH 
(Oberkochen, Germany= 
SN: 3943000950 
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ThermoMixer C Eppendorf (Hamburg, Germany) 5382000015 
Ultrapure Water System 
Thermo Scientific (Schwerte, 
Germany) 
SN:41801405 
Ultrasonic Cleaner 
VWR International GmbH (Darmstadt, 
Germany) 
USC-T 
Universal Vacuum System 
Thermo Scientific (Schwerte, 
Germany) 
UVS400A 
Vacuum manifold Waters Corporation (Milford, USA) S/N 2327 
Vortex Scientific Industries (Bohemia, USA) Vortex-Genie 2 
Water bath  
Thermo Scientific (Schwerte, 
Germany) 
SWB25 
WCS 2.0 Water Pump Covaris, Inc. (Woburn, USA) SN005516 
Kits   
Pierce BCA Protein assay Thermo Fisher (Karlsruhe, Germany) Ref: 23225; Lot: SL258365 
Pierce Quantitative Colorimetric 
Peptide assay 
Thermo Fisher (Karlsruhe, Germany) Ref: 23275; Lot: TK273137B 
Pierce Albumin Depletion Kit Thermo Fisher (Karlsruhe, Germany) Ref: 85160;Lot: TH269851 
Consumption material   
10 μL tips Gilson (Limburg, Germany) Ref: F171100 
1000 mL tips Neptune Scientific (San Diego, USA) Ref: BT1250 
200 μL tips Gilson (Limburg, Germany) Ref: F171300 
250 microliter tips 
Agilent Technologies (Santa Clara, 
USA) 
19477-002 
8-row reservoir 32 mL/row 
Agilent Technologies (Santa Clara, 
USA) 
201260-100 
96 AFA-TUBE TPX Plate Covaris, Inc. (Woburn, USA) 520272 
96-well SuperPlates, skirted 
Thermo Scientific (Schwerte, 
Germany) 
AB-2800 
Acclaim PepMap C18, 5 μm, 100 Å, 100 
μm x 2 cm)  
Thermo Fisher Scientific 
(Braunschweig, Germany) 
164564-CMD 
Acclaim PepMap RSLC C18, 2 μm, 100 Å, 
75 μm x 50 cm 
Thermo Fisher Scientific 
(Braunschweig, Germany) 
11342103 
AFA-tube TPX Strip Caps Covaris, Inc. (Woburn, USA) 500639 
BioPureSPE Midi 96-well plate Proto 
300 C18 
The Nest Group, Inc. (Southborough, 
USA) 
Part #: HNS S18V-M; Lot: 
BN1176-2E697 
Drain Caps Porvair Sciences Ltd. (Wrexham, UK) ML42115C M5 
Drain Caps Fisherbrand (Schwerte, Germany) 219005; Lot: 030961 
Gemini 3 μm C18 110 Å, LC Column 100 
x 1 mm 
Phenomenex (Aschaffenburg, 
Germany) 
SN: H15-233964 
HyperSep C18 unendcapped 96-well 
plate 
Thermo Scientific (Schwerte, 
Germany) 
60300-425, Lot: 517021-BE 
MicroLute Combinatorial 96-deep well 
plate 
Porvair Sciences Ltd. (Wrexham, UK) Lot: 031043 
Micro-pillar array columns (μPAC) 50 
cm 
Pharmafluidics (Ghent, Belgium) N/A 
Microplate 96-well (e.g., BCA) 
Greiner Bio-one GmbH 
(Frickenhausen, Germany) 
Ref: 655101 
Microplate 96-well conical bottom 
(High pH) 
Thermo Scientific (Schwerte, 
Germany) 
Ref: 249946; Lot: 1253565 
Millex-GS 0.22 μm filter Merck (Darmstadt, Germany) SLGS033SB 
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Mini-Protean TGX Gels (10-well comb) 
Bio-Rad Laboratories GmbH 
(Feldkirchen, Germany) 
Ref: 456-1084; Lot: L006936A 
Mini-Protean TGX Gels (15-well comb) 
Bio-Rad Laboratories GmbH 
(Feldkirchen, Germany) 
Ref: 456-1086; Lot: L006940A 
nanoEase MZ Peptide BEH C18 130 Å, 
1.7 μm, 75 μm x 250 mm 
Waters Corporation (Milford, USA) Ref: 186008795 
Oasis Prime HLB μElution Plate Waters Corporation (Milford, USA) 
Part #: 186008052; Lot: 
010737089A 
oneTUBE-10 AFA Strip Covaris, Inc. (Woburn, USA) 520225 
PCR Foil Seal 4titude Ltd. (Berlin, Germany) 4ti-0550 
PCR-8 stripes Ratiolab GmbH (Dreieich, Germany) 
Ref: 8610040; Lot: 8610040-
463668 
PicoTip Emitter New Objective, Inc. (Woburn, USA) FS360-20-10-D-20 
Reprosil-Pur Basic C18 for analytical 
columns 
Dr. Maisch GmbH (Ammerbuch, 
Germany) 
NA 
Sealing Mats 
Thermo Scientific (Schwerte, 
Germany) 
AB-0675 
Spin-X 0.45 μm filter 
Corning Incorporated (Salt Lake City, 
USA) 
Lot: 17418000 
X-Pierce film Sigma-Aldrich (Steinheim, Germany) Z721646-50EA 
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3. Experimental Methods 
3.1. Mass spectrometry methods 
The following mass spectrometry methods have been used throughout the study. However, 
several parameters and instrumental settings were evaluated and modified during this 
project to achieve optimal performance. Here, most method details are described while 
varying parameters between experiments are specified within individual paragraphs, if 
applicable: 
3.1.1. Liquid chromatography column setup 
Peptides were separated using an Easy NanoLC 1200 fitted with a two-column setup up 
comprised of a trap column and an analytical column. While the trapping column (Acclaim 
PepMap C18, 5 μm, 100 Å, 100 μm x 2 cm) (Thermo Fisher Scientific) remained mostly 
constant over time, several analytical columns (Figure 4E) were used within this work: 
initially Acclaim PepMap RSLC C18, 2 μm, 100 Å, 75 μm x 50 cm (Thermo Fisher Scientific) 
was used. Subsequently, we used self-packed analytical columns with Reprosil-Pur Basic 
C18, 1.9 μm, 100 Å, 75 μm x 40 cm material, which was packed into fused silica with an 
uncoated Pico-Tip Emitter with a 10 μm tip (New Objective) using a pressure bomb 
(Nanobaum). Here, the spray voltage was set to 2.5 kV to compensate for electrification at 
the T-piece connection between the trap column, the waste line, and the analytical column. 
A 50 cm micro pillar-array column (μPAC, Pharmafluidics) was used in a single-column setup 
at flow rates between 300 nL/min and 750 nL/min. Finally, we achieved the best 
performance using a nanoEase MZ Peptide BEH C18 Column, 130 Å, 1.7 µm, 75 µm x 250 
mm (Waters Corporation). The outlet of the analytical column was directly coupled to an 
Orbitrap Fusion (Thermo Fisher Scientific) or an Orbitrap Q-Exactive HF (Thermo Fisher 
Scientific) mass spectrometer via a Pico-Tip Emitter 360 μm OD x 20 μm ID; 10 μm tip (New 
Objective) and a spray voltage of 2 kV. 
3.1.2. Liquid chromatography gradients and data-dependent acquisition (DDA) 
The samples were loaded with a constant flow of solvent A at a maximum pressure of 800 
bar, onto the trapping column. The maximum pressure was set to 600 bar for the nanoEase 
MZ Peptide BEH C18 columns. (Waters Corporation). The μPAC column was limited to a 
maximal pressure of 200 bar. Solvent A was ddH2O, 0.1% (v/v) formic acid (FA) and solvent 
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B was 80% acetonitrile (ACN) in ddH2O, 0.1% (v/v) FA. Peptides were eluted via the 
analytical column at a constant flow of 300 nL/minute, at 55°C (between 300 nL/min and 
750 nL/min for the μPAC). The ion transfer capillary temperature was set to 275°C. 
Throughout this study, several different gradient lengths were used, in which all settings 
remained as described for the one hour and 10 minutes method unless otherwise stated in 
the corresponding paragraphs: 
1 hour 10 minutes: During elution, the percentage of solvent B was increased linearly from 
3 to 8% in 4 minutes, then from 8% to 10% in 2 minutes, then from 10% to 32% in 17 
minutes, and then from 32% to 50% in a further 3 minutes. Finally, the gradient was finished 
with 8 minutes at 100% solvent B, followed by 11 minutes at 96% solvent A. Full scan MS 
spectra with a mass range of m/z 350 to 1500 were acquired in the Orbitrap with a 
resolution of 60.000 full width half maximum (FWHM). The ion filling time was set to a 
maximum of 32 ms with an automatic gain control target of 3 x 106 ions. The top 2 or 20 
most abundant ions per full scan were selected for a tandem MS (MS2) acquisition. For MS2 
scans, the resolution was set to 15.000 FWHM with automatic gain control of 1 x 105 ions 
and a maximum fill time of 50 ms. The isolation window was set to m/z 2.0, with a fixed 
first mass of m/z 110, and stepped collision energy (n)ce of 26. The intensity threshold was 
set to 2 x 104 and isotopes, unassigned charges, charge 1, charge 5 to 8, and >8 were 
excluded. The dynamic exclusion list was set with a maximum retention period of 15 
seconds. 
1 hour 25 minutes: During elution, the percentage of solvent B was increased linearly from 
4 to 5% in 1 minute, then from 5% to 27% in 30 minutes, and then from 27% to 44% in a 
further 5 minutes. Finally, the gradient was finished with 10.1 minutes at 95% solvent B, 
followed by 13.5 minutes at 96% solvent A. Full scan MS spectra with a mass range of m/z 
300 to 1500 were acquired. The ion filling time was set to a maximum of 50 ms with an 
automatic gain control target of 3 x 106 ions. The top 10 most abundant ions per full scan 
were selected for an MS2 acquisition. For MS2 scans, the resolution was set to 15.000 
FWHM with automatic gain control of 5 x 104 ions and a maximum fill time of 50 ms. The 
isolation window was set to m/z 1.6, with a fixed first mass of m/z 120, and stepped collision 
energy (n)ce of 28. The intensity threshold was set to 1 x 105 and isotopes, unassigned 
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charges, and charges of 1 and >8 were excluded. The dynamic exclusion list was set with a 
maximum retention period of 60 seconds. 
2-hours: During the elution, the percentage of solvent B was increased linearly from 3 to 
8% in 4 minutes, then from 8% to 10% in 2 minutes, then from 10% to 32% in a further 68 
minutes, and then to 50% B in 12 minutes. Finally, the gradient was finished with 8 minutes 
at 100% solvent B, followed by 11 minutes 97% solvent A. The dynamic exclusion was set 
to 25 seconds. 
3-hours: During the elution, the percentage of solvent B was increased linearly from 3 to 
8% in 4 minutes, then from 8% to 10% in 2 minutes, then from 10% to 32% in a further 118 
minutes, and then to 50% B in 22 minutes. Finally, the gradient was finished with 8 minutes 
at 100% solvent B, followed by 11 minutes 97% solvent A. The dynamic exclusion was set 
to 35 seconds. 
4-hours: During the elution, the percentage of solvent B was increased linearly from 3 to 
8% in 4 minutes, then from 8% to 10% in 2 minutes, then from 10% to 32% in a further 175 
minutes, and then to 50% B in 25 minutes. Finally, the gradient was finished with 8 minutes 
at 100% solvent B, followed by 11 minutes 97% solvent A. The dynamic exclusion was set 
to 80 seconds. 
3.1.3. Proteomics data processing 
Raw files were processed using MaxQuant (version 1.5.1.2)287,288. The search was 
performed against the human Uniprot database (20170801_Uniprot_homo-
sapiens_canonical_reviewed; 20.214 entries) using the Andromeda search engine289 with 
the following search criteria: enzyme was set to trypsin/P with up to 2 missed cleavages. 
Carbamidomethylation (C) and oxidation (M) / acetylation (protein N-term) were selected 
as a fixed and variable modifications, respectively. First and second search peptide 
tolerances were set to 20 and 4.5 ppm, respectively. Protein quantification was performed 
using the label-free quantification (LFQ) algorithm of MaxQuant. LFQ intensities were 
calculated separately for different parameter groups using a minimum ratio count of 1, and 
the minimum and the average number of neighbors of 3 and 6, respectively. MS2 spectra 
were not required for the LFQ comparison. On top, intensity-based absolute quantification 
(iBAQ) intensities were calculated with a log fit enabled. Identification transfer between 
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runs via the matching between runs algorithm was allowed with a match time window of 
0.3 minutes. Peptide and protein hits were filtered at a false discovery rate of 1%, with a 
minimum peptide length of 7 amino acids. The reversed sequences of the target database 
were used as a decoy database. All remaining settings were set as default in MaxQuant. 
LFQ values were extracted from the protein groups table and log2-transformed for further 
analysis. No additional normalization steps were performed, as the resulting LFQ intensities 
are normalized by the MaxLFQ procedure287. Proteins that were only identified by a 
modification site, the contaminants, as well as the reversed sequences, were removed from 
the data set. All consecutive steps were performed in Microsoft Excel, Perseus (version 
1.6.1.3)290, and the software environment R (version 3.5.1). 
3.2. Methods taken from joint publications 
The following methods have been taken partially or in their entirety from joint publications, 
as listed below. Every section that was not written entirely by me is indicated with 
quotation marks: 
 
Hughes, C. S., Moggridge, S., Mueller, Torsten, Sorensen, P. H., Morin, G. B., Krijgsveld, J. 
(2019). „Single-pot, solid-phase-enhanced sample preparation for proteomics 
experiments.” Nature Protocols 14: 68-85. 
 
Mueller, Torsten, Kalxdorf, M., Longuespeé, R., Kazdal, D., Stenzinger, A., Krijgsveld, J. 
(2020). “Automated sample preparation with SP3 for low-input clinical proteomics”. 
Molecular Systems Biology 16(1): e9111. 
 
Hübner, J. M., Mueller, Torsten, Papageorgiou, D. N., Mauermann, M., Krijgsveld, J., 
Russell, R. B., Ellison, D. W., Pfister, S. M., Pajtler, K. W., Kool, M. (2019). „EZHIP/CXorf67 
mimics K27M mutated oncohistones and functions as an intrinsic inhibitor of PRC2 
function in aggressive posterior fossa ependymoma.” Neuro Oncology 21(7): 878-889. 
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3.2.1. Methods taken from “Single-pot, solid-phase-enhanced sample preparation for 
proteomics experiments.” 
The evaluation and optimization of the original single-pot, solid-phase-enhance sample 
preparation (SP3) method (Hughes et al. 2014)149 have led to an improved protocol version 
as comprehensively described for different protein input and working volume scenarios in 
Hughes et al., 2019291. In this study, the majority of applications were carried out with 10 
μg or less in a working volume smaller than 50 μL. 
3.2.1.1. Single-pot, solid-phase-enhanced sample preparation (SP3) bead preparation 
Magnetic beads were prepared by combining 20 μL of both, Sera-Mag Speed Beads A and 
B (Fisher Scientific, Germany), and washing them one time with 160 μL ddH2O and two 
times with 200 μL ddH2O, and re-suspending them in 20 μL ddH2O for a final working 
concentration of 100 μg/μL. The washing steps were carried out using an in-house designed 
and built magnetic rack for two PCR 8-stripes or in the case of larger volumes in a DynaMag 
2 magnet rack (Life technologies). For higher numbers of samples, the preparation of 
magnetic beads was carried out multiple times to provide at least 2 μL per sample. The pre-
washed magnetic beads were combined to a single-tube and vortexed before proceeding 
with the protein clean-up protocol. 
3.2.1.2. SP3 protein clean-up 
In brief, 10 μg or less of extracted protein were added to PCR tubes in a total volume of 10 
μL lysis buffer (1% sodium dodecylsulfate (SDS), 100 mM ammonium bicarbonate (ABC), 
pH 8.5). 2 μL of pre-washed magnetic beads, as well as 12 μL 100% ACN, were added to 
each sample to reach a final concentration of 50% ACN. Protein binding to the beads was 
allowed for 18 minutes, followed by 2 minutes incubation on a magnetic rack to immobilize 
beads. The supernatant was removed, and beads were washed two times, with 200 μL of 
80% ethanol (EtOH) and one time with 180 μL of 100% ACN. Beads were resuspended in 15 
μL of 100 mM ABC and sonicated for 5 minutes in a water bath. Finally, sequencing-grade 
trypsin was added in an enzyme:protein ratio of 1:20 (e.g., 5 μL of 0.1 μg/μL trypsin in 
ddH2O), and beads were pushed from the tube walls into the solution to ensure efficient 
digestion. Upon overnight or 4 hours incubation at 37°C and 1000 rpm in a table-top 
thermomixer, samples were acidified by adding 5 μL of 5% trifluoracetic acid (TFA) and brief 
vortexing. Beads were immobilized on a magnetic rack, and peptides were recovered by 
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transferring the supernatant to new PCR tubes. If necessary, samples were diluted by 
adding 0.1% FA to reach a suitable peptide concentration of approximately 1 μg/10 μL. At 
lower peptide concentrations, the entire sample volume was injected. MS injection-ready 
samples were stored at -20 C. 
3.2.1.3. SP3 peptide clean-up 
In brief, 10 μL of pre-washed beads and 100% ACN were added to each sample to a final 
concentration of 95% ACN. Peptides were allowed to bind to the beads for 18 minutes in a 
thermocycler at 750 rpm, followed by 2 minutes incubation on a magnetic rack (Life 
technologies, DynaMag 2) to immobilize the beads. The supernatant was removed, and 
beads were washed 2x with 800 μL of 100% ACN. Beads were air-dried for 2 minutes at 
37°C, resuspended in 17 μL of 0.1% FA, and sonicated in a VWR Ultrasonic Cleaner USC-T 
water bath for 5 minutes. Finally, samples were vortexed, quick-centrifuged, and placed 
into a magnetic rack to allow a clean transfer of the peptide-containing supernatant to a 
new reaction tube. MS injection-ready samples were stored at -20°C. 
3.2.2. Methods taken from “Automated sample preparation with SP3 for low-input 
clinical proteomics.” 
3.2.2.1. Cell culture of HeLa cells 
HeLa cells were cultured in regular DMEM medium (Gibco, Life Technologies) 
supplemented with 10% fetal bovine serum (Gibco, Life Technologies), 1% of a 100 x 
penicillin and streptomycin mix (Gibco, Life Technologies), and 1% of 100 x glutamine stock 
solution (Gibco, Life Technologies). Upon establishment of a stable culture, cells were 
harvested using trypsin and counted using Bio-Rad TC20 automated cell counter. Cell 
pellets were stored at -80°C until further use. 
For showing the use of the Bravo application starting from limited, small numbers of cells, 
HeLa cells were harvested, counted, resuspended in lysis buffer (1% SDS, 100 mM ABC pH 
8.5), and directly transferred to a 96-well plate. The total volume for different numbers of 
cells was adjusted using lysis buffer (1% SDS, 100 mM ABC pH 8.5). The entire 96-well plate 
was sonicated in a water bath for 10 minutes, followed by Benzonase (~40 Units) enzymatic 
cleavage of DNA and RNA for 15 minutes at 37°C. Subsequently, the buffer was adapted to 
a final concentration of 1% SDS, 100 mM ABC, 10 mM tris(2-carboxyethyl)phosphine 
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(TCEP), and 40 mM chloroacetamide (CAA) including protease inhibitor cocktail (PIC) before 
incubation for 5 minutes at 95°C. The plate was allowed to cool to 23°C before it was 
transferred to the Bravo deck for the SP3 processing, as described in the “automated SP3 
protocol” section. 
3.2.2.2. HeLa protein standard preparation 
Cell pellets of ~11.9 million cells were resuspended in 1 mL of lysis buffer (1% SDS, 100 mM 
ABC pH 8.5, and 50 μL 25x PIC) and probe sonicated for 5 times 20 seconds at a frequency 
of 10% using a Branson Sonifier. Cell lysates were kept on ice in-between cycles to avoid 
overheating. DNA or RNA contaminants were cleaved using 250 Units of Benzonase for 15 
minutes at 37°C and 750 rpm. Subsequently, the buffer was adapted to a final 
concentration of 1% SDS, 100 mM ABC, 10 mM TCEP, and 40 mM CAA, including PIC, before 
incubation for 5 minutes at 95°C in a CHB-T2-D ThermoQ heating device (Hangzhou BIOER 
Technologies). Reduced and alkylated proteins were quantified using a bicinchoninic acid 
assay (BCA) assay and stored at -20°C until further use in manual and automated SP3 
processing. 
3.2.2.3. Pulmonary adenocarcinoma (ADC) sample collection 
All pulmonary ADC specimens used for this study were obtained from the Thoraxklinik at 
Heidelberg University and diagnosed according to the criteria of the 2015 WHO 
Classification of lung tumors at the Institute of Pathology at Heidelberg University206. Tissue 
procession to formalin-fixed and paraffin-embedded (FFPE) tissue sections was carried out 
by the tissue bank of the National Center for Tumor Diseases (NCT; project: # 1746; # 2818) 
in accordance with its ethical regulations approved by the local ethics committee. 
A multiregional sample set consisting of 2-4 samples of eight tumors was constructed as 
described previously292. In short, a formalin-fixed central section of each tumor was 
segmented into multiple 5 x 5 mm regions according to a Cartesian grid. Ink marks ensured 
the retention of the original orientation of each segment during sample processing. Tumor 
regions considered for analysis were selected in accordance with the tumor size (larger 
tumor corresponds to more regions), different histological growth patterns as well as 
sufficient tumor cell content (≥ 10%). An experienced pathologist determined the 
histological growth pattern with the predominant portion in each segment. For each tumor, 
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two to four different growth patterns were excised. Samples were analyzed in replicates 
using one 5 µm section after deparaffinization as input, respectively. For deparaffinization, 
the sections were incubated for 20 minutes at 80°C, followed by three times 8 minutes 
incubation in Xylol and EtOH, consecutively. Finally, the sections were incubated in ddH2O 
for 30 minutes before the tissue was scratched off and collected in a well. Replicates were 
excised as consecutive cuts of the same region having the highest possible similarity. 
3.2.2.4. Automated SP3 protocol (autoSP3) 
As a reference, the SP3 protocol was carried out manually, as described in the 
corresponding paragraph 4.2.1.2 (Hughes 2019)291. In the automated version of the SP3 
protocol, the Bravo system is programmed to process 96 samples simultaneously, carrying 
out all handling steps including reduction and alkylation of proteins, aliquoting of magnetic 
beads, protein clean-up by SP3, protein digestion, and peptide recovery. The core SP3 
protocol is available in combination with reduction and alkylation either as a single-step 
using a TCEP/ CAA mix for 5 minutes at 95°C (Figure 6D) or as a two-step protocol using, for 
example, dithiothreitol (DTT)/ CAA consecutively with 30 minutes incubation for each 
reaction at 60°C and 23°C, respectively (Figure 6D). A shortened version is available that 
consists of the core SP3 protocol while omitting on-deck reduction and alkylation (Figure 
6D), saving time due to slow heating of the heating block (altogether taking one hour for 
heating and cooling), instead performing this off-deck (taking 5 minutes and 30 seconds to 
reach working temperature and 5 minutes for incubation) in a PCR thermocycler (CHB-T2-
D ThermoQ, Hangzhou BIOER Technologies) prior to initiation of the automated protocol. 
In addition, the PCR thermocycler provides lid heating, which prevents any unwanted 
evaporation or variation in the sample volume. This latter protocol (Protocol C, Figure 6D) 
was used in the work presented here. Each protocol is designed for a starting sample 
volume of 10 μL, which can easily be varied in the protocol files to add respective amounts 
of organic solvent to reach higher than 50% and to remove the resulting volume after 
protein binding. Next, either protocol A, B, or C (Figure 6D) aliquot 5 μL of a suspension of 
washed magnetic beads to protein samples previously collected in a 96-well plate. Different 
to the manual protocol (bead working concentration 100 μg/μL), the suspension of washed 
beads is prepared to have a working concentration of 50 μg/μL to allow more robust 
pipetting. Next, the respective volume of 100% ACN (20 μL in A; 25 μL in B, 15 μL in C) is 
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added to each sample followed by 18 minutes incubation off the magnetic rack with cycles 
of agitation at 1500 rpm and 100 rpm for 30 seconds and 90 seconds, respectively. Upon 
binding of the proteins to the beads, the sample plate is incubated on the magnetic rack 
for further 5 minutes to allow magnetic trapping of beads inside each well. Here, the beads 
will form a ring at the wall of each well, slightly above the bottom. The removal of any 
supernatant in the protocol is performed using well-specific tips in two consecutive steps 
to ensure complete liquid removal. Next, beads are washed two times with 200 μL of 80% 
EtOH and one time with 171.5 μL of 100% ACN. Due to the limited 200 μL pipetting volume 
of the Bravo and the limited reagent space, the respective washing volumes of 80% EtOH 
and 100% ACN were added in 4 and 7 consecutive steps of 50 μL and 24.5 μL, respectively, 
with in-between shaking at 500 rpm or 250 rpm for 30 seconds. Upon removal of residual 
washing solvents, the beads are resuspended in 35 μL of 100 mM ABC and 5 μL of 0.05 μg/ 
μL pre-prepared trypsin in 50 mM acetic acid to avoid autolysis. Of note, in the dilution 
series experiments, the trypsin amount was reduced to avoid abundant peptide features 
resulting from its autolysis. In a final shaking step at 1500 rpm for 60 seconds, the trypsin 
solution is mixed with the sample, and the plate is transferred to the heating deck position 
for incubation at 37°C. Subsequently, the plate was manually sealed and transferred to a 
PCR cycler to avoid lid condensation during a 4-hour incubation at 37°C. Next, after 
completion of either protocol A, B, or C and exchange of used pipette tips, a short protocol 
is provided for peptide acidification and recovery of LC-MS injection-ready samples to a 
new 96-well plate (Figure 6D). Alternatively, as used in this study, peptide acidification and 
recovery can be performed manually. Therefore, each sample was acidified by adding 5 μL 
of 5% TFA solution, sonicated in a water bath for 5 minutes to swirl the settled beads, and 
incubated on a magnetic rack for further 2 minutes. Finally, the peptide-containing 
supernatant was recovered into a new 96-well plate without transferring the beads. If 
necessary, samples were either diluted or directly frozen at -20°C until MS acquisition. 
Optionally peptide quantification assays (colorimetric assay kit, Thermo Scientific) were 
carried out using the Bravo liquid handling system. 
3.2.2.5. Quantitative proteomics analysis of FFPE tissue 
For proteomic analysis, 5 μm FFPE tissue sections were collected in stripes of 8 PCR tubes, 
centrifuged at 15.000 x g for 10 minutes to ensure that FFPE slices are at the bottom of the 
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tube, and stored at 4°C until further processing. Next, each tissue section was carefully 
reconstituted in 20 μL lysis buffer (4% SDS, 100 mM ABC, pH 8.5), sonicated at 4°C for 25 
cycles of 30 seconds on and 30 seconds off in a Pico Bioruptor, and heated for one hour at 
95°C. Samples were spun down and subjected to a second round of sonication and heating. 
The Pico Bioruptor (Diagenode SA) was equipped with a house-made tube holder, which 
allows the simultaneous processing of 28 samples. Subsequently, PCR tubes were 
centrifuged at 15.000 x g for 3 minutes, and the buffer was adjusted to a final concentration 
of 1% SDS, 100 mM ABC, 10 mM TCEP, and 40 mM CAA, including PIC. Samples were heated 
for 5 minutes at 95°C to denature proteins and to reduce and alkylate cysteine residues. 
Cooled to RT and again centrifuged at 15.000 x g for 3 minutes, 10 μL of each sample was 
further processed by our automated SP3 sample clean-up procedure, as described above. 
Here, protein digestion was allowed for 16 hours overnight before stopping the reaction by 
acidification to 0.5% with TFA. The peptide-containing supernatant was recovered to a new 
96-well plate without transferring the beads. MS injection-ready samples were stored at -
20°C, and about 25% of each sample was later used for data acquisition. 
3.2.2.6. Proteomics data acquisition 
For HeLa standard measurements, samples were diluted with solvent A (0.1% FA in ddH2O) 
to enable the injection of 1 μg in 10 μL volume. Peptides were separated using the Easy 
NanoLC 1200 fitted with a trapping (Acclaim PepMap C18, 5 μm, 100 Å, 100 μm x 2 cm) and 
an analytical column (Acclaim PepMap RSLC C18, 2 μm, 100 Å, 75 μm x 50 cm). The outlet 
of the analytical column was coupled directly to a Q-Exactive HF Orbitrap mass 
spectrometer (Thermo Fisher Scientific). Data were acquired using the one hour 25 minutes 
method as described in chapter 3.1.2. 
For FFPE lung ADC measurements, about 25% of each sample was used for direct injection. 
Peptides were separated using the Easy NanoLC 1200 fitted with a trapping (Acclaim 
PepMap C18, 5 μm, 100 Å, 100 μm x 2 cm) and a self-packed analytical column (Reprosil-
Pur Basic C18, 1.9 μm, 100 Å, 75 μm x 40 cm). The outlet of the analytical column was 
coupled directly to a Q-Exactive HF Orbitrap (Thermo Fisher Scientific) mass spectrometer. 
Data were acquired using the 2-hours methods, as described in chapter 3.1.2. 
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3.2.2.7. Proteomics data processing 
The data processing was carried out as comprehensively described in paragraph 4.1.3. 
Additional analyses were performed as follows: the differential expression analysis of the 
ADC samples was performed using Limma moderated t-statistics (R package version 
3.36.3)293. Here, the technical replicates and the patient-dependent batch effect were 
taken into account within the applied model. Proteins with a Benjamini-Hochberg-adjusted 
p-value lower than 0.05 and an absolute log2-fold change higher than 1 were considered as 
significantly changing. The resulting lists of significantly regulated proteins were subjected 
to a gene ontology (GO)-term enrichment analyses using the STRING: functional protein 
association network database294. The gene set enrichment analyses (GSEA) were 
performed using R package fgsea295 (version 1.6.0) with a p-value ranking of proteins, gene 
sets defined by the REACTOME pathway database (R package ReactomePA version 
1.24.0)296, the minimum size of gene sets set to 15, the maximum size of gene sets set to 
500, and the number of permutations set to 10.000. The t-distributed stochastic neighbor 
embedding (t-SNE) analyses were performed using R package tsne297 (version 0.1-3) with a 
perplexity set to 2 and the number of iterations set to 5000. 
3.2.2.8. Intra-day and inter-day precision 
To test the precision of SP3 sample handling, we followed guidelines of the European 
Pharmacopoeia and the European Medicines Agency for the number of replicates 
necessary to validate our method298,299. Specifically, we validated automated SP3 by an 
intra-day and inter-day component by processing a total of six 96-well plates with 10 μg 
protein of a HeLa batch lysate in each well in the morning and the afternoon of three 
different days, over roughly one month, resulting in a total of 575 individual samples. Five 
randomly picked samples per plate (10 samples per day) were selected for direct LC-MS 
analysis on the day of sample generation and a second technical-repeat injection of all 30 
samples in a single batch acquisition. The number of samples per plate to be analyzed was 
chosen as a fair compromise to determine the precision of our sample processing with a 
reasonable amount of data acquisition time. The selected samples allowed the evaluation 
of the inter-day precision and intra-day precision while taking different processing times, 
plates, and buffers into account (robustness). The second technical injection in one batch 
allowed us to evaluate the influence of longitudinal MS performance. Lastly, for the 
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comparison of manual SP3 sixteen times, 10 μg protein of a HeLa batch lysate were 
processed manually at the bench. 
3.2.2.9. Sensitivity of autoSP3 
To evaluate the lower limit of processing capabilities of the Bravo SP3 setup, we generated 
starting material dilution series as follows: A) a dilution series of our standard HeLa protein 
stock, ranging from 10 μg to ~5 ng in 1:2 dilution steps (10 μg, 5 μg, 2.5 μg, 1.25 μg, ~625 
ng, ~312 ng, ~156 ng, ~78 ng, ~39 ng, ~19 ng, ~10 ng, and ~5 ng). The dilution series was 
generated and processed in four replicates on the same 96-well plate (12 concentrations 
and n=4). B) a dilution series starting from small numbers of counted cells that were directly 
transferred to a 96-well plate, ranging from 10.000 down to 10 cells. The dilution series was 
generated and processed in two plates à four replicate series (7 concentrations and n=8). 
Here, the European Pharmacopoeia recommends a minimum of three concentrations à 
three replicates298. In addition, two empty control injections were performed upfront of 
the data acquisition of each dilution series. The dilution series were measured in blank-
interspaced blocks from lowest to highest concentrated samples to avoid potential carry 
over between injections. 
3.2.2.10. Assessment of cross-contamination  
To assess potential cross-contamination between samples, we processed 24 wells of 10 μg 
standard HeLa protein stock interspaced with 24 empty controls. Seven peptide-containing 
samples and eleven empty controls were randomly selected for direct LC-MS analysis. The 
number of samples to be analyzed was chosen as a fair compromise to determine potential 
carry over between wells during our sample processing with a reasonable amount of data 
acquisition time. 
3.2.3. Methods taken from „EZHIP/CXorf67 mimics K27M mutated oncohistones and 
functions as an intrinsic inhibitor of PRC2 function in aggressive posterior fossa 
ependymoma.” 
3.2.3.1. Cell Culture of HEK293T cells 
“HEK293T cells were cultured in regular DMEM medium (Gibco, Life Technologies) 
supplemented with 10% fetal calf serum. The medium was exchanged every second day, 
and cells were split at least once per week.” 
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3.2.3.2. Production of Lentiviral particles and generation of stable cell lines 
“Lentiviral constructs were generated by replacing the Ngn2 gene of the FUW-TetO-Ngn2-
T2A-puromycin construct published by Zhang et al. with DNA sequences encoding for the 
CXorf67 full-length protein or CXorf67 truncates carrying a C-terminal FLAG-HA-tag. 
Lentiviruses were produced by co-transfecting lentiviral constructs with psPAX2 and 
pMD2.G into low-passage HEK293T cells using FugeneHD (Promega). The medium was 
replaced 24 hours after transfection. On the next day, lentivirus-containing supernatant 
was harvested and passed through a 0.45 µm filter before being directly added to the target 
cells. To allow induction of gene expression by administration of Doxycycline, cells were 
additionally co-transduced with a rtTA carrying lentivirus. 24 hours after infection, protein 
expression was induced by addition of 1 µg/mL of Doxycycline followed by selection with 
Puromycin. HEK293 cells were selected with 1 µg/mL of Puromycin. For continuous protein 
expression, Doxycycline was replenished every two to three days.” 
3.2.3.3. Co-Immunoprecipitation for mass spectrometry and western blot 
“For co-immunoprecipitation (Co-IP) followed by mass spectrometry (MS) analysis, cells 
were resuspended in lysis buffer (20 mM Tris-HCl pH 8, 200 mM NaCl, 1 mM EGTA, 1 mM 
ethylenediaminetetraacetic acid (EDTA), 1% Triton X-100), vortexed and incubated on ice 
for 30 minutes. Subsequently, cellular debris was pelleted by centrifugation and the 
supernatant was transferred to a new tube. The supernatant was then pre-cleared for one 
hour at 4°C using mouse IgG agarose beads. Afterwards, beads were pelleted by 
centrifugation and the supernatant was again transferred to a separate tube. The 
supernatant was then incubated with FLAG-M2 affinity gel overnight at 4°C. Mouse IgG 
agarose beads used for pre-clearing were washed twice with lysis buffer and then twice 
with PBS. Next, the beads were resuspended in 30 μL of elution buffer (50 mM NH4HCO3, 
15 mM DTT, 0.1% SDS) and boiled at 95°C for 5 minutes. Eluted proteins were saved for MS 
analysis to determine the protein background. The next day, proteins were eluted from the 
FLAG-M2 affinity gel using the same procedure as for the mouse IgG agarose beads 
followed by MS analysis. For Co-IP followed by western blot analysis, proteins were only 
eluted from the FLAG-M2 affinity gel using 40 μL of western blot elution buffer (10 μL of 4x 
NuPAGE™ LDS Sample Buffer, 4 μL of 10x NuPAGE™ Sample Reducing Agent and 26 μL of 
lysis buffer).” 
Experimental Methods 
45 
3.2.3.4. Nuclear extraction and western blot analysis 
“For the separation of nuclear and cytoplasmic fractions, cells were harvested, washed 
once with ice-cold PBS, and incubated in 2ml of swelling buffer (10 mM Tris-HCl pH 6.8, 5 
mM KCl, 1 mM MgCl2) on ice for 20 minutes. Next, cell membranes were ruptured using a 
douncer. Nuclei were spun down at 1000 x g for 10 minutes at 4°C, and the supernatant 
was saved as the cytoplasmic fraction. The nuclei were washed once with swelling buffer 
and pelleted again via centrifugation. Then, nuclei were resuspended in Laemmli buffer 
(62.5 mM Tris-HCl pH 6.8, 10% Glycerol, 3% SDS, 150 mM DTT, 250 Units Benzonase) and 
cooked at 95°C for 10 minutes. Finally, insoluble debris was removed by centrifugation, and 
the supernatant was saved as the nuclear fraction. 
Whole-cell lysates, nuclear, and cytoplasmic extracts or eluted fractions from Co-
immunoprecipitation experiments were separated on a 4-12% Bis-Tris gradient gel 
(Invitrogen) followed by transfer onto a 0.2 µm PVDF membrane. The membrane was then 
blocked for 30 minutes, with 5% milk in Tris-buffered saline-Tween 0.05% (TBS-T). Primary 
antibody incubation was performed overnight at 4°C. The next day, the membrane was 
washed three times with TBS-T, followed by incubation with a secondary HRP-conjugated 
antibody for one hour at 23°C. Finally, the membrane was washed three times with TBS-T 
and covered in ECL Western Blotting Detection Reagent (GE Healthcare Life Sciences) 
followed by detection of chemiluminescence using the Intas Chemostar ECL Imager device 
(Intas Science Imaging). Primary antibodies used for western blot analysis were targeted 
against H3K27me3 (ab6002, abcam, 1:1000), histone H3 (ab1791, abcam, 1:5000), FLAG-
tag (F1804, Sigma-Aldrich, 1:1000), EZH2 (D2C9, Cell Signaling Technology, 1:1000), SUZ12 
(D39F6, Cell Signaling Technology, 1:1000), EED (09-774, Merck, 1:1000), β-tubulin (#2146, 
Cell Signaling Technology, 1:1000), or Lamin B1 (ab16048, abcam, 1:1000). Secondary 
antibodies used were goat anti-mouse-HRP (ab6789, abcam, 1:5000) and goat 
anti-rabbit-HRP (ab6721, abcam, 1:3000).” 
3.2.3.5. Protein digestion and SP3 peptide clean-up of Co-IP samples 
Samples obtained from the Co-Immunoprecipitation (stored at -20°C) were reduced with 
DTT (10 mM final concentration) at 45°C for 30 minutes. Subsequently, proteins were 
alkylated using 40 mM final concentration of CAA at 23°C for 30 minutes. Reduced and 
alkylated proteins were digested overnight at 37°C using 0.65 μg sequencing-grade 
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modified trypsin in 100 mM ABC. Next, samples were further processed by the SP3 peptide 
clean-up procedure (Hughes et al., 2014; Hughes et al., 2019)149,291 as briefly described in 
paragraph 3.2.1.3. MS injection-ready samples were stored at -20°C. 
3.2.3.6. Mass spectrometry data acquisition 
Peptides were separated using an Easy NanoLC 1200 fitted with a trapping (Acclaim 
PepMap C18, 5 μm, 100 Å, 100 μm x 2 cm) and a self-packed analytical column (Reprosil-
Pur Basic C18, 1.9 μm, 100 Å, 75 μm x 40 cm). The C18 material was packed into fused silica 
with an uncoated Pico-Tip Emitter with a 10 μm tip (New Objective) using a Nanobaum 
pressure bomb. The outlet of the analytical column was coupled directly to an Orbitrap 
Fusion (Thermo Fisher Scientific) mass spectrometer. Solvent A was ddH2O, 0.1% (v/v) FA 
and solvent B was 80% ACN in ddH2O, 0.1% (v/v) FA. The samples were loaded with a 
constant flow of solvent A at a maximum pressure of 800 bar, onto the trapping column. 
Peptides were eluted via the analytical column at a constant flow of 0.3 μL/minute, at 55°C, 
using the 2-hours gradient described in chapter 3.1.2. Peptides were introduced into the 
mass spectrometer at a positive spray voltage of 2.5 kV. The ion transfer tube temperature 
was set at 275°C. Full scan MS spectra with a mass range of m/z 375 to 1500 were acquired 
in the Orbitrap with a resolution of 120.000 FWHM. The filling time was set to a maximum 
of 50 ms with an automatic gain control target of 1 x 106 ions. Intensities were filtered at a 
threshold of 5 x 103.  The dynamic exclusion list was set with a maximum retention period 
of 40 seconds and a mass tolerance of 10 ppm, high and low, respectively. Isotopes, 
unassigned charges, and charges of 1, 5 to 8, and >8 were excluded. MS2 scan properties 
were set to use the quadrupole isolation mode with a window of m/z 1.6. Higher-energy 
collision-activated dissociation (HCD) was selected as an activation type at a percentage 
collision energy of 33%. MS2 scans were performed in the ion trap at a rapid scan rate with 
a first mass at m/z 120 and an automatic gain control target of 1 x 104 ions. The maximum 
injection time was set to 50 ms with ion injection for all available parallelizable time. MS2 
spectra were acquired in a centroid data type.  
3.2.3.7. Mass spectrometry data processing 
Raw files were processed using MaxQuant (version 1.5.1.2)287,288. The search was 
performed against the human Uniprot database (201708_Uniprot_homo-
sapiens_canonical_reviewed; 20214 entries) using the Andromeda search engine289 with 
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the following search criteria: enzyme specificity was set to trypsin/P with up to 2 missed 
cleavages. Carbamidomethylation (C) was selected as a fixed modification; oxidation (M) 
and acetylation (protein N-term) were set as variable modifications. The first and second 
search peptide tolerances were set to 20 and 4.5 ppm, respectively. The protein 
quantification was performed using the label-free quantification algorithm of MaxQuant. 
LFQ intensities were calculated using a minimum ratio count of 1, and a minimum and an 
average number of neighbors of 3 and 6, respectively. MS/MS were required for the LFQ 
comparison, and the stabilization of large LFQ ratios was enabled. iBAQ intensities were 
calculated with a log fit. Peptide and protein hits were filtered at a false discovery rate of 
1%, with a minimum peptide length of 7 amino acids. The reversed sequences of the target 
database were used as a decoy database. The remaining parameters of MaxQuant were 
left at the default settings. LFQ values were extracted from the protein Groups table and 
log2-transformed for further analysis. iBAQ values were extracted from the protein Groups 
table and log10-transformed for further analysis. The MaxQuant protein groups’ output 
table was filtered for contaminants, reverse hits, and hits only identified by site. No 
additional normalization steps were performed, as the resulting LFQ intensities are 
normalized by the MaxLFQ procedure287.LFQ intensities were log2-transformed, and ratios 
were calculated for each construct over its respective IgG control counterpart. Proteins 
without a positive ratio in the full-length experiment and those without a positive ratio in 
all three construct experiments were filtered from the protein list. Subsequently, LFQ ratios 
were uploaded in Perseus (v. 1.5.3.0)290, and hierarchical clustering was performed using 
Euclidean distances with an average linkage for both row and column tree clustering, 
respectively. 
3.3. Additional experimental methods 
3.3.1. Cell culture of stable cell lines  
The culturing of A375, RPMI-7951, UACC-62, and ISTMEL-1 cell lines was carried out by Dr. 
Gertjan Kramer. 
HeLa, HEK-293, and MCF7 were cultured in regular DMEM medium (Gibco, Life 
Technologies) supplemented with 10% fetal bovine serum (Gibco, Life Technologies), 1% of 
a 100 x penicillin & streptomycin mix (Gibco, Life Technologies), and 1% of 100 x glutamine 
stock solution (Gibco, Life Technologies). A375, RPMI-7951, UACC-62, and ISTMEL-1 cells 
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were cultured in DMEM medium (Gibco, Life Technologies) supplemented with 10% fetal 
calf serum (Gibco, Life Technologies), 1 mM sodium pyruvate (Thermo Fisher Scientific), 25 
mM HEPES (Thermo Fisher Scientific), 2 mM GlutaMAX (Gibco, Life Technologies), and 1% 
of a 100 x penicillin & streptomycin mix (Gibco, Life Technologies). Upon establishment of 
a stable culture, cells were harvested using trypsin and counted using Bio-Rad TC20 
automated cell counter. Cell pellets were stored at -80°C until further use. 
3.3.2. Cell culture of patient-derived EPN tumor cell lines 
The culturing of patient-derived EPN tumor cell lines was carried out by either Dr. Jens 
Huebner (Global EPN and CXorf67 related experiments), Dr. Kendra Maaß, or Mieke Roosen 
(Extracellular vesicle related experiments) from the collaborating groups of Prof. Marcel 
Kool and Prof Kristian Pajtler at the DKFZ. 
In total, four different patient-derived EPN tumor cell lines were available corresponding 
to two out of nine EPN subgroups: namely BT214 and EPD210 from PF-EPN-A, as well as 
BT165 and EP1NS from ST-EPN-RELA. The PF-EPN-A cell lines were cultured in 1:100 
Laminin-coated (Sigma-Aldrich) flasks in NeuroCult NS-A basal medium (Stem Cell 
Technologies) supplemented with 2 mM L-Glutamine (Gibco, Life Technologies), 75 μL/mL 
Bovine serum albumin (BSA), 10% NeuroCult NS-A proliferation supplement (Stem Cell 
Technologies), and 1x antibiotic/antimycotic reagent (Life Technologies). Growth factors 
were added to 50 mL aliquots of medium: 20 ng/mL recombinant human EGF and FGF (both 
from Peprotech). The ST-EPN-RELA cell lines were cultured in Geltrex-coated (Life 
Technologies) flasks in Neurobasal medium A (Life Technologies) supplemented with 1 
μg/mL Heparin (Sigma-Aldrich), 2 mM L-Glutamine (Gibco, Life Technologies), and 1% 
penicillin & streptomycin mix (Gibco, Life Technologies). Growth factors were added to 50 
mL aliquots of medium: 1 mL of B-27 supplement minus vitamin A (Life Technologies), 20 
ng/mL recombinant human EGF, and FGF (both from Peprotech). 
For splitting, the ST-EPN-RELA BT165 cell line and both PF-EPN-A cell lines were detached 
using Accutase (Sigma-Aldrich) for 5 minutes at 23°C. Only the ST-EPN-RELA EP1NS cell line 
was detached using Accumax (Thermo Fisher Scientific) for 5 minutes at 37°C. All cell lines 
were cultured at 37°C at 5% CO2. All cell lines were regularly tested for mycoplasma. Cell 
pellets were stored at -80°C until further use. 
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3.3.3. Additional methods for lysis of cells and tissue for protein extraction 
3.3.3.1. RapiGest SF Surfactant protein extraction 
Each vial of 1 mg RapiGest SF Surfactant was dissolved in 1 mL of 50 mM triethylammonium 
bicarbonate (TEAB) and mixed thoroughly to achieve a 0.1% solution. For large sample 
batches, multiple vials of RapiGest SF Surfactant were dissolved and combined. PIC (Roche 
Diagnostics) was added to 1x final concentration before adding 100 μL to each tissue 
sample. Samples were kept on-ice and probe sonicated for 2 times 15 seconds at 10% 
frequency using a probe sonicator (Branson). The sample viscosity was used as quality 
control for sufficient DNA shearing. Subsequently, lysates were centrifuged at 15.000 x g 
for 30 minutes at 4°C (Eppendorf 5430R centrifuge) to pellet residual cell- or tissue debris. 
The protein content was determined using a BCA protein assay (Pierce) according to the 
manufacturer's instructions. Based on the BCA results across all samples, the smallest 
possible volume for a certain amount of protein, e.g., 10 to 20 μg, was selected for further 
processing. The same amount of protein per sample was transferred to PCR 8-stripes and 
balanced to the same volume with 50 mM TEAB. Next, samples were incubated for 5 
minutes at 95°C, cooled to 23°C, and reduced with a final concentration of 5 mM DTT for 
30 minutes at 60°C. Upon incubation, samples were quickly vortexed and spun down prior 
to alkylation with a final concentration of 15 mM CAA for 30 minutes at 23°C. Proteins were 
digested overnight using a 1:50 ratio of trypsin (in 50 mM TEAB) to protein at 37°C and 500 
rpm. On the next morning, the digestion reaction was stopped by acidification to 0.5% TFA, 
followed by 30 minutes incubation at 37°C. Subsequently, samples were centrifuged at 
15.000 x g for 30 minutes to pellet the precipitated RapiGest SF Surfactant. The peptide-
containing supernatant was transferred to new tubes for storage at -20°C until data 
acquisition. 
3.3.3.2. Urea-based protein extraction 
For Urea-based protein extraction, a 10 M Urea stock solution was prepared as follows. In 
total, 24 g of Urea was mixed with 4 mL of 1 M ABC and topped up to 40 mL volume with 
ddh2O. The mixture was fully dissolved by additional vortexing and heating with warm tap 
water. One complete PIC tablet was added, and the solution was subsequently filtered 
through a 0.22 μm syringe filter (Millex-GS). The filtered stock solution was aliquoted in 2 
mL tubes and stored at -80°C. 
Experimental Methods 
50 
Cell or tissue samples were resuspended in 100 μL 10 M Urea and mixed at 800 rpm for 10 
minutes at 23°C. Subsequently, samples were either sonicated in a water bath or using a 
probe sonicator (Branson) for 2 times 15 seconds at 10% frequency. Here, samples were 
kept on-ice to avoid overheating and carbamylation of cysteines as a result. Samples were 
centrifuged at 18.214 x g (Eppendorf 5430R centrifuge) for one hour at 10°C, and the 
resulting supernatant was transferred to a new 2 mL tube. Precaution was taken to not 
transfer any of the residual sticky DNA at the tube bottom. The protein content was 
determined using a BCA protein assay (Pierce) according to the manufacturer's instructions. 
On the basis of the BCA results across all samples, the smallest possible volume for a certain 
amount of protein, e.g., 10 to 20 μg, was selected for further processing. Samples were 
further reduced with a final concentration of 5 mM DTT for 30 minutes at 40°C. Upon 
incubation, samples were quickly vortexed and spun down prior to alkylation with a final 
concentration of 15 mM CAA for 30 minutes at 23°C. Before protein digestion, samples 
were diluted to a final Urea concentration below 1.6 M for enzyme compatibility. Proteins 
were digested overnight using a 1:50 ratio of trypsin (in 50 mM TEAB) to protein at 37°C 
and 500 rpm. On the next morning, the digestion reaction was stopped by acidification to 
0.5% TFA, followed by 30 minutes incubation at 37°C. The resulting peptide samples were 
further cleaned up and desalted using the Oasis protocol described in chapter 3.3.9. 
3.3.4. DNA extraction 
DNA was extracted from mouse kidney tissue (~ 2 mg wet weight). The tissue pieces were 
cut in a glass Petri dish on dry-ice using a commercial razor blade. The cut tissue parts were 
transferred within 600 μL TNES buffer (10 mM Tris-HCL pH 7.5, 400 mM NaCl, 100 mM 
EDTA, and 0.6% SDS) and 35 μL Proteinase K (Thermo Scientific) to a 1 mL Dounce 
homogenizer. Samples were digested overnight in a 2 mL tube at 50°C after 20 pestle 
strokes for complete tissue solubilization. Next, 166.7 μL 6 M NaCl was added, and samples 
were vigorously vortexed for 20 seconds and centrifuged at 20.238 x g for 10 minutes at 
23°C. The resulting supernatant was transferred and mixed with 800 μL ice-cold 100% EtOH. 
The tube was inverted several times to ensure sufficient gentle mixing and starting of DNA 
precipitation. The samples were further centrifuged at 15147 x g for 20 minutes at 4°C. The 
supernatant was discarded, and the DNA pellet was washed with 500 μL 100% EtOH and 
several times inversion of the sample tube. The washing step was performed for a second 
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time with 70% EtOH before the remaining EtOH was entirely removed by spinning down 
and discarding the supernatant and air-drying the DNA pellet for 5 minutes. The pellet was 
resuspended in ddh2O, and the amount of extracted DNA [ng/μL] was measured using a 
Nanodrop 1000 spectrophotometer device to read the absorbance at 260/280 nm and 
260/230 nm. (Thermo Fisher Scientific). Besides, samples were checked by loading different 
amounts on agarose gels, as described previously. 
3.3.5. E. coli spike-in sample preparation 
E. coli lyophilized sample (Bio-Rad) was resuspended in ddH2O to achieve a stock 
concentration of 2 μg/μL. 100 μL (200 μg) were incubated at 95°C for 5 minutes, followed 
by reduction and alkylation using DTT (10 mM final concentration) at 37°C for one hour and 
CAA (40 mM final concentration) at 23°C for 45 minutes at 500 rpm. Reduced and alkylated 
proteins were digested overnight at 37°C in a table-top thermomixer at 700 rpm using 
sequencing-grade modified trypsin (Promega) in ddH2O. Upon overnight protein digestion, 
each sample was acidified to a final concentration of 1% TFA (Biosolve Chimie). 
Subsequently, stocks of spike-in samples were prepared with a constant amount of HeLa 
peptides and increasing spike-ins of 0%, 3%, 4.5%, 6%, 7.5%, and 9% E. coli peptides (n= 3). 
MS injection-ready samples were stored at -20°C. 
3.3.6. Agarose Gels for DNA visualization 
Agarose gels were prepared by dissolving 1.2 g of agarose (Sigma) in 100 mL TAE buffer (50 
mM EDTA, 2 M Tris, and 1 M glacial acetic acid) in an Erlenmeyer flask. The solution is 
heated for 2 minutes in a commercial microwave and cooled to room temperature. 
Immediately upon reaching near 23°C SYBR safe DNA stain mix (Invitrogen) was added to 
the gel solution. Eight-well combs were inserted, and gels were poured in a gel running 
device (Biostep GmbH) to polymerize. 
Samples were mixed in a 1:6 ratio with loading dye (Thermo Scientific). Combs were 
removed, and samples were loaded. Gels typically ran for about 30 minutes at 140 V. DNA 
marker (Thermo Scientific) was used in each gel. 
3.3.7. SDS-Gels for protein visualization 
Samples were incubated for 10 minutes at 95°C with a 1x final concentration of Laemmli 
buffer stock solution (Bio-Rad Laboratories, Inc.) supplemented with 50 mM DTT. 
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Subsequently, samples were cooled to room temperature before loading into SDS-gels 
(either a 10-comb or a 16-comb commercial solutions). Precision plus protein standard (Bio-
Rad Laboratories, Inc.) was used in each gel. Gels were either run at 120 or 160 V for a time 
range of 45 to one hour and 45 minutes until the running front almost reached the gel 
bottom. Gels were run in Mini-Protean Tetra system chambers (Bio-Rad Laboratories, Inc.) 
using a Power PAC universal power supply (Bio-Rad Laboratories, Inc.). Gels were removed 
from the running chamber and washed once with ddH2O and fixed for one hour at room 
temperature in 50% EtOH, 10% acetic acid, and 40% ddH2O. Three consecutive ddh2O 
washes removed the fixation solution before leaving the gel in ddh2O overnight for 
rehydration. 
That followed, SDS-gels were washed twice with ddh2O and sensitized using 0.02% sodium 
thiosulfate for 1 minute at room temperature and three ddh2O washes. The silver staining 
was performed for 20 minutes at 4°C using a 0.1% silver nitrate solution with 0.02% 
formaldehyde added right before use. After an additional three consecutive ddh2O washes, 
gels were developed using 3% sodium carbonate with freshly added 0.05% formaldehyde. 
The development was terminated quickly at sufficient signal intensity by a single ddh2O 
wash, followed by 5 minutes incubation in 5% acetic acid. Gels were stored for a short term 
in 1% acetic acid. Gels were digitalized using a scanner. 
3.3.8. Cell-surface labeling and protein enrichment 
The cell-surface labeling and protein enrichment was performed using an adapted version 
of Kalxdorf et al., 2017300. In brief, frozen ST-EPN-RELA ependymoma tissue samples with 
an average wet weight of 9.16 mg were transferred in 500 μL 1x PBS to a Dounce 
homogenizer for six gentle pestle strokes. The resulting homogenate and residual solid 
structures were transferred to a 1.5 mL tube and centrifuged at 1000 x g for 1 minute at 
23°C to remove the supernatant. The remaining pellet was washed once with 1 mL of 1x 
PBS before performing a second round of centrifugation at 1000 x g for 1 minute at 23°C. 
The supernatant was again discarded, and the cell-debris pellet was resuspended in 1 mL 
of ice-cold 1x PBS with 1 mM sodium metaperiodate to oxidize carbohydrates for ten 
minutes with occasional gentle mixing on-ice and in the dark. Each sample was washed 
once with ice-cold 1x PBS and centrifugation at 1000 x g for 1 minute at 23°C to remove the 
supernatant. Next, biotinylation was performed with 400 μL of 1x PBS, 1 mM EZ-Link 
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Alkoxyamine-PEG4-Biotin, and 10 mM Aniline for ten minutes and occasional gentle mixing 
on-ice and in the dark. Subsequently, the supernatant was removed, and samples were 
washed once more with ice-cold 1x PBS. Upon centrifugation at 1000 x g for 1 minute at 
23°C and discarding of the supernatant, the labeled cell-surface protein samples were 
frozen at -80°C until further processing. 
In the meanwhile, the high capacity neutravidin-agarose resin was blocked to achieve 
trypsin-resistance by an in-house developed protocol. In brief, 210 μL of neutravidin-
agarose bead slurry was transferred to a 2 mL tube. Subsequently, the slurry was washed 
three consecutive times with 1 mL of 1x PBS, 0.1% Tween, and centrifugation at ~100 x g 
for 1 minute to remove the supernatant. Unless otherwise stated, all following washing 
steps were performed in the same way (three times, 1 mL of 1x PBS, 0.1% Tween, and 
centrifugation at ~100 x g for 1 minute). The beads were resuspended in 800 μL 1x PBS, 
0.1% Tween plus additional 200 μL 1 M NaOH (final pH > 12). The solution was further 
transferred to a new 2 mL tube containing 8.6 mg of 1,2-cyclohexadione (CDH), inverted 
several times to dissolve the CDH completely, and incubated with constant stirring in a PTR-
35 multi-rotator (Grant-bio Instruments) for 5 hours at 25°C. Upon incubation, the bead 
slurry was centrifuged at ~100 x g for 1 minute, and the supernatant was discarded. The 
beads were further washed three times and resuspended in 500 μL of 200 mM sodium 
cyanoborohydride in 1x PBS and 500 μL 4% formaldehyde in 1x PBS, followed by two hours 
of incubation at 23°C with occasional vortexing. The reaction was stopped by adding 500 
μL of 1 M Tris-HCl, pH 7.6, and three consecutive washes. Finally, the washed beads were 
resuspended in 210 μL 1x PBS, 0.1% Tween. Protease-resistant neutravidin-agarose beads 
were stored at 4°C until further processing. 
Previously labeled cell-surface proteins were thawed, resuspended in 100 μL 4% SDS, 100 
mM ABC pH 8.5, and heated for 5 minutes at 95°C. Samples were further probe sonicated 
(Branson) for 10 seconds at 10% frequency, kept on-ice, and topped with 900 μL 1x PBS. 
Next, 30 μL of prepared protease-resistant neutravidin-agarose bead slurry was added to a 
Microlute combinatorial 96 deep-well filter plate (Porvair Sciences Ltd.), sucked through 
using a vacuum manifold (Waters Corporation), and washed with 1 mL of 1x PBS. The 
diluted samples were added to the conditioned 96 deep-well plate with the bottom closed 
using a sealing mat (Porvair Science Ltd.). The top of the plate was closed using a sealing 
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mat (Thermo Scientific) for incubation with overhead rotation in a PTR-35 multi-rotator 
(Grant-bio Instruments) for two hours at 23°C. That followed, the liquid was sucked through 
using a vacuum manifold, and the plate was centrifuged at 314 x g for 1 minute (Heraeus 
Megafuge 40, Thermo Scientific) to remove the residual liquid. The neutravidin-agarose 
beads were washed successively with 300 μL steps and sucking through with the vacuum 
manifold as follows: three times with 400 mM NaCl, 0.4% SDS, 20 mM ABC; eight times with 
400 mM NaCl, 20 mM ABC; and eight times with 2 M Urea, 50 mM ABC. Proteins were 
consecutively reduced and alkylated for 30 minutes at 23°C using 30 μL of 45 mM DTT, 100 
mM ABC and 30 μL 100 mM CAA, 100 mM ABC, respectively. The residual liquid was 
removed by centrifugation at 314 x g for 2 minutes before and after five additional washes 
with 300 μL 2 M Urea, 50 mM ABC. Proteins were digested on-bead in 60 μL of 1.5 M Urea, 
60 mM ABC, and 0.42 μg of trypsin. For overnight digestion at 23°C and 500 rpm on top of 
a ThermoMixer C (Eppendorf), the top and bottom of the 96 deep-well plate were closed. 
Peptides were eluted into a new 96-well plate by centrifugation at 314 x g for 2 minutes, 
followed by a second elution with 50 μL 100 mM ABC. The peptide samples were dried in a 
vacuum centrifuge at 45°C, resuspended in 100 μL 0.1% FA, and cleaned using a HyperSep 
C18 plate as described in chapter 3.3.9. The resulting samples were stored at -20°C until 
data acquisition. 
3.3.9. Desalting and clean-up of peptide samples 
For the desalting and clean-up of peptide samples, either Oasis PRiME HLB μElution plates 
(Waters Corporation) or HyperSep C18 (Thermo Scientific) were used as indicated in the 
individual paragraphs. For both, the packed material was activated through consecutive 
washes of 100 μL as follows: 100% ACN, then 80% ACN, 0.1% FA, and then 0.1% FA. In each 
step, the liquid was sucked through using a vacuum manifold. Subsequently, samples were 
loaded in 0.1% FA and sucked through twice. The bound peptide samples were washed 
three times with 200 μL 0.1% FA and finally eluted with two times 50 μL 80% ACN, 0.1% FA. 
Eluted peptides were dried in a vacuum centrifuge at 45°C, resuspended in 50 to 100 μL 
0.1% FA depending on the sample amount, and stored at -20°C until data acquisition. 
3.3.10. High pH reversed-phase fractionation of proteomic samples 
The high pH fractionation of peptide samples was performed using an Agilent Infinity 1260 
HPLC system (Agilent) equipped with a Phenomenex Gemini 3 μM, 110 Å, C18, 100 x 1 mm 
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column (Phenomenex). Solvent A was changed from 20 mM ammonium hydroxide to 20 
mM ammonium formate during the course of this project. Unless otherwise stated, all data 
within this work were generated using ammonium formate. Solvent B was 100% ACN due 
to its low absorbance at 206 nm, among other organic solvents. Peptides were eluted from 
the Phenomenex column at a constant flow of 0.1 mL/minute. During the elution, the 
percentage of solvent B was constant at 0% for 2 minutes, then increased linearly from 0% 
to 65% in 58 minutes, and then from 65% to 85% in 2 minutes. Finally, the gradient was 
finished with 5 minutes at 85% solvent B, followed by 8 minutes at 0% solvent B. Fractions 
were collected during the first 60 minutes of the gradient for every 1.5 minutes, resulting 
in a total of 40 fractions per sample. Sample pick-up and fraction collection were performed 
at a constant 4°C. Each sample’s peptide map was monitored through the absorbance at 
206 nm. The resulting peptide fractions were dried in a vacuum centrifuge at 50°C, further 
concatenated to either 8, 16, 24, or 32 individual fractions, and resuspended in 0.1% FA. 
The actual number of concatenated fractions is indicated in the individual paragraphs. 
Peptide fractions were stored at -20°C until data acquisition. 
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3.3.11. Extracellular vesicle sample preparation 
Every section that was not written entirely by me is indicated with quotation marks. Besides 
the proteomic sample preparation, the majority of the EV-related work was performed by 
Dr. Kendra Maaß or Mieke Roosen. 
3.3.11.1. Patient-derived EPN cell culture 
“Patient-derived EPN tumor cell lines were used as an experimental model. The ST-EPN-
RELA cell lines, BT165 and EP1NS, were cultured in Geltrex-coated (Life Technologies) flasks 
in Neurobasal medium A (NBA, Life Technologies) supplemented with 1 μg/mL Heparin 
(Sigma), 2 mM L-Glutamine (Gibco, Life Technologies), 1% penicillin & streptomycin (Gibco, 
Life Technologies), and growth factors added to aliquots. The growth factors were added 
to 50 mL aliquots of the above-mentioned supplemented medium in the following 
concentrations: 1 mL B-27 supplement minus vitamin A (50x, Life Technologies) and 20 
ng/mL recombinant human EGF (Peprotech) and 20 ng/mL recombinant human FGF 
(Peprotech). The PF-EPN-A cell lines, BT214 and EPD210, were cultured in 1:100 Laminin- 
(Sigma, in PBS) coated flasks in NeuroCult NS-A Basal Medium (Human, Stem Cell 
Technologies) supplemented with 2 mM L-Glutamine, 75 μg/mL Bovine Serum Albumin 
(BSA), 10% NeuroCult NS-A proliferation supplement (Human, Stem Cell Technologies), and 
growth factors added to aliquots. The growth factors were added in the following 
concentrations to 50 mL aliquots: 20 ng/mL recombinant human EGF and FGF. Human fetal 
astrocytes were cultured in 1:150 matrix-gel (Corning, in DMEM) coated flasks in DMEM 
high glucose medium supplemented with 10% fetal calf serum depleted of exosomes, 1% 
glutamax (Gibco, Life Technologies), 1% sodium pyruvate (Gibco, Life Technologies), and 
1% N2 supplement (Gibco, Life Technologies). For splitting, BT165 and the PF-EPN-A cell 
lines were detached by 5 minutes incubation with Accutase (Sigma) at 23°C. The cell line 
EP1NS was detached by a 5 minutes incubation with Accumax (Thermo Fisher Scientific) at 
37°C. The astrocytes were detached with a 5 minutes incubation with trypsin (Sigma 
Aldrich) at 37°C. All cell lines were cultured at 37°C with 5% CO2. The cells were regularly 
tested for mycoplasm.” 
3.3.11.2. Exosome and microvesicle isolation 
“Exosomes and microvesicles were isolated from cell culture supernatant of four cell lines: 
namely BT214 and EPD210 from PF-EPN-A, as well as BT165 and EP1NS from ST-EPN-RELA. 
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80 mL of supernatant was collected from confluent flasks. The supernatant was centrifuged 
at 2000 x g for 20 minutes at 4°C to remove cell debris and apoptotic cells (2k pellet). 
Afterwards, the supernatant was transferred to ultra-centrifugation tubes (Beckman 
Coulter) coated with 70% EtOH for ultra-centrifugation in a Becket Optima L-70 ultra-
centrifuge with a SW28 rotor. The supernatant was centrifuged at 10.000 x g for 20 minutes 
at 4°C (10k pellet). The supernatant was further transferred to new EtOH-coated ultra-
centrifugation tubes and centrifuged at 100.000 x g for two hours at 4°C (100k pellet). 
Afterwards, the supernatant was discarded. The microvesicles (10k pellet) and the 
exosomes (100k pellet) were vortexed for 1 minute and frozen at -20°C or -80°C depending 
on the further processing steps. When the vesicles were stained with BODIPY TR ceramide 
dye (Invitrogen, D7540), 2 μL of dye was added to 100 μL PBS and incubated for 20 minutes 
at 37°C. The BODIPY TR ceramide dye has absorption and emission maxima of ~589 nm and 
617 nm, respectively. 
After the initial centrifugation steps, the purity of the pellets was enhanced by loading the 
samples on an IZON 35 nm qEV single size exclusion column. The first fraction was collected 
after 1 mL, and the subsequent fractions of 0.2 mL were collected according to the 
manufacturer protocol. The protein amounts in the different fractions were measured with 
the Qubit protein assay (Molecular Probes, Life Technologies, Q33211). The vesicles were 
permeabilized with 0.2% SDS and vortexed for 30 seconds. The remaining steps were 
carried out according to the manufacturer protocol. The fractions with the peak protein 
amount were used for further analysis.” 
3.3.11.3. Immunogold electron microscopy 
“After a glow-discharge in a Baltec SCD005 Sputter Coater, 300 Mesh Formvar-carbon 
coated Copper grids (Plano) were floated on 10 μL drops of isolated vesicles solution, for 
20 minutes at 23°C. After 3x washes with 15 μL PBS drops, the vesicles were blocked with 
Aurion blocking solution for Au-conjugates (PB) 1:10 in PBS for 20 minutes at 23°C, 
incubated with primary antibody (Ab) (Mouse-α-CD63, Santa Cruz, diluted 1:50 in PB) 
solution for 30 minutes at 23°C, washed 6x with PB, incubated with linker-IgG (Rabbit-α-
mouse, Dako Denmark, 1:150 in PB) for 40 minutes at 23°C, washed 6x with PB, incubated 
with Protein-A-Gold 5 nm (UMC Utrecht, PAG 5 nm/S, 1:50 in PB) for 50 minutes, and 
washed again 6x with PB. After 2x washes with PBS, the samples were fixed in 1% 
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Glutaraldehyde in PBS for 7 minutes at 23°C, washed again with PBS, and 4x with ddH2O. 
Finally, a negative stain of 1% aqueous uranyl acetate was applied for 2 minutes, and after 
a ddH2O wash, the grids were air-dried. In negative controls, the primary antibody was 
omitted. All samples were investigated with a Zeiss EM900 transmission electron 
microscopy (TEM), at an 85.000x magnification. Images taken were further processed with 
ImageJ (version 1.52a)301.” 
3.3.11.4. Nanoparticle tracking analysis (NTA) 
“Two μL of exosomes or MVs were diluted in sterile-filtered PBS and visualized using the 
LM10 NTA device (Malvern Instruments). Each sample was measured 5 times for 60 
seconds (Screen Gain 1.0, camera level 11) to obtain particle concentration and size 
distribution.” 
3.3.11.5. Qubit protein quantification assay 
“The approximate protein content of exosomes and MVs in the isolation solutions was 
determined using a Qubit Protein Assay (Molecular Probes, Life Technologies). For this, the 
vesicles were lysed with 3x Laemmli buffer, and its protein content was later dissolved in 
0.2% SDS and vortexed for 30 seconds. For the rest of the assay, the manufacturer’s 
guidelines were followed.” 
3.3.11.6. Protein digestion and SP3 protein clean-up of EV samples 
The extracellular vesicle fractions described in chapter 3.3.11.2 were further processed 
using SP3. Therefore, equal protein amounts per sample (previously determined by Qubit 
assay) were transferred to PCR stripes, and the volume reduced in a vacuum centrifuge at 
55°C. Subsequently, samples are resuspended in a small volume (between ~10 μL and 20 
μL) of 4% SDS and 100 mM ABC. Samples were sonicated in a Pico Bioruptor (Diagenode 
SA) using 25 cycles of 30 seconds on and off at 4°C. Subsequently, the buffer was adapted 
to a final concentration of 1% SDS, 100 mM ABC, 10 mM TCEP, and 40 mM CAA, including 
PIC, before incubation for 5 minutes at 95°C in a CHB-T2-D ThermoQ heating device. That 
followed, samples were rested to reach 23°C for subsequent SP3 processing. The SP3 
protocol was carried out as previously described in chapter 3.2.1.2. Samples are stored at -
20°C and data acquired using the 2-hours method. 
Experimental Methods 
59 
3.4. Additional data analysis 
3.4.1. Differential expression 
The differential expression analysis of all samples (unless otherwise indicated) were 
performed using Limma moderated t-statistics (R package version 3.36.3)293. If applicable, 
the technical replicates and the patient-dependent batch effect were taken into account 
within the applied model. Proteins with a Benjamini-Hochberg-adjusted p-value lower than 
0.05 and an absolute log2-fold change higher than 1 were considered as significantly 
changing unless otherwise indicated in the corresponding chapter. The resulting lists of 
significantly regulated proteins were used for further analysis. 
3.4.2. Gene set enrichment analysis (GSEA) and gene ontology (GO) 
Lists of proteins or significantly regulated proteins were subjected to GO-term enrichment 
analyses using the STRING: functional protein association network database294. The GSEA 
were performed using R package fgsea295 (version 1.6.0) with a p-value ranking of proteins, 
gene sets defined by the REACTOME pathway database (R package ReactomePA version 
1.24.0)296 or the Broad Institute gene sets302, the minimum size of gene sets set to 15, the 
maximum size of gene sets set to 500, and the number of permutations set to 10.000. 
3.4.3. t-SNE and umap 
The t-SNE analyses were performed using R package tsne297 (version 0.1-3) with a perplexity 
set to 2 and the number of iterations set to 5000. The uniform manifold approximation and 
projection (umap) analyses were performed using the R package umap303 (version 0.2.3) 
with neighbors (equivalent to perplexity) were set to 3 and the number of iterations set to 
5000. 
3.4.4. Gene- and protein expression correlation 
The gene expression data were used from Pajtler et al., 201573. To see gene/protein-specific 
correlation differences, we calculated the median gene and protein intensities. Next, we 
plot the mean intensity correlations between both transcriptome and proteome data and 
determine a mean linear regression model. Subsequently, the linear model is used to 
determine the deviation for every gene/protein from this general model. Based on the 
residuals, we could define which genes/proteins are significantly deviating from the model. 
The residuals are calculated by predicting gene expression from protein expression using 
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the linear model and subtracting the gene expression from predicted intensities for every 
gene and every sample. The residuals were normally distributed. Next, proteins were 
determined that show a significant deviation between the proteome and transcriptome by 
comparing residuals per gene/protein that deviate from zero. The significance was 
determined using Limma moderated t-statistics (R package version 3.36.3)293.  The 
threshold was set to a Benjamini-Hochberg-adjusted p-value lower than 0.05, and an 
absolute log2-fold change higher than 1 were considered. 
3.4.5. Copy number variation (CNV) correlation to gene- and protein expression 
The CNV and gene expression data were used from Pajtler et al., 201573. Data were batch 
corrected using the Limma moderated t-statistics (R package version 3.36.3)293. The gender 
for each sample was predicted from the X- and Y-Chromosome intensities. This was utilized 
to correct for gender-specific expression changes across all samples. To visualize whether 
CNVs per EPN subgroup result in changes of gene or protein expression, we calculated the 
intensities as CNV-varied (CNV > +/- 0.2) and CNV-stable (-0.2 < CNV < 0.2) samples per 
tumor subtype. Next, we calculate for both gene and protein expression intensities, the 
ratios between each sample, and the median intensity of the CNV-stable samples. This was 
ordered by the chromosomal position per gene and their observed intensity relative to the 
CNV-stable samples. CNV segments were plotted with a line for every sample and 
chromosomal region, highlighted in colors corresponding to the CNV status: blue= neutral, 
red= deletion (CNV < -0.15), or green= amplification (CNV > 0.15). Individual dots indicate 
the mean gene expression at a corresponding genomic locus for each sample (color-coded 
for its CNV status) relative to the gene expression in the CNV neutral samples. 
3.4.6. Multi-omics factor analysis (MOFA) 
Proteome data were median normalized. Transcriptome and DNA-Methylation data were 
batch- and gender-corrected. The top 20% variable proteins (1745 proteins), top 20% 
variable genes (3890 genes), and the top 1% variable CpG sites (4260 CpGs) were selected 
for MOFA135. The multi-omics factor analysis (MOFA)+ framework was used with default 
settings and the number of factors set to 15. 
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4. Results 
Copyright Disclaimer 
The work presented in this thesis was carried out by me, Torsten Müller, and under the 
supervision of Prof. Jeroen Krijgsveld. Throughout this thesis, the pronoun “we” is used to 
refer to myself, my supervisor, if applicable the helping hand of co-workers, and in some 
cases, collaborators. Collaborations and their contribution are specifically highlighted in the 
main text as well as in the method sections. As a general rule, all mass spectrometry-based 
“proteomics” experiments within this work were performed by me. Dr. Mathias Kalxdorf 
supported the bioinformatic analysis. Results and experiences outlined in the first chapter, 
“4.1.2”, involving the optimization of SP3, have contributed to an updated version of the 
protocol in Hughes et al., Single-pot, solid-phase-enhanced sample preparation for 
proteomics experiments, Nature Protocols, 2019291. The second chapter of this thesis, “4.2”, 
summarizes the automation of SP3 that has been published in Müller et al., Automated 
sample preparation with SP3 for low-input clinical proteomics, MSB, 2020304. Also, a 
preprint of this publication is accessible on bioRxiv under the same title305. The collaborative 
project about CXorf67, outlined within chapter, “4.3.2.1”, has been published in Hübner et 
al., EZHIP/CXorf67 mimics K27M mutated oncohistones and functions as an intrinsic 
inhibitor of PRC2 function in aggressive posterior fossa ependymoma, Neuro Oncology, 
2019257. The second collaborative project about extracellular vesicle cargo in ependymoma, 
outlined within the last chapter, “4.3.4”, has not been published yet. In this thesis, we solely 
focus on the comparison to our global EPN proteome data. Our collaborators plan to publish 
this work with a significant contribution of our proteomics data. The remaining results 
outlined throughout the last chapter, “4.3”, have not been published and are originally 
presented in this thesis. We note that plans exist to publish these results, irrespective of the 
embargo period on this thesis, and with significant input from our collaborators with regard 
to the provision of previously acquired sequencing data as well as clinical context. 
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4.1. Proteomic profiling in systems medicine 
In the first chapter of this thesis, we systematically evaluated and optimized all relevant 
steps that are crucial for proteomic sample preparation workflows in light of clinical 
integration. During this step-wise development of a scalable workflow, we specifically 
focused on the extraction of proteins from a wide range of sample material and low 
quantities, the subsequent protein processing to generate peptides, their chromatographic 
separation, and LC-MS data acquisition. Due to distinct advantages of the in-house 
developed single-pot, solid-phase-enhanced sample preparation (SP3) method (Hughes et 
al., 2014; Hughes et al., 2019)149,291, we specifically tailored the optimization of preceding 
steps for SP3 compatibility and its subsequent automation (Chapter 4.2). 
Parts of the following chapters, including Figures and Tables, were taken in part or their 
entirety from the joint publications listed below. 
Hughes, C. S., Moggridge, S., Mueller, Torsten, Sorensen, P. H., Morin, G. B., Krijgsveld, J. 
(2019). „Single-pot, solid-phase-enhanced sample preparation for proteomics 
experiments.” Nature Protocols 14: 68-85. 
Mueller, Torsten, Kalxdorf, M., Longuespeé, R., Kazdal, D., Stenzinger, A., Krijgsveld, J. 
(2020). “Automated sample preparation with SP3 for low-input clinical proteomics.” 
Molecular Systems Biology 16(1): e9111. 
4.1.1. Cell- or tissue lysis and protein extraction 
The efficient extraction of proteins is the first critical step in any proteomics methodology. 
Dependent on the type and quantity of a specimen, different approaches are commonly 
used in a research environment151,155,156,158,291,306–308. They are typically comprised of 
different lysis buffer combinations and mechanical disruption strategies to facilitate the 
efficient breakup of cell- or tissue structures and to release proteins. Here, different 
proteins, such as transmembrane proteins, can significantly differ in their physicochemical 
properties, requiring different solubilization strategies to avoid any selectivity. In this 
process, the majority of lysis buffers are comprised of chemicals, such as chaotropes, salts, 
or detergents, to ensure the disruption of the phospholipid bilayer and that proteins remain 
in-solution for subsequent proteolytic digestion. For the integration of a method into 
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clinical practice, a vast number of requirements need to be fulfilled beyond high 
performance, reproducibility, and cost-efficiency. 
 
Figure 1: Evaluation of cell- and tissue lysis, followed by protein extraction. A) Cell lysis facilitated by four 
different lysis buffers (2% SDS, 4% SDS, RIPA, and 8 M Urea) and quantification of extracted protein mass. B) 
Fresh-frozen tissue (mouse kidney and liver) lysis facilitated by four different lysis buffers, as in panel A, and 
quantification of extracted protein mass. C) Lysis of different cell quantities in 4% SDS with additional 
mechanical disruption using a probe sonicator (blue) or Bioruptor Pico (red), and quantification of extracted 
protein mass. D) Lysis of different tissue quantities (mouse liver (blue) and kidney (red)) in 4% SDS with 
additional mechanical disruption using a probe sonicator, and quantification of extracted protein mass. 
In an initial attempt, we aimed to avoid any mechanical disruption of cell- or tissue samples 
to achieve broad applicability without the need for specialized equipment and well-trained 
personnel, aiming for a lossless integration with SP3 in a single tube. Four commonly used 
lysis buffers (2% SDS, 4% SDS, radioimmunoprecipitation assay (RIPA) buffer, and 8 M Urea) 
were used for sample solubilization and protein extraction from 500.000 HeLa cells (Figure 
1A) and mouse kidney and liver tissue (Figure 1B). Consistent protein yields could be 
extracted from cells irrespective of the lysis buffer and within the expected range of ~0.1 
ng protein per cell. This was verified in four randomly selected cell lines, in three varying 
quantities (5000, 50.000, and 500.000 cells), and using 2% and 4% SDS (Supplementary 
Figure 1A). The amount of protein that could be extracted from fresh-frozen tissue did not 
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scale linearly with the input material and conform with yield expectations (~ 10% of tissue 
weight corresponds to proteins) (Figure 1B)309. The highest and lowest quantities of protein 
were extracted using 4% SDS and 8 M Urea, respectively. 
Despite the overall reasonable protein yields, the mechanical-free sample lysis appeared to 
be incompatible with the following SP3 protocol (Supplementary Figure 1B). The 
processing of different protein quantities resulted in >50% sample losses for most 
conditions. The highest consistency in relative and absolute peptide recoveries were 
achieved using 4% SDS. During SP3, proteins and nucleic acids compete for the binding 
capacity of the beads and omitting a proper mechanical DNA and RNA shearing could 
account for the weak recovery of peptides (Supplementary Figure 1C; further discussed in 
chapter 4.1.2). Indeed, we could show that enzymatic cleavage of nucleic acids can be 
achieved by using Benzonase (Supplementary Figure 1C) and that SP3 recoveries can be 
improved as a result (further discussed in chapter 4.1.2). This required the adaption of 
detergent concentrations in the lysis buffer, now including RapiGest SF surfactant, to allow 
the enzymatic activity of Benzonase. The lower detergent concentrations reduced the 
protein yield by more than 50% in most conditions and thereby did not qualify for minute 
amounts of sample (Supplementary Figure 1D). 
We further assessed mechanical disruption to achieve efficient lysis and protein extraction 
with sufficient DNA and RNA shearing. Therefore, a classical probe sonicator (Branson) and 
a Bioruptor Pico (Diagenode SA) were utilized to process varying numbers of HeLa cells 
(5000, 10.000, 50.000, 100.000, and 500.00 cells) (Figure 1C) and different amounts (sub-
mg to >7 mg) of fresh-frozen mouse kidney and liver tissue (Figure 1D). The quantities of 
extracted proteins were reproducible and in line with our expectations, while additionally 
exhibiting a linear correlation between protein yield and tissue input in comparison to 
mechanical-free lysis. The one-by-one processing using the probe sonicator remains 
insufficient, taking the anticipated goal of a scalable workflow into account. 
Next, we compared the processing efficiency of all methods accessible to us, which can 
process several samples at a time, namely a LE220R-plus focused-ultrasonicator (Covaris 
Ltd, UK), a standard water bath (Thermo Scientific), and the Bioruptor Pico (Diagenode SA). 
The latter is limited to the simultaneous processing of 32 samples, utilizing a custom-made 
PCR-tube adapter, while both others can run in 96-well formats. The LE220R-plus focused-
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ultrasonicator utilizes adaptive focused acoustics (AFA) to dis-integrate tissue, extract 
proteins, and enhance the efficiency of DNA shearing by the delivery of highly-controlled 
and reproducible energy. Hereinafter they are referred to as Covaris, water bath, and 
Bioruptor. The Covaris achieved the highest protein extraction efficiency and 
reproducibility from 100.000 HEK-293 cells or MCF7 cells using 4% SDS, irrespective of the 
processing volume (20 μL Figure 2A, 50 μL Figure 2B, and 100 μL Figure 2C). Overall 
minimized volumes are desirable to reduce the plastic surface and the associated loss of 
proteins. The Bioruptor performed equally well at low volumes with comparable standard 
deviation, for example, σ= 3.11% (1.03%) and 3.21% (1.7%) for processing of HEK-293 
(MCF7) cells using the Covaris or Bioruptor. The water bath processing resulted in the 
lowest protein yield and largest variability (σ= 7.2% [HEK-293] and 3.54% [MCF7]). This is 
because the water bath sonication suffers from an incomplete shearing of DNA, as opposed 
to the Covaris (data not shown). Only for minute amounts of cells (1 to 10.000) in small 
processing volumes (<20 μL) this is not evident and results in an average of 4.5% and 13.7% 
more quantified proteins for HEK-293 and MCF7 cells, respectively, using the water bath 
and SP3 (Figure 2D). All other sample types (fresh-frozen or FFPE tissue, and higher cell 
numbers) require processing with the Covaris to achieve sufficient lysis. The amount of 
protein that could be extracted from fresh-frozen tissue (pig heart (n=16), mouse liver 
(n=16), and mouse kidney (n=8)) scaled linearly with the mass of wet tissue input material, 
liberating ~100 μg protein per mg heart tissue, and ~130 μg per mg liver and kidney tissue, 
as expected from the literature (Figure 2E)309. 
In summary, both mechanical-free and mechanical cell disruption methods achieve 
effective cell lysis, irrespective of the buffer composition. This does not hold for the 
extraction of proteins from fresh-frozen tissue where 4% SDS outcompetes all other buffers 
in terms of protein yield and its linearity. However, the mechanical-free sample lysis is not 
sufficient to shear nucleic acids and thus remains incompatible with downstream SP3 
processing or minute amounts of sample. In contrast, probe sonication or Bioruptor 
processing, result in reproducible, high and linear protein yields, but remain limited in the 
sample throughput. The most efficient and high-throughput processing of all sample types 
and quantities could be achieved using the Covaris, which seamlessly integrates with 
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downstream SP3. Altogether, SDS detergent shows the best extraction efficiencies and 
remains the most frequently used component of common lysis buffers. 
 
Figure 2: Evaluation of high-throughput cell- and tissue lysis methods followed by protein extraction. A-C) 
Lysis of 100.000 HEK-293 and MCF7 cells in 20 μL (A), 50 μL (B), or 100 μL (C) of 4% SDS with additional 
mechanical disruption using a Covaris LE220R-plus (green), a sonication water bath (red), or a Bioruptor Pico 
(blue), and quantification of extracted protein mass. D) Lysis of different HEK-293 or MCF7 cell quantities 
(10.000 to 1 cell) in 4% SDS with additional mechanical disruption using a Covaris LE220R-plus (green) or a 
sonication water bath (red), followed by SP3 processing and LC-MS. E) Lysis of different tissue quantities 
(mouse liver (green) and kidney (blue), and pig heart (red)) in 4% SDS with additional mechanical disruption 
using a Covaris LE220R-plus, and quantification of extracted protein mass. Panel E modified from Mueller et 
al., Mol. Syst. Biol., 2020. 
4.1.2. Single-pot, solid-phase-enhanced sample preparation (SP3) 
The next step after the extraction of proteins from a specimen, most commonly facilitated 
by SDS, comprises the proteolytic digestion to peptides95,104. In practice, this is limited by 
the incompatibility of SDS with protease activity and protein digestion as a result. It 
additionally has an ion suppression feature310,311, further highlighting the necessity of a 
compatible workflow to remove SDS. The SP3 method is a fast and straightforward clean-
up procedure for unbiased retrieval and purification of proteins and peptides to remove all 
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kinds of contaminants, including SDS (Hughes et al., 2014; Hughes et al., 2019)149,291. Its 
broad range of features renders it an attractive solution to tackle common sample 
preparation bottlenecks and ease the emergence of an automated, routine pipeline for 
clinical proteomics. For the subsequent automation of the SP3 protocol, we firstly went 
through a series of evaluation and optimization steps to achieve maximal performance. 
The method utilizes paramagnetic beads in the presence of an organic solvent (>50% ACN 
or EtOH) to promote protein binding to the beads, allowing extensive washing to eliminate 
contaminants. Beyond SDS, this can include other detergents such as Triton X-100 and NP-
40, which are commonly used in proteomics experiments or chaotropes and salts. 
Subsequently, proteins can be digested on the beads without hindrance, and the resulting 
peptides are thereby released into the aqueous digestion buffer, which is directly 
compatible with LC-MS analysis (Figure 3A). Another distinctive feature of SP3 is its 
efficiency in protein capture and release, facilitating low- and high-input applications while 
consistently maintaining in-depth proteome coverage. The combined characteristics of 
tolerance to detergents, speed and ease of operation, and scalability qualify SP3 as a 
universal methodology that enables a wide variety of applications. In practice, this includes 
cases that involve challenging sample types, as diverse as FFPE tissue168,312 and historical 
bones313. SP3 performs particularly well for low-input applications307, for example, allowing 
the analysis of single human oocytes314, and micro-dissected tissue315,316. 
4.1.2.1. Optimization of protein binding 
The principle of SP3 is explained by a mechanism similar to hydrophilic interaction 
chromatography (HILIC) and aggregation. Increasing the organic proportion of the protein-
containing mobile phase induces the formation of a water-rich (aqueous) layer around the 
hydrophilic surface of the stationary phase, namely carboxylate-modified paramagnetic 
beads. This phase separation causes the concentration of polar (hydrophilic) side chains of 
amino acids to the aqueous surrounding of the beads. While in the original protocol, the 
capture of proteins was performed under acidic conditions, resulting in the protonation of 
R-COO- to neutral R-COOH, we observed that the binding capacity is increased and more 
reproducibility in a neutral pH environment. In the latter scenario, polar interactions occur 
between positively charged amine groups of proteins and, for example, arginine and lysine 
side chains, and the negatively charged carboxylate ions (R-COO-) on the bead surface 
Results 
68 
(Figure 3B and Supplementary Figure 2A). Together with prolonged incubation times of up 
to 18 minutes, this adaption of pH increased the efficiency of SP3 as compared to in-
solution digestion of 2 μg and 10 μg HeLa protein, resulting in reproducible numbers of 
peptide spectrum matches and quantified proteins (Figure 3B). 
On the other hand, DNA and RNA are also attracted to the aqueous solvation layer due to 
their overall hydrophilic character. We reasoned that the mere proximity of nucleic acids 
to the bead surface has the potential to influence the protein binding capacity, irrespective 
of the negatively charged DNA backbone. To show this, we utilized isolated DNA from 
mouse kidney tissue (Supplementary Figure 2B) in different amounts (0.5 μg, 1 μg, 2 μg, 
and 5 μg DNA) and fragment sizes (fully digested, partially digested, and undigested DNA), 
generated by both probe sonication and Bioruptor Pico treatment (Supplementary Figure 
2C). In fact, we demonstrated an increased loss of unbound proteins in the SP3 supernatant 
with increasing DNA background (Supplementary Figure 2D) in a size-dependent manner, 
where small fragment sizes significantly minimize the interference. Upon change to the 
aqueous digestion buffer, nucleic acids are released from the beads due to their negative 
charge repulsion, while the polar protein-bead interaction is only reversed by proteolytic 
digestion during our protocol. The highest binding efficiency of proteins and its 
reproducibility can be achieved in the absence of large nucleic acid fragments. 
Concerning the planned automation of the SP3 workflow, we further tested two additional 
types of beads (ReSyn Biosciences, RSA), namely MagReSyn HILIC and MagReSyn Amine. 
These beads have several potential advantages: I) they are comprised of a hyper-porous 
polymer matrix, providing an exceptionally high surface area and binding capacity, II) a 
higher magnetite content to support fast and efficient immobilization on the magnetic rack, 
and III) the increased sensitivity and correspondingly reduced material consumption to 
cope with the financial burden in a clinical environment. While the surface chemistry of the 
HILIC beads is proprietary, the Amine beads are characterized by an amine group (NH2). 
They can capture biomolecules, such as proteins or peptides, through polar interaction 
similar to the carboxylate-modified beads used in the classical SP3 method. Despite the 
potential advantages, a comparison of all three bead types (Carboxylate-, Amine-, and HILIC 
beads) and amounts (50 μg, 100 μg, 200 μg, and 250 μg) for the capture and release of 10 
μg protein yielded no significant differences on the level of quantified proteins 
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(Supplementary Figure 2E). However, at the peptide level, we found at least 10% more 
identifications using the classical SP3 beads (Supplementary Figure 2F). This could point to 
incomplete digestion of proteins on the hyper-porous polymer matrix of the MagReSyn 
beads or a biased recovery and release of peptides into the digestion buffer. We continued 
with the carboxylate-beads that are used in the classical SP3 method. 
 
Figure 3: Evaluation and optimization of single-pot, solid-phase-enhanced sample preparation (SP3). A) 
Schematic illustration of the SP3 protocol, including sample lysis, reduction & alkylation, protein clean-up, 
proteolytic digestion, and acidification & peptide recovery. B) Comparison of acidic and neutral pH conditions 
for the SP3 protein binding step. C) Assessing the protein binding capacity of varying amounts of paramagnetic 
SP3 beads (50 to 400 μg) by monitoring peptide spectrum matches (PSMs) and the number of quantified 
proteins. D) Assessing the protein binding scalability for varying amounts of protein inputs (2 to 100 μg) by 
monitoring peptide spectrum matches (PSMs) and the number of quantified proteins. Panel A modified from 
Mueller et al., Mol. Syst. Biol., 2020. 
4.1.2.2. Capacity and reproducibility of SP3 
Upon the optimization of effective protein binding and recovery conditions, we further 
assessed the capacity of beads (50 μg, 100 μg, 200 μg, 300 μg, and 400 μg) at a fixed protein 
concentration of 10 μg (Figure 3C). In all conditions, we observed almost no loss of unbound 
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proteins (Supplementary Figure 2G). The lowest variation in numbers of quantified 
proteins was observed at a bead to protein ratio of 20:1 (200 μg beads). Further increasing 
the ratio did not yield more protein quantifications and only added an average of ~4% 
peptide spectrum matches. In contrast, lowering to a 5:1 ratio of beads to proteins caused 
a loss of roughly 25% of quantified proteins. Unless otherwise indicated, we have chosen 
to use 200 μg beads for most of the following experiments. 
In parallel, we evaluated the scalability of the method using varying amounts of protein (2 
μg, 10 μg, 25 μg, 50 μg, and 100 μg) at a fixed concentration of beads (Figure 3D). Again, in 
all conditions, we observed almost no loss of unbound proteins (Supplementary Figure 2H). 
Upon SP3 processing, an equivalent of 500 ng peptides were measured per sample, 
resulting in consistent numbers of quantified proteins (μ= 1998 and σ= 90.2). This indicates 
a high reproducibility (CV= 4.5%), a nearly complete sample recovery across all LC-MS runs 
(average peptide intensities CV= 4.84%), and high sensitivity of the method for low protein 
quantities (2 μg) with an average peptide intensity of 93.7% compared to the highest 
observed average (25 μg) (see also Figure 2D for sub-μg protein input). For both, low and 
high protein input, the number of peptide spectrum matches (PSMs) was slightly decreased 
(CV= 6.67%), illustrating the importance of optimized ratios between beads, proteins, and 
the working volume (Figure 3D). 
We further compared our optimized SP3 method to a standard in-solution digest (without 
detergents) and the commonly used filter-aided sample preparation (FASP) 
method155,158,307. The aim was not to repeat all proof-of-concept experiments for SP3 but 
to understand whether our optimization could cause undesired effects. This could manifest 
itself as a bias towards specific peptides or proteins. The overlap of identified HeLa peptides 
between all three methods was high (~49% shared) (Supplementary Figure 3A). Between 
5% (FASP) and 8% (In-solution) of peptides were uniquely identified using one method. This 
is well within the expected range of overlap due to the stochastic nature of LC-MS, in which 
also technical replicates show similar values. We did not find any significant difference in 
the distribution of molecular weights (Supplementary Figure 3B), compared to the whole 
proteome (Uniprot), and the average hydrophobicity (GRAVY score)317 (Supplementary 
Figure 3C). A GO annotation for cellular compartments illustrated a highly similar 
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distribution of identified proteins between the HeLa in-solution digest and SP3 
(Supplementary Figure 3D). 
All in all, SP3 has room for minor optimization in different conditions in order to achieve 
optimal performance according to the starting amount of protein and the working volume. 
However, it is a highly sensitive method that allows the reproducible processing of a variety 
of sample types and minute amounts without a selective enrichment of specific proteins or 
peptides. It qualifies as a universal building block for an end-to-end proteomics workflow, 
resulting in peptides samples compatible with downstream applications, such as tandem 
mass tag (TMT) labeling and high-pH fractionation, or direct LC-MS. 
4.1.3. LC-MS data acquisition 
During each LC-MS measurement for global proteome profiling, the objective is to analyze 
the entire set of peptides that are present within a sample. In practice, this is limited by the 
complexity of samples and the sensitivity and scan rate of the mass spectrometer94. One 
way to improve the depth and coverage of peptide identifications is the increase of 
measurement time to disperse the analyte over time and provide the instrument with more 
scanning time. This can be achieved by either longer gradients for every LC-MS run318 
(Figure 4A and Figure 4B) or, for example, by additional offline high-pH fractionation using 
a reversed-phase C18 column to further separate peptides into multiple fractions319. Each 
fraction or concatenated fractions of the same sample are measured in consecutive LC-MS 
runs and compiled using a computer. The analysis time is significantly increased per sample 
leading to higher peptide coverage. On the other hand, both approaches require a higher 
sample input (Figure 4A and Figure 4B), which in practice is often a limiting factor in a 
clinical environment. Especially here, the balance between data depth and measurement 
time is a pivotal aspect to generate useful data in acceptable turn-around times. 
In proteomic profiling, we are not only interested in consistent and maximized numbers of 
identifications of peptides or proteins across many samples, but further aim for accurate 
quantification94. Here, a compromise is necessary with the number of samples, their 
analysis depth, and accurate quantification on the one hand, and the data acquisition time 
and overall turn-around time on the other hand. To achieve this, we evaluated a hybrid 
approach to uncouple identification and quantification by I) firstly generating a library of 
protein and peptide identifications through extensive high-pH fractionation of a 
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representative pool of all available samples, and II) secondly, focusing on quantification in 
short LC-MS runs of individual samples. Here, we modified our standard MS methods to 
collect more data points for every peptide feature and achieve better quantification as a 
result. The associated loss of peptide identifications in individual short runs was 
subsequently recovered by the integration of the sample-specific peptide library. This is 
achieved by matching of identified peptides to unidentified features based on retention 
time and mass-to-charge ratios287,288. This hybrid approach allows fast data acquisition per 
sample while conserving a good proteome coverage at optimal quantification. 
 
Figure 4: Optimization of liquid chromatography (LC)-setup for increased peak capacity. A) Comparison of 
peptide injection amount (1 μg, 2 μg, 5 μg, 10 μg, 15 μg, and 20 μg) and LC-MS gradient lengths (45, 60, 90, 
120, 160, and 220 minutes) for the highest number of unique identified peptides. B) Illustration of panel A to 
show the identified unique peptides per minute for the different peptide injection amounts and LC-MS 
gradient lengths. C) Assessment of LC-MS time consumption and proteome depth using three peptide 
injection amounts (1 μg, 2 μg, 5 μg) and different gradient lengths (45, 60, 90, 120, 160, and 220 minutes). D) 
Assessment of full width half maximum (FWHM) average peak width for the different peptide injection 
amounts and LC-MS gradient lengths in panel C. Additional comparison to published datasets from similar LC-
MS setups. E) Evaluation of different commercial and self-packed analytical columns for improving the peak 
width. 
4.1.3.1. Library generation and LC optimization 
Initially, we evaluated and optimized the performance of our Infinity 1260 HPLC system 
(Agilent) for high-pH fractionation. Sample losses during fractionation were negligible when 
comparing the number of quantified proteins from concatenated samples to omitted 
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fractionation with an average (n=4) of 1910 and 2085, respectively. (Supplementary Figure 
4A). This is particularly beneficial in light of quantity-limited material. The high-pH 
ammonium hydroxide buffer was exchanged for high-pH ammonium formate because it 
eliminates the need for another clean-up step of the concatenated fractions. Additionally, 
it was previously demonstrated that low concentrations of ammonium formate could 
enhance the ionization efficiency during ESI-MS320, depicted by increased numbers of 
peptide spectrum matches (average: 5151 versus 4364) and quantified proteins (average: 
2393 versus 2220) per fraction (Supplementary Figure 4B). The chromatographic 
performance remained unaffected by the buffer exchange, as highlighted by the number 
of peptide sequences solely identified in one or two fractions (Supplementary Figure 4C). 
In an ideal scenario, a sample- or cohort-specific peptide library is generated once, whereas 
individual patient samples can be matched continuously. We determined the feasible scope 
of a library by generating multiple examples comparing different numbers of concatenated 
fractions (8, 16, 24, and 32) and different gradient length (1-hour and 2-hours) 
(Supplementary Figure 4D). The library sizes correlate positively with the instrument time 
for LC-MS. While it is indisputable that the largest library depth is desired, the optimum 
balance depends on the overall number of samples and corresponding relative time 
investment of library generation compared to the acquisition of each sample. In the 
remaining part of this thesis, the number of fractions and utilized gradient length is 
indicated for individual experiments. 
Following the generation of a deep-proteome library, we first evaluated different gradient 
lengths and peptide loadings (1 μg, 2 μg, 5 μg, 10 μg, 15 μg, and 20 μg) to determine the 
best balance of time consumption and proteome depth in individual runs (Figure 4A, Figure 
4B, and Figure 4C). The data illustrate that a high sample input (>10 μg) is necessary to 
benefit from longer gradients (Figure 4A). The absolute numbers of unique peptides and 
their relative identification per minute have guided us to step away from the originally 
planned 4-hours gradients and further focus on either 1-hour or 2-hours per sample (Figure 
4A and Figure 4B). Consequently, more patient samples can be measured in a shorter time 
to generate higher statistical power with less sample consumption. As another by-product 
of the evaluation, we noticed that our average peak width at FWHM was significantly higher 
(~4 to 6 seconds) compared to published data (Figure 4D), irrespective of the gradient 
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length. We extensively tested and evaluated different packing materials for self-packaged 
columns, as well as commercially available columns from different vendors (Figure 4E). The 
transition to a 25 cm BEH-C18 1.7 μm analytical column (Waters Corporation) improved the 
peak width and peak capacity per minute as a result. In a 1.5-hours method, we could 
increase the number of quantified proteins and identified peptides by 9.6% and 13.9%, 
respectively. The LC column setups that were used are described in detail within the 
corresponding method sections. 
At a later stage of this study, we additionally evaluated a recently released technology, 
namely μPAC (PharmaFluidics)321. It is a novel type of column comprised of highly 
structured micro-pillars covered with C18 and produced by lithographic etching. The nearly 
perfect order of the stationary separation bed leads to a uniform flow distribution and low 
analyte dispersion, resulting in high sensitivity. The μPAC runs at very low back pressure 
(<50 bar compared to >650 bar for packed columns) and potentially offers a long lifetime 
for itself and the LC, which would be superior for clinical applications. Going through a 
series of trials to evaluate and optimize the LC-MS setup, we were not able to achieve 
results comparable to our initial setup (data not shown), which is even outperformed after 
the latest testing of different columns. However, the technology is still in its infancy, and 
by its continuous development might become a great tool when robustness and lifetime is 
a key demand. 
4.1.3.2. Match-between-runs and optimal quantification 
Next, we measured replicates of a HeLa digest (n=3) with a 2-hours gradient utilizing a 
standard ‘Top-20’ or ‘Top-2’ method. Hereinafter they are referred to as T20 and T2. The 
latter was designed to generate MS2 scans for the two most abundant precursor ions per 
MS1 scan, resulting in a substantially reduced cycle time and more data points (MS1 scans) 
per peptide feature to increase the quantification accuracy. As a consequence, less time 
remains available for the acquisition of MS2 spectra that are used for peptide identification. 
The T2 method recorded an average of 1.6 MS2 scans per MS1 scan (7.4 in T20). This sacrifice 
of MS2 scans for peptide identification was conserved by using the sample-specific 
proteome library paired with the MaxQuant matching-between-runs algorithm. In both 
methods, similar numbers of proteins (Supplementary Figure 4E) and peptides 
(Supplementary Figure 4F) were identified with the library approach. Nearly half of the 
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peptide identifications (49.5% in T2) originate from matching to the library (19.07% in T20). 
The T2-library approach identified an average of 5555 (22%) additional peptides compared 
to the T20 approach without a library. A comparison of average CV [%] values for identified 
peptides (T20= 24.6% and T2= 23.7%) and quantified proteins (T20= 13.3% and T2= 12.7%), 
however, did not reveal a significant difference in quantification accuracy between both 
methods (Supplementary Figure 4G). Outliers were removed for visualization, resulting in 
marginally reduced average CV [%] values for quantified proteins (T20= 10.7% and T2= 
9.6%). Low abundance peptides and proteins are the main effectors that contribute to the 
minor, negligible difference (Supplementary Figure 4G). The increased number of data 
points per peptide feature in T2 over T20 cannot improve the description of the area under 
the curve (AUC). 
During the early phases of this project, we had access to fresh-frozen tumor samples to 
establish our sample preparation workflows. This set of 17x pilot samples was subsequently 
used to compare the T20 and T2 method in a realistic scenario. The data were acquired 
using a 1-hour and a 2-hours gradient with and without library support. For the 1-hour 
method, we utilized a peptide library composed of either 16 or extended 32 fractions. On 
average, we identified and quantified 22% (T20) and 42.8% (T2) more proteins using the 2-
hours method. The proportion of peptides identified by matching decreased from roughly 
50% (1-hour T20 & T2) to 30% (2-hours T20) and 36% (2-hours T2). Stepping from 1-hour 
T2 to 2-hours T2 (T20), we observed a decrease in the relative number of missing values by 
4.76% (peptide-level) (0.6%) and 8.04% (protein-level) (4.5%). The library-matching 
approach reduced the percentage of missing values by 10 to 15% on peptide- and protein 
level. The effect was more pronounced using the library based on 32 fractions. More 
instrument time and lower sample complexity improve the library depth and only require 
a one-time higher expenditure of time. In line with our previous observation, the accuracy 
of quantification, assessed by calculating the CV [%] on peptide- and protein-level, did not 
reveal any advantage using the T2 method. We identified 4268 additional peptides using 2-
hours for data acquisition and 5956 peptides by employing the library-matching. Therefore, 
the majority of clinical samples within this work have been acquired using the classical T20 
method in combination with a sample-specific library, unless otherwise indicated. 
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Despite the implementation of the matching-between-runs algorithm in the MaxQuant 
software and its established usage in the proteomic community, the degree of false 
transfers and its associated credibility has only recently been investigated by Lim MY. et al., 
2019322. Similar to their two-proteome model, we had preliminary results from acquiring a 
constant amount of HeLa peptides with increasing spike-ins of 0%, 3%, 4.5%, 6%, 7.5%, and 
9% E. coli peptides (n= 3). Here, the transfer of identifications between samples resulted in 
an average of additional 33.5% human peptides compared to without the matching 
algorithm. For the E. coli spike-ins, the identification transfer rate increased with decreasing 
E. coli peptide concentration from 24% (3% E. coli) to 63.9% (9% E. coli) (Figure 5A). This 
leveraged the total number of E. coli peptides to an average of 1160 (n= 3), which could be 
identified from as little as 3% spike-in compared to the constant HeLa background (Figure 
5B). In the pure HeLa measurement (0% E. coli), we falsely identified an average of 179 E. 
coli peptides via the matching-between-runs (Figure 5C). This corresponds to an average of 
0.97% false peptide identification transfers. The majority of these peptide features were 
identified with a low intensity or a low posterior error probability (PEP) score (Figure 5D). 
Another 42 E. coli peptides were identified by MS2 spectra (Figure 5C). Roughly 25% of the 
unexpected E. coli peptides in the pure HeLa measurement, either identified via MS2 or per 
matching, could also match to a human protein sequence (Figure 5E). This indicates that 
peptides were likely assigned to the wrong database. In the recent study by Lim MY. et al. 
(2019)322, the authors reported similar percentages of false peptide transfers. However, 
also in accordance with our observations, the vast majority of these matches did not pass 
thresholds set within the LFQ calculation in the MaxQuant software. As a result, the number 
of falsely annotated and quantified E. coli proteins (0% E. coli: Figure 5F) only represent 
1.6% of all quantified proteins (0% E. coli: Figure 5F and Figure 5G). We further reduced the 
allowed time window for matching from default 0.7 minutes to 0.3 minutes (data not 
shown), which reduced the false transfers by one-third. This gave us sufficient confidence 
to employ the matching-between-runs functionality and benefit from higher peptide 
numbers that contribute to protein quantification and less missing values across samples. 
Recapitulating, we have evaluated and optimized several parameters and data acquisition 
strategies to achieve the highest proteome coverage with optimal quantification in the 
least amount of time. We could improve the performance of high-pH fractionation and 
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evaluated the relation between peptide library depth and time expenditure for its 
generation. Emerging from a series of experiments and evaluations, we finally settled for 
the classical data-dependent acquisition strategy with 2-hours per sample and a Top20 
spacing. The sample-specific peptide library (32 fractions) approach paired with matching-
between-runs (0.3 minutes match time window) was employed, despite that, we could not 
improve the quantification accuracy by focusing on MS1 scans. The increased number of 
peptide identifications, low numbers of missing values across multiple samples, and the low 
false transfer rate were persuasive. This setup was used for all clinical sample cohorts 
unless otherwise indicated. 
 
Figure 5: Two-proteome model for the evaluation of matching-between-runs in MaxQuant. A-B) The 
numbers of identified E. coli (A) or HeLa (B) peptides by matching-between-runs or per MS2 in our two-
proteome (HeLa, E. coli) spike-in series, comprising different amounts of E. coli (3%, 4.5%, 6%, 7.5%, 9%, and 
0%) with a constant HeLa background. C) The numbers of identified E. coli peptides by matching-between-
runs or per MS2in the pure HeLa samples (0% E. coli). D) Global comparison of the posterior error probability 
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(PEP) score for all E. coli, all human, and all unexpected E. coli (IDs in the pure HeLa sample) peptide 
identifications. E) Distinguishing between true and false identifications via matching-between-runs or per MS2 
based on peptide features that are likely false annotated as they also match to a human protein sequence. F-
G) The numbers of identified and quantified E. coli (F) or HeLa (G) proteins by matching-between-runs or per 
MS2 in our two-proteome (HeLa, E. coli) spike-in series, comprising different amounts of E. coli (3%, 4.5%, 6%, 
7.5%, 9%, and 0%) with a constant HeLa background. 
4.2. Automated SP3 (autoSP3) 
In the first phase of this project, we established and optimized a manual pipeline for 
proteomic sample preparation and LC-MS data acquisition. Following the 96-well format 
lysis of all types of specimens for protein extraction and DNA shearing, the core of our 
workflow comprises the SP3 method to facilitate the handling of detergents and to utilize 
its unique sensitivity for low-input applications. In the second chapter of this thesis, we 
focused on exploiting the amenability of protein clean-up and digestion using SP3 to 
establish a fully automated pipeline that seamlessly integrates with preceding sample lysis 
and protein extraction using the Covaris ultrasonicator. This potential of SP3 originates 
from the paramagnetic nature of the employed beads, rendering the possibility to perform 
the entire procedure on a robotic liquid handling platform. The resulting advantages of 
hands-free processing can solve several remaining bottlenecks that are important for 
clinical integration of proteome profiling: I) robustness and reproducibility; II) throughput 
and turn-around times; III) low costs and simplicity, and IV) a one-for-all method for 
universal sample preparation. 
In other systems biology disciplines, such as genomics, automated sample preparation was 
introduced almost a decade ago323 and is now widely used through commercial kits from 
different vendors. In the field of proteomics, it remains far less common and limited to 
specific purposes, for example, sub-proteome enrichment (e.g., AssayMap to purify 
phosphorylated peptides324), protein digestion and peptide clean-up161, or detergent-free 
applications, such as plasma proteomics (iST, on an automated system to process plasma 
and cell lysates325). 
Parts of the following chapter, including Figures and Tables, were taken in part or their 
entirety from the joint publication listed below. 
Mueller, Torsten, Kalxdorf, M., Longuespeé, R., Kazdal, D., Stenzinger, A., Krijgsveld, J. 
(2020). “Automated sample preparation with SP3 for low-input clinical proteomics”. 
Molecular Systems Biology 16(1): e9111. 
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4.2.1. Establishment of autoSP3: generic sample preparation 
Many different liquid handling systems are available on the market with their pros and 
cons. Here, we selected a Bravo liquid handling system (Agilent Technologies) for 
establishing our method because it offers a small bench-top footprint, and it is widely 
available to many laboratories. The automation of SP3 (autoSP3) required the 
establishment, optimization, and subsequent validation of a vast number of tasks and 
associated parameters. This included the positioning of required consumables, the 
reservoir capacity for reagent and waste volumes, as well as the Bravo accessories, such as 
a 96-well magnet, an orbital shaker, and a heating block. We had to ensure the accessibility 
of each consumable, reagent, or respective deck position to allow uninterrupted running 
of the entire procedure. The full capacity and functionality of the Bravo were utilized to 
automate the processing of 96 samples simultaneously. As a result, autoSP3 smoothly 
connects with the preceding extraction of proteins, facilitated by the Covaris (96-well 
format) or other methods that provide sufficient DNA shearing (Figure 6A). The resulting 
peptides are directly compatible with LC-MS or other downstream applications. 
For the development of autoSP3, a HeLa cell lysate was used as an input to evaluate and 
execute each task from reduction and alkylation of proteins, their clean-up, and proteolytic 
digestion, to the final recovery of peptides (Figure 6B and Figure 6C). Initially, we 
implemented the reduction and alkylation of proteins using DTT and CAA (“Protocol A”, 
Figure 6D). However, to minimize the number of protocol tasks and simultaneously 
decrease the number of reagents, we adapted the procedure for a combined reaction with 
TCEP and CAA for 5 minutes at 95°C (“Protocol B”, Figure 6D). The core SP3 protocol 
(“Protocol C”, Figure 6D) was programmed with the ability to be executed independently 
to allow the processing of samples that were reduced and alkylated otherwise. This was 
also of interest because the Bravo heating accessory is rather inefficient in heating and 
cooling, taking more than one hour to reach 95°C. Altogether, we provide three protocol 
options to either integrate reduction and alkylation with SP3 processing in a continuous 
procedure or to perform this off-deck in any preferred way to enhance speed and flexibility 
before transferring samples to the Bravo deck. While the latter is favorable in an academic 
research environment covering all eventualities, the complete workflow is attractive for a 
clinical setting. 
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During the autoSP3 protocol, both the paramagnetic bead stock as well as the enzyme 
solution (for example, trypsin) and optionally reducing and alkylating reagents, are 
deposited in a second 96-well plate to ease pipetting of small volumes and to avoid 
uneconomical dead volumes of expensive reagents (Figure 6B). The autolysis of trypsin is 
prevented during the execution of the protocol by its storage in 50 mM acetic acid, and 
dilution with an adequate volume of 100 mM ABC at the time of mixing with the protein 
samples to achieve a digestion-compatible pH range. The addition of reagents or solvents 
to the samples is performed by successively dispensing row-by-row across the entire 96-
well plate. All liquid dispensing heights were adjusted such that the pipette tips never 
contact the sample surface. In more detail, this alludes to variable dispensing heights along 
with the entire protocol, corresponding to the sample volume in every step. This eliminates 
the risk of cross-contamination. The removal of any liquid is carried out with well-specific 
pipette tips throughout the protocol. In pipetting tasks, additional air plugs are used to 
prevent spilling of hanging droplets from the tips. The aspirating and dispensing velocities 
for each step are defined specifically for different liquid classes. Combining row-by-row 
adding and well-specific removal of solvents and reagents, we were able to establish the 
SP3 protocol for 96-samples using only two pipette tip boxes, contributing to the overall 
low costs. 
After manual or automated reduction and alkylation of proteins, the autoSP3 protocol 
either begins or continues with the aliquoting of the paramagnetic bead suspension to each 
sample (Figure 6B). This is achieved by spotting 5 μL beads (50 μg/μL in ddH2O) as a droplet 
to the wall of each well and gently moving them into the sample solution by agitation in 
the orbital shaking accessory. The bead concentration was optimized as compared to the 
manual SP3 method (100 μg/μL in ddH2O) to improve the pipetting precision. In the next 
step, protein binding to the beads is induced by the addition of ACN to a final concentration 
of 50% organic (see also chapter 4.1.2.) (Figure 6B). While we could achieve ~8% and ~6% 
more identified peptides and quantified proteins using EtOH to promote polar interactions 
with the beads, the pipetting properties of ACN exhibit a better reproducibility (data not 
shown). The homogenous distribution of beads for the efficient formation of protein-bead 
aggregates is achieved by continuous alternating between fast and slow agitation rather 
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than pipette mixing. The latter resulted in a severe sample loss due to the tendency of 
beads sticking to the pipette tips under the >50% organic condition. 
 
Figure 6: A schematic overview of the automated single-pot, solid-phase-enhanced sample preparation 
(autoSP3) workflows. A) Illustration of the end-to-end workflow from fresh-frozen tissue or cells to injection-
ready peptides and LC-MS. B) The overview shows the different steps of the autoSP3 protocol from protein 
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input to enzymatic digestion. The setup of the Bravo deck is shown for the core clean-up protocol. C) The 
overview shows the steps and Bravo deck setup of the autoSP3 peptide acidification and recovery protocol. 
The protocol ends with MS injection-ready peptide samples. D) A schematic overview of all available autoSP3 
protocol versions. The autoSP3 procedure is provided with three options for reduction and alkylation and 
with post-digestion peptide recovery. Protocol A: one-step reduction and alkylation using a TCEP/CAA mixture 
for 5 minutes at 95°C, followed by autoSP3. Protocol B: two-step reduction and alkylation using DTT and CAA 
consecutively with 30 minutes incubation at 60°C and 23°C, respectively, followed by autoSP3. Protocol C: 
the core autoSP3 protocol is omitting reduction and alkylation such that the user can flexibly pre-treat 
manually prepared samples. Protocol D: post-digestion acidification and recovery, delivering MS injection-
ready peptides to a new sample plate. Modified from Mueller et al., Mol. Syst. Biol., 2020. 
The protein-bead aggregates are rinsed with two times 80% EtOH and one time 100% 
ACN291 (Figure 6B). The potency of each cleansing task is increased by orbital shaking. For 
the disposal of the washing solvents, sample plates are stalled on the magnetic rack to allow 
the beads to settle in a ring shape above the well-bottom. The removal of the wash solvent 
was split into two consecutive aspiration tasks to minimize the residual liquid volume 
effectively. Here, EtOH was observed to drain from the sidewall in each well due to its 
viscosity. Neglecting the second aspiration step reduced the clearance of contaminants and 
potentially interfered with the subsequent digestion. A low residual concentration of less 
than 5% ACN (~2 μL) might enhance the protein digestion by assisting in protein unfolding 
and maximizing the accessibility of amino acid sequence cleavage sites as a result. However, 
this was not experimentally tested, and we tried to avoid exceedingly high residual ACN 
concentrations not to affect the protease activity. After the last washing step, proteins 
trapped on the paramagnetic beads are covered in digestion buffer, plates are manually 
sealed, and transferred to a PCR thermocycler incubation. We chose a thermocycler with 
lid heating to avoid evaporation during the process. Following enzymatic digestion, 
resultant peptides were automatically acidified and recovered to a new sample plate. The 
acidification and peptide recovery tasks were programmed as an independent protocol 
(Figure 6C) because supplying a new set of tips was required. 
Initially, we benchmarked the performance of autoSP3 compared to the manual procedure 
by processing replicates of the same sample. Between both methods, we observed similar 
ion intensities (base peak and total ion chromatograms) and CV [%] values for numbers of 
identified peptides (1%) and quantified proteins (1%) (Figure 7A). The lack of cross-
contamination was demonstrated by running a 96-well plate of HeLa lysate alternating with 
empty controls. In comparison to sample-containing injections, most control samples had 
a residual MS intensity of less than 0.03% (Figure 7B). The residual intensities were 
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primarily attributed to autolytic peptides of trypsin (added to each sample, including empty 
controls), and to (non-peptidic) contaminants with a +1-charge state (Figure 7C). This was 
sharply contrasting with rich chromatograms from protein-containing samples (Figure 7C). 
 
Figure 7: autoSP3 reproducibility and proof of absent cross-contamination. A) A comparison of three versus 
three individually processed samples using the manual SP3 protocol or autoSP3. The upper panel (red) shows 
the base peak and total ion chromatogram (TIC) of three autoSP3 HeLa samples, while the lower panel (black) 
shows base peak and TIC of three manual SP3 HeLa samples. The number of proteins and peptides identified 
by either workflow is indicated per replicate. B) Schematic representation of the experimental design to 
demonstrate the absence of cross-contamination between wells. Half a plate (48 wells) was processed with 
10 μg protein of a HeLa batch lysate in every second well (highlighted in blue) interspaced with empty wells 
as a control (highlighted in red). Randomly selected wells (highlighted in solid) were selected for direct LC-
MS. Bar plots of the summed intensities of protein groups across selected samples. A total of seven sample-
containing injections were performed, and a total of twelve empty controls. Asterisks indicate intensities 
<0.03%. C) Exemplary base peak MS1 spectrum for an empty control injection (top) and a sample-containing 
injection (bottom). Modified from Mueller et al., Mol. Syst. Biol., 2020. 
We established, optimized, and benchmarked the SP3 protocol on a Bravo liquid handling 
system, taking care of all sample handling steps304. AutoSP3 directly interfaces with 96-well 
format lysis, protein extraction, and DNA shearing facilitated by the Covaris. Alternatively, 
the protocol can start from 96 cell- or tissue lysates from any source that provides a 
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sufficient sample quality. A complete run of the Bravo SP3 protocol takes one hour and 23 
minutes for 96 samples (“Protocol C”, Figure 6D) with an additional 45 or 65 min for 
optional reduction and alkylation with DTT/ CAA (“Protocol A”, Figure 6D) or TCEP/ CAA 
(“Protocol B”, Figure 6D), respectively. The peptide-containing supernatant can be 
recovered without further clean-up for direct LC-MS data acquisition or any compatible 
downstream protocol, such as high-pH fractionation (e.g., for library generation) or TMT 
labeling. The recovery of samples can be performed using a separate acidification and 
peptide recovery protocol, which takes about 7.5 minutes to complete (“Protocol D”, Figure 
6D). 
4.2.2. Evaluation of autoSP3 precision 
Reproducibility and precision are the main focus of any automated procedure. The latter is 
defined, for example, by the European medicines agency (EMEA) as the variability observed 
within a laboratory299. For autoSP3, we assessed both by determining the intra-day 
precision and the longitudinal inter-day precision throughout one month326. Therefore, we 
utilized reduced and alkylated proteins extracted from HeLa cells with sufficient DNA and 
RNA shearing. A total of six 96-well plates, corresponding to 576 individual samples, were 
processed in the morning and in the afternoon of three different days (3 times intra-day) 
(Figure 8A). Choosing “Day-1” and following “Day-13” and “Day-27” for the sample plate 
processing covered a period of roughly one month and allowed to infer the inter-day 
precision by correlating data obtained across all six plates. In more detail, the LC-MS 
analysis was performed for five randomly selected samples per 96-well plate immediately 
after autoSP3 sample processing on the same day. In the end, the same set of selected 
samples was re-measured as a coherent batch, resulting in a total of 60 LC-MS runs. This 
allowed us to determine the potential influence of autoSP3 processing or longitudinal MS 
performance fluctuations. Taken together, the acquired data allowed us to assess the 
variability within a single plate, within a single day (two 96-well plates), across three days, 
as well as including and excluding the variance imposed by the MS performance. As the first 
indication of reproducibility, the observed intensities of all identified peptides were 
consistent within and across days (Pearson correlation R= 0.9) (Figure 8B). 
To evaluate the data more deeply and assess the intra-day precision at the level of proteins, 
we initially filtered the list of observations obtained from a single day (10 samples) for at 
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least three quantified values (3 out of 10). This filtering resulted in 2672, 2537, and 2663 
quantified proteins for “Day-1”, “Day-13”, and “Day-27”, respectively (Figure 8C). More 
than 91% of quantified proteins exhibited a CV [%] within each day of less than 30%. The 
median CV’s [%] per day ranged from 10.9% to 12.9%. This highlights an overall consistent 
quantification of proteins across sequentially processed replicates originating from 
different plates within a day (intra-day). 
 
Figure 8: Longitudinal assessment of autoSP3 performance and reproducibility. A) A schematic 
representation of the experimental design. 96 times 10 μg protein of a HeLa batch lysate were processed in 
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the morning (Plate A) and the afternoon (Plate B) at three different days (Day-1, Day-13, and Day-27) over a 
month. From each plate, five randomly selected samples were subjected to direct LC-MS analysis (red dots). 
In addition, all 30 samples (ten per day) were measured in a single combined batch to judge the influence of 
MS variability B) Box-whisker plots of log2-transformed peptide intensities across all 60 raw files. The color-
coding highlights the plate in which each sample was processed. C) Cumulative frequency curve [%] of the 
observed coefficient of variation (CV) of proteins that were identified and quantified with a minimum of three 
valid values within each day. Here, the ten raw files of each day are evaluated individually. The resulting 
median and average CV [%] for each day are shown. D) Bar plot summarizing the number of quantified LFQ 
protein groups across 60 HeLa samples. Samples originating from different days and the consecutive 
injections of the same samples are highlighted in grey scales. E) A line chart is showing the proportion of 
quantified proteinGroups across all 60 autoSP3 HeLa samples. The data are shown with and without the use 
of match-between-runs. F) Histogram showing CV’s [%] of quantified proteins across all 60 automatically 
prepared HeLa samples, proportional to CV’s [%] of sixteen manually prepared samples. The median and 
average CV [%] is shown for both automatically and manually prepared samples. A dotted line highlights the 
ratio of 1. G) Histogram showing CV’s [%] of quantified proteins from sixteen randomly selected out of 60 
samples, proportional to sixteen manually prepared samples. The median and average CV [%] is shown for 
both automatically and manually prepared samples. A dotted line highlights the ratio of 1. H) Pearson 
correlation heatmap of all 60 raw files and an additional sixteen manually prepared HeLa SP3 samples. The 
displayed data are filtered for 75% data completeness (Table 1). Please note the narrow scaling (1-0.94). 
Modified from Mueller et al., Mol. Syst. Biol., 2020. 
We further determined the inter-day precision of the autoSP3 performance by considering 
the entire dataset (all 60 LC-MS runs). On top, we manually prepared 16 replicates of the 
same sample using SP3. The average number of identified peptides and quantified proteins 
was 14.140 and 3191, respectively (Figure 8D). By applying the MaxQuant matching-
between-runs feature, we could increase the proportion of consistently (non-missing 
values) quantified proteins from 33.62% to 58.37%. This increased the number of proteins 
that are considered for our assessment to n=3750, with a median and average CV [%] of 
18.1% and 20.5%. Hereinafter, we additionally calculated the CV’s [%] of quantified 
proteins with either a minimum of three valid values (3 out of 60; n=3688 proteins) or ¾ 
valid values (45 out of 60; n=2964 proteins). The latter requirement is equivalent to the 
minimum data completeness of 75% and covers 78.04% of the entire list of observed and 
quantified proteins (Figure 8E). CV’s [%] were calculated for within each day, across days, 
without the LC-MS performance variability as one batch, and overall 60 measurements 
(Table 1). The comparison of CV’s [%] of samples that were analyzed on the day of sample 
preparation (median 13.3%, Table 1) to the acquisition of the same samples as a single 
batch (median 14.3%, Table 1) did not reveal a negative influence driven by the longitudinal 
LC-MS performance. We obtained excellent CV [%] values irrespective of the time of sample 
preparation or data acquisition over extended time periods (here four weeks). Across all 60 
(+16) LC-MS runs we could see a marginal improvement of median and average CV’s [%] 
between autoSP3 (14.6% and 17.2%; n=60 runs) and manual SP3 (16.3% and 18.6%; n=16 
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runs). Yet, these numbers compare favorably to what is generally observed for label-free 
quantitation (20-30%). The frequency distribution of CV [%] ratios between autoSP3 and 
manual SP3 position towards consistent lower variation using the automated workflow on 
a per-protein basis (Figure 8F and Figure 8G). 
 
Table 1: Summary of the observed coefficient of variation (CV’s) Corresponding to Figure 8, the table 
summarizes median and average coefficient of variation (CV) [%] values for individual days, across days, with 
and without the MS-imposed variability, and manual SP3. CV [%] values were calculated with either 75% data 
completeness requirement (~80% of all available quantified proteins) or with a minimum of three valid values 
across 60 samples. Modified from Mueller et al., Mol. Syst. Biol., 2020. 
Both autoSP3 and manual SP3 yielded robust protein quantification with a Pearson 
coefficient of higher than 0.97 across all 60 LC-MS runs and an additional 16 manually 
processed samples (Figure 8H). We could not observe a considerable difference between 
quantified proteins from “Day-1”, “Day-13”, and “Day-27”, respectively. This is a good 
indication for excellent inter-day precision. The correlation between autoSP3 and manual 
SP3 data was marginally reduced at >0.94, which is likely reflecting minor differences in 
both procedures, for example, processing volumes. 
High abundant proteins are more reproducibly quantified across the entire autoSP3 
dataset. This is highlighted by varying CV [%] value distributions based on protein 
abundance (Supplementary Figure 5A). Intensity bins were defined from highest to lowest 
as follows: ‘A’: 1-500; ‘B:’ 501-1251; ‘C’: 1252-2001; and ‘D’:2002-2964. The CV [%] values 
were calculated within each bin range. More than >97.5% of proteins in groups ‘A’ and ‘B’ 
exhibited a CV [%] of less than 30% (median <10%), contrasting to 39.1% (CV<30%) of 
proteins in group ‘D’. The lowest abundant proteins in group ‘D’ are comprised of the ~1000 
proteins recovered by the matching-between-runs feature in MaxQuant. Disabling 
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matching-between-runs reduces the number of quantified proteins from n=2964 to 
n=2019, while increasing the percentage of proteins with a CV [%] value below 30% to 
76.2% in group ‘D’ (Supplementary Figure 5B). A selection of previously described 
housekeeping proteins327 and two randomly selected low abundant proteins showed CV 
[%] values below 5% and 25% for the highest abundant and low abundance proteins for 
both, within and across all days (Supplementary Figure 5C). 
Taken together, we could demonstrate the robustness and high performance of SP3 for 
automated and manual handling. The autoSP3 procedure slightly improved the median CV 
[%] values, while adding a large sample processing throughput and minimizing hands-on 
time as a result. The longitudinal performance was highly reproducible for four weeks and 
irrespective of the LC-MS. 
4.2.3. Assessment of autoSP3 sensitivity 
A permanent challenge in the field of proteomics is the handling and analysis of low-input 
material149,307,313,314,328,329. This originates either from inefficient sample preparation and 
associated losses of material or from suboptimal liquid chromatography interfaces and 
confined mass spectrometer performances. In this chapter, we harnessed the unique 
sensitivity of autoSP3 to handle sub-microgram amounts of protein input. As a key asset of 
SP3, this was previously demonstrated for manual handling in a number of scenarios149,314. 
Here, we demonstrated the ability of autoSP3 to handle minute amounts of a sample by 
processing a 2-fold serial dilution of our HeLa protein stock (10 μg to ~5 ng; n=4 per 
concentration) (Figure 9A). The potential of carry-over between samples was eliminated by 
injecting from the lowest to the highest amount of proteins in blocks with blanks in-
between. For the four highest input amounts (10 μg to 1.25 μg), an estimated equivalent 
of 1 μg was measured to avoid the overloading of the analytical column. As a result, the 
number of absolute quantified proteins and their summed intensities reached a plateau, 
indicative for overall good recovery of peptides from the autoSP3 beads. The remaining 
samples (< 1 μg) were sufficient for a single-shot injection. Across the whole range of 
protein input amounts, we observed narrow error distributions. This illustrated a high 
degree of reproducibility across all sample amounts. The injection of sub-microgram 
amounts of the sample was sufficient to quantify, for example, 403 and 681 proteins from 
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~39 ng and ~80 ng material, respectively. The data illustrate the efficiency of autoSP3 (SP3) 
to capture and rinse proteins, and to release peptides ready for LC-MS. 
 
Figure 9: Evaluation of autoSP3 sensitivity. A) Schematic representation of the experimental design with a 
1:2 dilution series of a HeLa batch lysate starting from 10 μg down to 5 ng. The distribution of samples across 
the 96-well plate is shown. The dilution series was prepared in four replicates, and samples were injected 
from the lowest to the highest concentration. For the four highest concentrated samples, 1 μg material was 
injected, whereas, for sub-microgram samples, the entire sample was used. The average number of quantified 
proteins per sample, as well as the corresponding sum iBAQ intensities, are shown with error bars from the 
4 replicates. B) Schematic representation of the experimental design of processing small numbers of HeLa 
cells. Series of decreasing cell numbers were prepared from 10.000 to 10 cells in 8 replicates. The average 
number of quantified proteins per sample, as well as the corresponding sum iBAQ intensities, are shown with 
error bars from the eight replicates. Modified from Mueller et al., Mol. Syst. Biol., 2020. 
Taking this one step further, we started a similar experiment with counted numbers of cells 
to replace the HeLa batch lysate. This represents a more realistic scenario of limited input 
material, such as applications with patient-derived or FACS-sorted cells. In more detail, we 
counted a single-cell suspension of HeLa cells and directly transferred equivalents of 10.000 
to 10 cells into a 96-well plate, corresponding to a range of 1 μg to 1 ng protein (assuming 
0.1 ng protein per cell). To increase the reliability of the experiment, we processed a total 
of eight replicates per cell number in two independent 96-well plates (Figure 9B; see also 
Figure 2D). The entire sample processing, including cell lysis, DNA shearing, and autoSP3, 
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were performed without changing the sample plate. For each sample, the entire volume 
was subjected to LC-MS. Both numbers of absolute quantified proteins, as well as their 
intensities, scaled with the protein input. For the 1 μg-sample (10.000 cells), we quantified 
almost 2000 proteins, which is in range with our expectations (compared to Figure 9A and 
Figure 2D) and considering the utilized LC-MS setup and gradient length. A great end-to-
end reproducibility was further highlighted by the overall narrow error distributions across 
all replicates and two independent sample plates. This was also seen in a similar experiment 
using the Covaris for cell lysis and DNA shearing (Figure 2D). As little as 100 cells of starting 
material was sufficient to quantify 459 proteins on average. 
In summary, our autoSP3 workflow is capable of reproducibly processing minute amounts 
of starting material and providing sufficient sample quality. This allows the quantification 
of several hundreds of proteins from as few as 100 to 1000 cells or below 100 ng protein. 
Beyond the scope of this work, this opens the path for exciting new applications for which 
no reliable sample processing was available. This can be part of particular interest in a 
clinical context, in which sample availability is scarce, but demands in data depth and 
quality are high. Providing the ability to process these samples in an automated fashion 
eliminates the inflated issue of reproducibility when handling low amounts of material. 
4.2.4. autoSP3 and challenging specimens 
An important requirement to establish a broad involvement of proteome profiling is the 
intrinsic ability to convert difficult-to-handle samples to high-quality data. FFPE samples 
comprise the most obvious source of challenging input material159,168,330–332. They are the 
specimen of choice for histopathological diagnosis and routinely collected for cancer 
patients or other diseases, making it an invaluable resource in translational research. 
Formalin induces cross-linking between proteins to conserve and stabilize the integrity of 
the tissue and enables long-term storage. Both linked proteins (linked peptides) and 
paraffin interfere with global proteome profiling and require a suitable sample preparation 
strategy. The de-crosslinking of peptides and proteins is commonly achieved by treatment 
with SDS, which can be efficiently removed before the tryptic digestion by autoSP3 (SP3). 
Its robustness, sensitivity, and flexibility are additional assets that uniquely qualify autoSP3 
(SP3) for the processing of FFPE specimens. Here, we combined the ability to process low 
amounts of material with a clinical real-world FFPE tissue cohort of pulmonary ADC. 
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4.2.4.1. End-to-end sample preparation 
Thus far, the complete workflow from a raw specimen to injection-ready peptides for LC-
MS is fully established for cells and fresh-frozen tissue using the Covaris interfaced with 
autoSP3. To demonstrate the efficient end-to-end processing, we lysed 100.000 HeLa cells 
(n=15) and varying amounts (1.5 to 7.5 mg wet weight) of different fresh-frozen tissue 
types, as previously mentioned (Figure 2E). Upon extraction of proteins in the Covaris 96-
well AFA-tube TPX plates, they were transferred directly to the Bravo liquid handling robot 
for autoSP3 using the established protocols. From each processed sample type (HeLa cells, 
pig heart tissue, mouse kidney, and mouse liver tissue), we randomly selected five 
replicates and continued to acquire LC-MS data, resulting in highly consistent numbers of 
identified peptides with an average Pearson correlation of higher than 0.94 (Figure 10A). 
 
Figure 10: End-to-end proteome profiling using ultrasonication interfaced with autoSP3. A) Pearson 
correlation heatmap of peptide intensities across five replicates of each sample type (heart, liver, kidney, 
HeLa cells) with the corresponding average. B) The relative number of identified and quantified proteins 
across the five replicates of each sample type. The average number of identified proteins and the standard 
deviation across five replicates is shown on top. C) Cumulative frequency curve [%] of the observed coefficient 
of variation (CV) [%] of proteins that were identified and quantified in at least three out of five replicates in 
each sample type. The resulting median and average CV [%] for each sample type are shown. Modified from 
Mueller et al., Mol. Syst. Biol., 2020. 
HeLa cells exhibited a marginally lower average at 0.87, which likely reflects variation in 
manual cell counting and aliquoting of small cell numbers. Similarly, the number of 
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quantified proteins per sample type was highly reproducible (Figure 10B). The CV [%] 
distribution within each sample type revealed that more than 84% of all proteins could be 
quantified with a CV [%] lower than 30% (Figure 10C). Median CV’s [%] between 10.4% 
(liver) and 15.5% (HeLa cells) demonstrated the processing precision spanning the entire 
procedure from tissue lysis to data acquisition using LC-MS. The end-to-end workflow takes 
about 3.5 hours for 96 samples, including one hour for ultrasonication for tissue lysis, 
protein extraction, and DNA shearing. For FFPE tissue, we are currently still working on the 
full integration of the AFA-based de-paraffinization (Covaris) and the subsequent 
interfacing with the autoSP3 setup. Therefore, the ADC FFPE cohort was collected in PCR 8-
strips and lysed in two batches using the Bioruptor Pico with a customized tube holder. 
Upon protein extraction with sufficient DNA shearing, we manually transferred all samples 
in a random order to a 96-well plate to perform autoSP3. 
4.2.4.2. Pulmonary adenocarcinoma (ADC) FFPE 
Five different growth patterns of ADC are recognized by the WHO but yet remain without 
a comprehensive clinical implication. Gene expression differences have only been identified 
between lepidic ADCs and all other histologic patterns217. The remaining growth patterns 
(acinar, papillary, solid, and micropapillary) have not been characterized, despite their 
known higher invasiveness. Here, we aimed to perform proteomic profiling to potentially 
identify functional differences, a causality for the different growth patterns, or biomarkers 
and therapeutic targets. 
We collected consecutive 5 mm x 5 mm x 5 μm sections of tumors blocks that originated 
from eight different lung cancer patients. Every section was histologically classified 
(Hematoxylin and Eosin (H&E) staining) to locate and distinguish the multi-regional 
composition of growth patterns. Subsequently, two to four growth patterns could be 
selected per tumor, resulting in a total of 51 samples that were processed using our pipeline 
(Figure 11A). All samples were randomized during sample preparation and LC-MS 
acquisition. On average, we quantified 3576 proteins across the entire cohort (Figure 11B) 
using ¼ of the available sample material. Consecutive sections (biological replicates) 
exhibited a nearly perfect similarity (Figure 11C and Figure 11D) despite their 2-fold 
randomization during the process. This particularly highlights the reproducibility of our 
workflow. The grouping was mainly driven by the patient of origin (Figure 11C) rather than 
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the respective growth patterns (Figure 11D). Taking this into account as a batch-effect, we 
applied a linear regression model and achieved a rudimental separation of the three 
superordinate groups as a result (Figure 11E). The superordinate groups are defined as: I) 
lepidic (low grade; group 1), acinar and papillary (intermediate grade; group 2), and solid 
and micropapillary (high grade; group 3). Both lepidic and papillary growth patterns could 
now be separated from all other samples. At the same time, consecutive sections with the 
highest likelihood to be similar were still grouped. The dissimilarity within papillary 
samples, split into two distinct subclusters and separated from group 2 (acinar), was 
somewhat unexpected. While the tumor cell content (TCC) might explain this observation, 
it was rather randomly distributed over all samples (Figure 11F). 
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Figure 11: Proteome profiling of tumor growth patterns of pulmonary Adenocarcinoma (ADC) FFPE tissue. 
A) Schematic illustration of the sample collection. Samples were collected from eight different patient tumors. 
For each tumor, sections were processed with hematoxylin & eosin (H&E) staining to locate different growth 
patterns of lepidic (low-grade; group 1), acinar and papillary (intermediate grade; group 3), and solid and 
micropapillary (high-grade; group 3). Two to four growth patterns per tumor were selected and sectioned in 
two consecutive 5 μm iterations to provide replicates with the highest possible similarity, resulting in a total 
of 51 samples (one iteration was missing). B) Bar plot summarizing the number of quantified LFQ protein 
groups per sample. C) t-distributed stochastic neighbor embedding (t-SNE) analysis of the uncorrected 
proteome data. The samples are color-coded according to their patient origin. D) Same as in C, now color-
coded according to their tumor growth pattern. E) t-distributed stochastic neighbor embedding (t-SNE) 
analysis of the proteome data corrected via a linear regression model. The different growth patterns are 
color-coded as in panel A. F) Same as in E, now color-coded for the tumor cell content (TCC) [%] of each 
sample. G) Volcano plot showing differential expression analysis using Limma moderated t-statistics for the 
comparison of lepidic samples against all other samples. Proteins passing significance thresholds of -log10 p-
value < 0.05 (Benjamini-Hochberg adjusted) and an absolute log2 fold change of >1 are highlighted in orange. 
H) Summary of significantly expressed proteins in the comparison of each growth pattern against all others. 
Modified from Mueller et al., Mol. Syst. Biol., 2020. 
A comparison between both subclusters of papillary samples (Supplementary Figure 6A) 
revealed 73 differentially expressed proteins (Supplementary Figure 6B and 
Supplementary Figure 6C). Collagen- and extracellular matrix-related gene sets were found 
to be enriched within papillary_2 (Supplementary Figure 6D), using a gene-set enrichment 
analysis, which might hint to differing tumor microenvironments. In papillary_1, we found 
an overrepresentation of mRNA nonsense-mediated decay and translation. The elimination 
of dysfunctional mRNAs might show a selective impairment in one of both subclusters. 
More analyses, beyond the scope of this project, are needed to unravel these phenomena 
in more detail. 
Next, we used a Limma moderated t-statistics differential expression analysis to identify 
growth pattern-specific proteins (Figure 11G and Figure 11H). This was done by comparing 
the expression profiles of each group against all other groups. The highest number of 
differentially abundant proteins (167) was found in lepidic tissue (Figure 11G). We further 
subjected these proteins to a gene ontology (GO)-term enrichment analysis 
(Supplementary Figure 6E). Again, collagens were among the high abundant proteins, 
possibly reflecting a different composition of the extracellular matrix. Lung cancer growth, 
invasion, and metastasis have previously been linked to collagens333,334. Mitochondrial 
ribosomal proteins (MRPs), previously reported as a predictor of survival and progression 
with potential prognostic value in NSCLC335, were found among the significant proteins. 
Gene sets were enriched for metabolism of polyamines and glucose metabolism in all 
groups compared to lepidic samples (Supplementary Figure 6F). The increased capability 
of polyamine synthesis is linked to accelerated tumor spreading and invasiveness336. 
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Another key characteristic of the majority of NSCLC tumors is the absorption of glucose and 
metabolism towards anaerobic pathways, which is strongly associated with higher 
aggressiveness337. All of the mentioned observations are in line with the already known 
high aggressiveness and unfavorable prognosis of intermediate and high grade (group 2 
and group 3) growth patterns as compared to low-grade lepidic samples206. 
We further identified 24 proteins that were significantly different between papillary and all 
remaining samples. Among them, a subunit of the glycosylphosphatidylinositol 
transamidase complex, namely PIGT, was overexpressed. This deregulation has been 
associated with NSCLC in comparison to small cell lung carcinoma and healthy lung tissue. 
The potential implication for disease diagnostics, prognostics, and therapeutic intervention 
has been proposed338. Golgi-associated vesicle budding, intra-Golgi, and Golgi-to-ER 
trafficking, as well as retrograde transport at the trans-Golgi network, were identified 
among the top 10 most significantly enriched gene sets (Supplementary Figure 6G). This 
might implicate the involvement of the secretory pathway. Taken together, our data 
suggest that papillary-specific pathology extensively interacts with its environment. A 
coherence between NSCLC and secreted proteins has been postulated previously339. A 
differentiation between individual ADC growth patterns on the molecular level did not exist 
up until now. Here, we could identify regulated proteins for lepidic and papillary growth 
patterns. For the remaining three growth patterns, we could not identify differentially 
abundant proteins. 
The primary purpose of the generated dataset was to demonstrate the applicability of our 
autoSP3 workflow and showcase the processing of a realistic, clinically-relevant FFPE cohort 
with quantity-limited material. Despite the randomization of samples during the sample 
preparation and during the LC-MS analysis, we found a tight grouping of the consecutive 
FFPE sections. This illustrates a high precision of the autoSP3 protocol. Further, the end-to-
end processing virtually eliminates most manual sample handling steps, where an active 
user is only required for the plate transfer from the Covaris to the Bravo to the PCR cycler 
for proteolytic digestion, and back to the Bravo. In the end, injection-ready peptides can be 
recovered into a new sample plate, which is directly compatible with the LC autosampler. 
The overall hands-on time is reduced to less than 5 minutes. In addition to the technical 
aspects, our other interest was the molecular characterization of the histologic ADC growth 
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patterns. Due to the wide range of different tumor cell contents per sample, we refrain 
from drawing any conclusion besides confirming previous knowledge. However, we 
anticipate further experiments with firstly, microdissection of FFPE slides to achieve 
maximal TCC, and secondly with a fully established end-to-end processing for FFPE, 
including the de-paraffinization (Covaris) in combination with autoSP3. Both will add to the 
biological data quality and enable an improved interpretation of functional differences 
between ADC growth patterns and their potential clinical implications. 
4.3. Ependymoma (EPN) brain tumors 
In the last chapter of this thesis, we aimed to demonstrate the added value of large-scale 
protein expression profiling, complementary to other NGS-layers, for translational 
research. For this purpose, we utilized a cohort of EPN pediatric brain tumors, which have 
been extensively characterized by our collaborators on various levels, including genetic, 
epigenetic, transcriptional, demographical, and clinical data73. Nine distinct molecular 
subgroups were classified based on the DNA methylome, expanding histopathological 
grading that suffers from a limited clinical utility, poor interobserver reproducibility, and 
lack of predictive potential for a patients’ outcome. Despite the superiority of molecular 
classification to histological grading, the majority of subgroups still lack a functional 
explanation, and genetic drivers remain unknown. In many cases, the correlation between 
cancer entities or states and their corresponding proteome composition is unclear. This 
also applies to ependymoma and its nine molecular subgroups. Here, the proteome 
profiling has the prospect to elevate our current understanding of EPN biology and identify 
actionable, subgroup-specific pathways, and targets. 
For proteomic profiling, we utilized fresh-frozen tissue in the range of 3.5 to 6.6 mg wet 
weight and the following numbers of samples per subgroup: SP-EPN (n= 5), SP-MPE (n= 7), 
SP-SE (n= 3), PF-EPN-A (n= 24), PF-EPN-B (n= 12), PF-SE (n= 7), as well as ST-EPN-RELA (n= 
20), ST-EPN-YAP1 (n= 4), ST-SE (n= 5), and healthy (n= 5). The sample preparation was 
carried out simultaneously to the evaluation and optimization of the SP3 protocol (Chapter 
4.1) and before its automation (Chapter 4.2). The acquisition of the final dataset was 
performed using the parameters described in the method section. In total, we identified 
and quantified 8248 proteins in the EPN cohort. 
Results 
97 
Parts of the following chapter, including Figures and Tables, were taken in part or their 
entirety from the joint publication listed below. 
Hübner, J. M., Mueller, Torsten, Papageorgiou, D. N., Mauermann, M., Krijgsveld, J., 
Russell, R. B., Ellison, D. W., Pfister, S. M., Pajtler, K. W., Kool, M. (2019). „EZHIP/CXorf67 
mimics K27M mutated oncohistones and functions as an intrinsic inhibitor of PRC2 
function in aggressive posterior fossa ependymoma.” Neuro Oncology 21(7): 878-889. 
4.3.1. Proteome profiles of molecular subgroups 
Protein expression is dynamically regulated in a spatiotemporal manner and exhibits a high 
complexity as a consequence90. Hence, we firstly investigated whether the global proteome 
information suffices to discriminate between the molecular subgroups as defined based on 
DNA methylation patterns (n= 515; Figure 12A). Affymetrix gene expression profiles (n= 
135; Figure 12B), as well as proteome profiles (n= 103; Figure 12C), result in a fine 
recapitulation of the classification across all tumor types and CNS compartments. This is 
further indicated by the observed silhouette scores per omics layer (methylome s= 0.57, 
transcriptome s= 0.59, and proteome s= 0.43). The clearest separation is observed from the 
transcriptome data and the methylome data. For the latter, the top 5% of CpG probes with 
the highest standard deviation were used (~21.000 CpG probes). 
Both methylome and transcriptome data exhibit an additional sub-subgroup within PF-EPN-
A tumors. Although less obvious, this observation holds for the proteome level when 
focusing on the individual subgroup (Figure 12D). The proteome additionally revealed a 
subgrouping within ST-EPN-RELA tumors (Figure 12E). To demonstrate this, we utilized an 
unsupervised hierarchical clustering of the top 1000 most variable proteins (Figure 12F). 
The vast majority of samples were clustered according to their molecular subgroup. The 
separation of subgroups based on their anatomical location (PF, ST, and SP) was less 
pronounced as compared to the methylome data73. For example, SP-EPN samples were 
clustered close to ST-EPN-YAP1 rather than the remaining SP subgroups. Using the 
proteome data, we identified 2 and 3 sub-subgroups for ST-EPN-RELA and PF-EPN-A, 
respectively. A more detailed analysis of underlying differences is provided in chapter 
4.3.3.4. 
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Altogether, the generated proteome profiles of the EPN cohort seem to recapitulate the 
previous molecular classification. The differences between anatomical regions are less 
prominent as compared to the methylome data. Still, it is interesting that all omics-layer 
lead to a similar subgrouping. This might be expected following the basic principle of 
silenced or active chromatin regulating the expression of genes and proteins as a result. 
However, the driving features per omics-layer (underlying genes of driving CpGs, driving 
transcripts, and driving proteins) are different. Hence, we continue with an in-depth 
analysis of gene- and protein expression to further investigate subgroup-specific functional 
implications. 
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Figure 12: Molecular classification of ependymoma (EPN) tumors and sub-subclassification. A-C) t-
distributed stochastic neighbor embedding (t-SNE) analysis of EPN methylation patterns (n= 515, top 5% of 
CpG probes with the highest standard deviation) (A), the transcriptome gene expression (n= 135), and the 
proteome profiles (n= 103). D-E) umap and t-SNE analysis of PF-EPN-A (D) and ST-EPN-RELA (E) tumors, 
revealing sub-subgroups in the proteome composition. F) Hierarchical clustering of the top 1000 most 
variable proteins. Methylome and transcriptome data were provided by our collaborators from Pajtler et al., 
2015. 
4.3.2. Subgroup-specific putative marker proteins 
The comprehensive dataset provides a unique opportunity to identify molecular features, 
such as genes or proteins, that can be utilized as indicative biomarkers for a (patho)-
physiological state or an EPN subgroup. The extraction of biomarkers or functional 
signatures can be increasingly challenging as a result of more complex datasets. Here, 
proteins that are exclusively expressed within a single EPN subgroup represent easily 
accessible candidates. We could identify several uniquely expressed proteins for each 
subgroup, some of which are additionally found within the healthy reference tissue (Figure 
13A). The vast majority of the latter group of proteins do not exhibit a significantly changing 
expression compared to the healthy control group. Other proteins, such as SLC38A1 (in PF-
SE), an amino acid transporter, are solely found within a respective subgroup and not in the 
healthy tissue. SLC38A1 has been associated with proliferation, migration, and tumor 
progression in other cancer entities but not EPN. 
The highest number of unique proteins was identified within ST-EPN-RELA. Among them, 
we consistently observed ARAP3 (in 15/ 20 samples; Figure 13B), a GTPase-activating 
protein for ARF and RHO family members. It is known as a genuine effector of the 
phosphoinositide 3-kinase (PI3K) signaling pathway and involved in downstream regulation 
of angiogenesis340. Interestingly, a previous supervised gene expression analysis has 
suggested ARAP3 as a signature gene for ST-EPN-RELA tumors and a significant enrichment 
of angiogenesis in a pathway analysis in Pajtler et al., 201573. 
4.3.2.1. CXorf67 (EZHIP): an intrinsic inhibitor of PRC2 in PF-EPN-A 
The overexpression of chromosome X open reading frame 67 (CXorf67) was previously 
discovered as a hallmark of PF-EPN-A tumors by our collaborators265. Matching to their 
observation, CXorf67 was solely identified and quantified in PF-EPN-A tumors (in 22/ 24 
samples, Figure 13C) and overexpressed compared to the healthy control in our proteome 
data. Statistically, we could not determine a fold change because it was only observed in a 
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single healthy sample. Its expression has recently been proposed as a mechanism for the 
downregulation of the repressive histone H3 lysine 27 trimethylation (H3K27me3) mark, 
another characteristic feature of these tumors. The negative regulation stems from the 
interaction of CXorf67 with the enhancer of zeste homolog 2 (EZH2) methyltransferase, a 
constituent of the polycomb repressive complex 2 (PRC2). The PRC2 histone 
methyltransferase primarily functions to trimethylate H3K27 to promote the silencing of 
genomic regions341. Its inhibition drives the H3K27 hypomethylation and de-repression of 
target genes as a result. 
 
Figure 13: Ependymoma (EPN) subgroup-specific protein expression and CXorf67, an intrinsic inhibitor of 
PRC2 in PF-EPN-A. A) The numbers of uniquely expressed proteins for each subgroup (dark grey) and with 
additional expression in the healthy reference samples (light grey). B-C) Boxplot illustration of ARAP3 (B) and 
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CXorf67 (C) protein expression across all EPN subgroups. D) PRC2 core component interaction heatmap with 
the CXorf67 deletion mutants (CX-C, CX-M, and CX-N) and the full length (CX-Full) protein, generated by co-
immunoprecipitation. E) Western blot analysis for PRC2 components (EZH2, SUZ12, and EED) against all three 
deletion mutants and the full-length CXorf67 protein. F) Western blot analysis showing the absence of the 
H3K27-trimethylation (me3) mark in CX-Full and CX-C. G-H) Differential expression analysis using Limma 
moderated t-statistics for the comparison of PRC2 target gene expression (G) and protein expression (H) in 
PF-EPN-A tumors against all others. Genes (G) or proteins (H) passing significance thresholds of -log10 p-value 
< 0.05 (Benjamini-Hochberg adjusted) and an absolute log2 fold change of >1 are highlighted. I) Correlation 
analysis of significantly changing PRC2 targets on gene and protein-level to identify specific or common 
effects. The co-IP and western blot experiments were performed by Dr. Jens Huebner (Huebner et al., 2019). 
The transcriptome data were provided by our collaborators from Pajtler et al., 2015. Panel D-F were modified 
from Huebner et al., Neurooncology., 2019. 
Here, we continued to unravel the precise mechanism of action of CXorf67-mediated 
inhibition of PRC2. This was done in collaboration with Dr. Jens Hübner, Dr. Marcel Kool, 
and Dr. Kristian Pajtler257. In brief, HEK293T cell lines were transfected with a doxycycline-
inducible expression system for the full-length CXorf67 protein and three different CXorf67 
deletion mutant constructs as follows: I) amino acids 1 to 150 (N-terminal region), II) amino 
acids 151 to 300 (Middle region), and III) amino acids 301 to 503 (C-terminal region) 
(Supplementary Figure 7A). Hereinafter they are referred to as CX-Full, CX-N, CX-M, and 
CX-C. Their selective expression and additional localization to the nucleus was confirmed 
using western blot analysis (Supplementary Figure 7B and Supplementary Figure 7C). 
Subsequently, we performed a co-immunoprecipitation (co-IP) using an anti-FLAG antibody 
followed by LC-MS analysis to identify putative interaction partners for each construct 
compared to the CX-Full. The vast majority of identified PRC2 components exclusively 
interacted with CX-Full and CX-C, indicating a functional domain in the C-terminal region of 
CXorf67 (Figure 13D). The MS results were cross-validated using western blot analysis 
(Figure 13E), which showed an additional marginal interaction of EZH2 and SUZ12 with CX-
M. The pull-down of EED could not be validated using western blot analysis. 
Next, the MS results were further validated by staining all transduced cell lines for the 
presence of Flag-tagged proteins (CXorf67, CX-N, CX-M, and CX-C) and H3K27me3. This 
indeed revealed a hypomethylation of H3K27 in cell lines expressing CX-Full or CX-C, 
indicating that the C-terminal region of CXorf67 is sufficient for the inhibitory effect on 
PRC2 (Supplementary Figure 7D). The results were cross-validated using western blot 
analysis showing the absence of the H3K27me3 mark in CX-Full and CX-C (Figure 13F). 
Highly similar transcriptional changes, including enrichment of PRC2 target genes, were 
observed in CX-Full and CX-C cell lines as a result of the hypomethylation257. 
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Finally, we utilized the available global gene expression profiles and our proteome profiling 
data to investigate the effect of CXorf67-mediated inhibition of PRC2 and the de-repression 
of its target genes compared between molecular subgroups. The list of relevant targets was 
extracted from MsigDB342. Neither on the level of gene expression nor in the proteome 
profiles, we could observe a statistically significant difference between PF-EPN-A tumors 
and all others (Supplementary Figure 8E and Supplementary Figure 8F). For the gene 
expression data, we did not have access to any healthy reference data or the SP-SE 
subgroup. Using a Limma moderated t-statistics differential expression analysis, we could 
find a subset of PRC2 target genes that are regulated in PF-EPN-A tumors compared to all 
others on the transcriptome (196/585) (Figure 13G) and proteome (27/125 identified) 
(Figure 13H) level. The vast majority of transcriptional changes were not identified on the 
proteome-level (Figure 13I). Very few protein targets show a regulation in both omics-
layers (n= 12) or exclusively in the protein data (n= 15) (Figure 13I). The fact that we see a 
significant regulation of PRC2 targets in the CX-Full and CX-C might be the artificial 
overexpression of CXorf67, which is generally low abundant in the PF-EPN-A proteome 
data. Also, we do not have any global proteome data for the CX-Full and CX-C transduced 
cell lines. 
Recapitulating, we could identify a number of proteins that exhibit subgroup-specific 
expression. Among them, ARAP3 in ST-EPN-RELA and CXorf67 in PF-EPN-A are interesting 
examples. The exclusive expression of CXorf67 was already known in part, but the precise 
mechanism was unraveled in a collaborative project. Here, we identified the putative 
interaction partners for the N-terminal region, the middle region, and the C-terminal region 
of CXorf67 (Supplementary Figure 7A). Most importantly, the PRC2 core components 
exclusively interacted with either the full-length protein (CX-Full) or the C-terminal region 
(CX-C). Using our tumor proteome profiles, we could further investigate the influence of 
PRC2 inhibition on its targets compared to other EPN subgroups. Other exclusively 
expressed candidates are under further investigation. 
4.3.3. Protein- and gene expression 
The identification of proteins that are exclusively expressed within a single subgroup 
presents the ideal scenario for the discovery of biomarkers or functional differences. In 
practice, exclusively expressed proteins only present the surface of the several hundreds of 
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identified and quantified observations. In the following chapter, we systematically 
examined our proteome data with and without the available gene expression data. Initially, 
we performed a correlation analysis between the previously generated gene expression 
and our newly generated proteome profiles. The coefficient of determination (R2= 0.1) 
illustrates a weak overall correlation between intensity data of gene- and protein 
expression (Figure 14A). This observation is expected due to various regulatory 
mechanisms during protein biosynthesis that lead to a non-linearity from genes to 
proteins90. On the other hand, the additional value of proteome profiles immediately 
becomes evident by I) proteins that are either non-correlating but significant or II) 
correlating with their gene expression. 
In order to identify both groups of proteins, we utilized the mean intensity correlation 
between gene and protein expression and calculated a corresponding linear regression 
model. This allowed us to determine the deviation of each protein from this general model 
(residuals of true observed and expected intensities) and to perform a gene/protein-wise 
comparison whether the normally-distributed values are significantly deviating from zero. 
A detailed description of the process is provided in the respective method section. Using 
this analysis, we could identify a large number of proteins that deviate in their intensities 
in one of the two ways: I) higher gene expression as expected from the proteome data 
(red), or II) higher protein expression as expected from gene expression data (blue) (Figure 
14A). The remaining set of genes/proteins are statistically not significantly (p-value > 0.05) 
varying between both expression layers and were thus classified as correlating. 
Interestingly, the correlating group of proteins showed enrichment of mitochondrial matrix 
proteins in a cellular component GO analysis (Figure 14B). This might reflect a tight 
regulation of the energy household as an essential mechanism for a cell’s functional 
integrity. Other vital mechanisms are among the non-significant gene sets, for example, 
centrosome, Golgi stack, proteasome accessory complex, or the replication fork. The non-
correlating proteins, on the other hand, exhibited a significant enrichment for structural 
constituents of ribosomes (GO-molecular function) (Figure 14C) and correspondingly the 
cytosolic large and small ribosomal subunits (GO-CC) (Figure 14B). In addition, we found 
proteins enriched that are localized in extracellular exosomes, secretory granule, cell 
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surface, and the collagen-containing extracellular matrix. Some of these observations will 
be picked up again throughout the thesis. 
 
Figure 14: Global gene- and protein expression correlation. A) Global correlation of transcriptome and 
proteome intensities showcasing an overall weak correlation. B-C) Gene ontology analysis of cellular 
components (B) or molecular function (C) for correlating and non-correlating genes/proteins. Significance 
(brown) is defined with a log10 p-value < 0.01 (Benjamini-Hochberg adjusted). D) Boxplot illustration of CD44 
protein expression across all ependymoma (EPN) subgroups. E-F) Gene ontology analysis of cellular 
components (E) or molecular function (F) for genes/proteins that are either higher in the transcriptome or 
proteome. Significance (brown) is defined with a log10 p-value < 0.01 (Benjamini-Hochberg adjusted). The 
transcriptome data were provided by our collaborators from Pajtler et al., 2015. 
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Among the deviating genes/proteins, we also found a significant enrichment of focal 
adhesion proteins. The cell-surface receptor CD44, a non-kinase transmembrane 
glycoprotein that mediates focal adhesion343–346, has previously been linked to PF-EPN 
tumors as an independent predictor of survival347. While the gene expression is reduced for 
PF-EPN-B and SP-EPN tumors, the protein-level intensities of CD44 are highly upregulated 
for all tumors compared to the healthy reference (logFC μ= 6.2 across all subgroups) (Figure 
14D). PF-EPN-B tumors show a more variable CD44 protein expression, while the vast 
majority of samples still exhibit a significant upregulation. The physiological role of CD44 
comprises the maintenance of organ and tissue structure, but it also plays various roles in 
tumor initiation, invasion, and metastasis343,348. Its functional role in tumorigenesis is very 
much in the focus of ongoing research efforts. For example, its expression has been linked 
to a high expression of the signal transducer and activator of transcription (STAT3) protein 
and increased cell proliferation as a result. This is in line with the protein expression data 
for STAT3 in all tumors but SP-MPE (data not shown). The inhibition of CD44-STAT3 complex 
formation has been reported as a target in breast cancer349. In several other cancer entities, 
CD44 was reported as a potential molecular target for therapy against its tumorigenesis 
promoting role. Several preclinical and clinical trials are on their way, targeting CD44 
expression348,350,351. 
Next, we evaluated whether we can observe an enrichment of gene sets for genes/proteins, 
which are either higher or lower expressed in the proteome than expected from the 
transcriptome. The majority of previously found GO annotations were identified to have a 
higher expression in the gene expression data and correspondingly did not translate equally 
to the protein-level (Figure 14E and Figure 14F). The majority of proteins with an 
unexpected high expression were localized to the extracellular matrix or extracellular 
exosomes. Extracellular matrix (ECM)-related proteins are often enriched in cancer entities 
and can be associated with differences in the tumor microenvironment. The potential role 
of ECM-related proteins is further discussed throughout the thesis and particularly in 
chapter 4.3.3.4. Extracellular exosomes are discussed in more detail in chapter 4.3.4. 
Beyond the global correlation of gene- and protein expression, we wanted to come back to 
the evaluation of differences between the molecular subgroups. This was achieved by 
performing the differential expression and GO-enrichment analysis for each subgroup 
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against all others. Very few subgroup-specific changes were identified (data not shown). 
This alludes to, for example, the increased intensities of ECM organization proteins in PF-
EPN-B or cilium, sodium transport, and axonemal dynein complex in ST-EPN-RELA. ECM 
proteins were higher on the transcript level for PF-EPN-A and ST-EPN-RELA, which might be 
associated with their higher aggressiveness and worst prognosis. Since the overall outcome 
of this analysis was limited, with only a few significant observations, we decided to proceed 
with a more targeted approach, as outlined below. 
4.3.3.1. Signature gene translation to proteins 
Next, we directed our attention to a shortlist of characteristic genes per subgroup. These 
were previously determined by our collaborators based on their exclusive gene expression 
or significant overexpression compared to all other subgroups73. Here, we reviewed 
whether these signature genes translate to the proteome-level, emphasizing their role 
within a respective subgroup. 
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Figure 15: Translation of signature genes to signature proteins. A) Heatmap visualization of protein 
expression of subgroup-specific signature genes (Pajtler et al., 2015). B) Heatmap visualization of proteins 
that additionally show differential expression (DE) on the proteome-level, as determined by a Limma 
moderated t-statistics DE analysis. The significance threshold was set at a threshold of Benjamini-Hochberg 
adjusted p-value < 0.01 and an absolute abundance change of 2-fold. C-E) Boxplot illustration of NQO1 (C), 
ALDH1L1 (D), and FAM129A (E) protein expression across all EPN subgroups. 
Therefore, we extracted the intensities for all identified and quantified proteins 
corresponding to the subgroup-specific signature genes. In total, 122 of 241 signature 
genes could be recovered on the proteome-level. The separation of subgroups based on 
protein intensities of these signature genes is notably less pronounced and suffers from a 
large proportion of missing values (Figure 15A). Here, imputation was used to allow 
visualization of the data. A large number of proteins do not differ in abundance compared 
to either the healthy reference or other subgroups. Using a Limma moderated t-statistics 
differential expression analysis, we could pinpoint those signature genes that translated to 
statistically significant signature proteins for the individual subgroups (Figure 15B). Here, 
the differential expression analyses were performed between each subgroup and all others 
without including the healthy reference for which we did not have gene expression data. 
This reduced the list to 49 signature proteins across eight out of nine subgroups, with no 
signature proteins for SP-EPN tumors (Figure 15B). 
The majority of these signature proteins also varied in their expression compared to the 
healthy reference and showed implications in other cancer entities. For example, quinone 
oxidoreductase 1 (NQO1) was overexpressed in PF-SE (logFC= 3.11) and linked to 
reprogramming of glycolysis, proliferation, and metastasis (Figure 15C). The downstream 
effectors and NQO1 itself were suggested as promising therapeutic targets to prevent 
tumor progression352. Another interesting observation was ALDH1L1, a cytosolic 
dehydrogenase, that was highly overexpressed in PF-EPN-A tumors (logFC= 5.34 compared 
to all other tumors and logFC= 9.55 compared to healthy tissue) (Figure 15D). It is involved 
in folic acid metabolism and ATP production353. A knockdown of ALDH1L1 has previously 
been shown to reduce the production of ATP by 60% in NSCLC. The PF-EPN-A cell line also 
exhibits the overexpression of ALDH1L1 and could be utilized for a follow-up experiment 
using an ALDH inhibitor (e.g., gossypol) to reduce ATP production. In ST-EPN-YAP tumors, 
the expression of ABLIM1 (logFC= 3.25), FAM84B (logFC= 3.88), SNTB1 (logFC= 5.76), 
LMCD1 (logFC= 2.36), and FAM129A (logFC= 3.11) were clearly distinguishing from all other 
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tumors and healthy. Among them, FAM129A is involved in inhibition of apoptosis and 
promotion of migration and proliferation in human cancers (Figure 15E)354. 
 
Figure 16: Characteristic fusion protein involving C11orf95 and RELA drive oncogenic activation of NF-kB 
signaling. A-B) Boxplot illustration of C11orf95 (A) and RELA (B) protein expression across all EPN subgroups. 
C-D) Global expression of NF-kB target genes per subgroup on the transcriptome-level (C) and proteome-level 
(D). E-F) Differential expression analysis using Limma moderated t-statistics for the comparison of NF-kB 
target gene expression (E) and protein expression (F) in ST-EPN-RELA tumors against all others. Genes (E) or 
proteins (F) passing significance thresholds of -log10 p-value < 0.05 (Benjamini-Hochberg adjusted) and an 
absolute 2-fold change are highlighted. I) Correlation analysis of significantly changing NF-kB targets on gene 
and protein-level to identify specific or common effects. The transcriptome data were provided by our 
collaborators from Pajtler et al., 2015. 
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ST-EPN-RELA tumors are characterized by a recurrent fusion protein involving the 
uncharacterized C11orf95 and the signature protein RELA (logFC= 1.87) (Figure 16A and 
Figure 16B)259. The fusion has been linked to driving oncogenic activation of NF-kB-signaling 
in these tumors. RELA is the principle effector of this signaling pathway and was found 
among the list of signature proteins in our dataset. Similar to the analysis of PRC2 target 
genes in PF-EPN-A tumors, we investigated the expression levels for a list of NF-kB-
signaling-related target genes355. Neither gene nor proteome profiles revealed statistically 
significant differences between ST-EPN-RELA and all other tumors (Figure 16C and Figure 
16D). For the gene expression data, we did not have access to healthy reference data or 
the SP-SE subgroup. Interestingly, it seemed that NF-kB target genes are marginally 
upregulated on the proteome level as compared to healthy (Figure 16D). Using a Limma 
moderated t-statistics differential expression analysis, we could find a subset of NF-kB 
target genes that are regulated in ST-EPN-RELA tumors compared to all others on the 
transcriptome (20/83) (Figure 16E) and proteome (11/31 identified) (Figure 16F) level. A 
subset of NF-kB targets showed a significant regulation exclusively in the protein data (n= 
5) or in both omics-layers (n= 6) or (Figure 16G). For example, a known regulator of 
apoptosis (BCL2) was identified among them. Another protein with strong cancer-related 
implications is S100A6, which is involved in the regulation of proliferation, invasion, 
migration, and angiogenesis356. The NF-kB complex subunit - NFKB1 was exclusively 
regulated on the protein level. 
From the preceding analysis, we could identify several proteins (n =49) that indeed follow 
their subgroup-specific signature gene expression profiles. They are capable of delineating 
the different tumor subgroups and deserve a closer investigation in the following chapter. 
A large proportion of signature genes was either not identified on the proteome level 
(~50%) or did not translate to a signature protein (~40%). In addition, we could show the 
impact of abnormal NF-kB activation between different tumor subgroups on the proteome 
level. We continued with a protein-centric analysis to include all of the above and to 
additionally identify previously unknown protein signatures. 
4.3.3.2. Differential expression determines signature proteins 
Hitherto assessment of our data was primarily coined by attempting to learn from the gene 
expression profiles. In the following section, we solely focused on a proteome-centric 
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approach, whereas the subgroup annotation is based on the DNA methylome. We 
performed Limma moderated t-statistics differential expression analysis to compare the 
proteome profiles of each subgroup, firstly against all other subgroups (exemplary Figure 
17A), and secondly against the healthy reference samples (exemplary Figure 17B). The 
significance threshold was defined at a 2-fold change in absolute abundance and a BH-
adjusted p-value lower than 0.01. Besides, we required each protein to be quantified at 
least twice within the compared groups. A correlation analysis revealed whether proteins 
were only significantly regulated against other tumors, healthy, or both (exemplary Figure 
17C). 
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Figure 17: Subgroup-specific differential expression (DE) analysis reveals signature proteins. A-B) 
Exemplary, DE analysis using Limma moderated t-statistics for the comparison of protein expression in each 
ependymoma (EPN) subgroup against all other subgroups (A) and against the healthy reference (B). Significant 
proteins, at a threshold of Benjamini-Hochberg adjusted p-value < 0.01, and an absolute abundance change 
of 2-fold, are highlighted (red). C) Exemplary, correlation analysis of significantly changing proteins against 
the healthy reference and/or against all other tumor subgroups. D) Summary of DE analysis results for each 
EPN subgroup. E) Hierarchical clustering analysis using signature protein intensities relative to the mean 
expression in all other tumors. 
Following from this, we identified several novel signature proteins for each tumor subgroup 
(Figure 17D) additionally to those that correlate with signature gene expression (Figure 
15B). Using signature protein intensities relative to the mean expression in all other tumors 
for a hierarchical clustering analysis (Figure 17E), we could nearly perfectly recapitulate the 
different EPN subgroups. It follows that we have identified a large number of signature 
proteins based on our proteome profiling that previously remained undetected. They 
provide an expansive view of the underlying EPN biology, pathway activation, and potential 
subgroup-specific therapeutic targets. In order to get a better insight into subgroup-specific 
differences, we performed GO annotation and GSEA for each comparison. For example, 
extracellular matrix structural constituents were enriched in ST-EPN-RELA tumors. This is 
outlined in more detail in chapter 4.3.3.4. Further, the localization of proteins to the plasma 
membrane or as integral components of the plasma membrane was identified in PF-EPN-
A. In both tumors, this might be a common theme towards their higher aggressiveness 
compared to all others (see also chapter 4.3.3.4). The most stable genomes are observed 
in SE tumors across all anatomical regions. Interestingly, mRNA splicing via the spliceosome 
was observed as the only significant term in both PF-SE and ST-SE tumors, compared to all 
others. 
Next, we investigated the top 10 differentially regulated markers per tumor subgroup 
(Table 2), as determined by a differential expression analysis (exemplary Figure 17A). The 
significance threshold was set to an absolute fold change higher than 2-fold and an adjusted 
p-value <0.01. Importantly, the top 10 markers were still sufficient to separate the majority 
of subgroups (Supplementary Figure 8A and Supplementary Figure 8B). We outline a few 
interesting hits with potential therapeutic implications. Quinolinic acid 
phosphoribosyltransferase (QPRT) shows a high expression in human malignant gliomas as 
well as in PF-EPN-A and PF-SE tumors in our global proteome data (Supplementary Figure 
8C)357. It is involved in utilizing quinolinic acid, which is produced by microglia cells, for 
NAD(+) synthesis, and its high levels have been linked to increased resistance to oxidative 
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stress upon radio-chemotherapy and overall malignancy. QPRT, alkylating agents, or direct 
NAD(+) synthesis inhibitors have been proposed as therapeutic approaches for gliomas357. 
 
Table 2: Summary of top 10 significantly differential abundant proteins per Ependymoma molecular 
subgroup The top 10 signature proteins per EPN subgroup were determined using a differential expression 
analysis facilitated by Limma moderated t-statistics. The significance threshold was set to Benjamini-
Hochberg adjusted p-value < 0.01 and an absolute abundance change of 2-fold. The subset of proteins 
corresponds to Figure 17 and Supplementary Figure 8. 
Furthermore, we identify an almost exclusive expression of the GPR50 receptor, a member 
of G protein-coupled receptors (GPCRs), in PF-EPN-A and PF-EPN-B tumors (Supplementary 
Figure 8D)358. Of note is that the expression levels are significantly different between both 
with an average of ~21 [log2] and ~29 [log2] in PF-EPN-A and PF-EPN-B, respectively. While 
GPR50 has previously been associated with ERK signaling, it might also serve as a potential 
biomarker to differentiate between both EPN subgroups359. Another protein, CYB5R1, a 
NADH-cytochrome b5 reductase that is involved in desaturation and elongation of fatty 
acids, is upregulated in all tumors except SP-MPE (Supplementary Figure 8E). Its highest 
expression is observed in PF-EPN-B tumors. In a previous study, it was identified as a 
potential therapeutic target against the development of glioblastoma by systematic 
genome-wide expression analysis. Using real-time PCR, the authors confirmed CYB5R1 as 
targetable by the demethylation drug 5’aza-desoxycytidin360. A potential implication in EPN 
tumors could be investigated further. Furthermore, we found an exclusive upregulation of 
the exto-5’-nucleotidase (NT5E) in SP-EPN tumors. It has been shown that its blockage can 
facilitate the suppression of self-renewal, tumor growth, and progression in gliomas. This 
can be achieved via microRNA-30a treatment, which may present an interesting 
therapeutic strategy. 
Altogether, we could identify novel signature proteins per tumor subgroup that were 
previously unknown by using our proteome-centric differential expression analysis. Among 
the top 10 markers per subgroup, we find a number of potentially actionable targets, 
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partially with implications related to gliomas or other cancer entities. Here, we highlighted 
a few representative examples to illustrate the added value of proteome profiling on top 
of or complementary to preceding -omics strategies. 
4.3.3.3. Genetic structural aberrations (CNVs) to phenotype 
The paucity of recurrent mutations is a common characteristic of many childhood 
malignancies361, such as medulloblastoma362, retinoblastoma363, glioblastoma364, ATRTs365, 
neuroblastoma366, and also ependymoma367. A limited number of recurrently mutated 
genes are known for EPNs259,260,277,367. This includes a common deletion of CDKN2A in ST-
EPN-RELA or a mutation of the NF2 gene in spinal tumors, for example368. The latter shows 
implications in restricting proliferation and promoting angiogenesis, while CDKN2A might 
play a role in the ST-EPN-RELA characteristic chromothripsis of chromosome 11. In our 
proteome data, we rarely quantified CDKN2A and found no differential expression of NF2. 
The majority of EPNs instead suffer from recurrent structural aberrations, including copy 
number variations (CNVs)367. Gains and losses of entire chromosomal arms are frequently 
observed, but their role and impact remain largely unknown. Here, we utilized our 
collaborators DNA methylation array-based CNV data to investigate the impact of recurrent 
structural aberrations on the proteome level. A detailed description of the following 
analysis is provided in the respective method section. Briefly, we compared the gene and 
protein expression for every available sample in relation to the observed CNV per sample 
and chromosomal region. For each sample and all its chromosomes, a line represents its 
CNV status as neutral (blue), deletion (red), or amplification (green) (exemplary Figure 18A 
to 18F). The mean relative expression values for genes or proteins are highlighted as dots 
at their genomic locus compared to the expression in CNV neutral samples. This illustration 
allowed us to obtain a global view of CNV impact on both expression levels for each tumor 
subgroup. 
The gain of chromosome arm (chr) 1q is the most frequently observed CNV in PF-EPN-A. It 
has shown implications as an important prognostic factor within this tumor subgroup as it 
correlates with differences in overall survival. The same observation did not hold for PF-
EPN-B and ST-EPN-RELA tumors, albeit they have the chr 1q gain in 18% and 24% of all 
cases, respectively73. The effect was restricted to an increased expression for a few genes, 
whereas the proteome seemed mostly unaffected (Figure 18A to 18F). The most 
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substantial genomic instability is observed in PF-EPN-B (Figure 18C and Figure 18D) and ST-
EPN-RELA tumors (Figure 18E and Figure 18F). Especially PF-EPN-B are characterized by a 
number of aneuploidy events, including monosomy of chr 6 (61%), chr 10 (38.7%), and chr 
17 (33.5%), as well as trisomy of chr 5 (31%), chr 8 (23.5%), and chr 18 (51.9%)73,260. 
 
Figure 18: Gene- and protein expression following recurrent structural aberrations. A-F) Exemplary, an 
illustration of ependymoma (EPN) copy number variation (CNV) and the corresponding gene- and protein-
expression for PF-EPN-A (A-B), PF-EPN-B (C-D), and ST-EPN-RELA (E-F). The CNV status per chromosome and 
subgroup is indicated as neutral (blue), deletion (red), or amplification (green). The mean relative expression 
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values to the expression in CNV neutral samples are highlighted for genes or proteins as dots at their 
corresponding genomic locus. The CNV and transcriptome data were provided by our collaborators from 
Pajtler et al., 2015. Dr. Mathias Kalxdorf generated the CNV plots. 
Besides the amplification of chr 8, the majority of these changes seem to translate to the 
gene expression level. The proteome is less affected with the vast majority of proteins not 
showing a significantly different abundance. However, few trends can be observed on the 
proteome level, including a decrease in chr 6 and chr 10, or amplification in chr 5. Further 
common loss of chr 6 and chr 13q in PF-EPN-B can be more or less observed on both 
expression levels. The latter has been proposed as a novel marker for PF-EPN-B tumors. 
Based on our global proteome profiles, we identified two signature proteins, MIPEP and 
NBEA, located on chromosome 13. 
Across all three anatomical regions, the SE tumors exhibit the most stable genomes (data 
not shown). Neither CNVs nor the expression of genes or proteins seemed to show 
apparent global trends. For SP-SE tumors, we did not have access to gene expression data. 
Similarly, ST-EPN-YAP1 tumors are characterized by no obvious changes and they exhibit a 
mostly stable genome. The most obvious effect on the proteome level of ST-EPN-RELA 
tumors was the frequent deletion of chr 9 and chr 3 (Figure 18E and Figure 18F). About 90% 
of spinal tumors are characterized by loss of chr 22q, which carries the NF2 gene that is 
frequently mutated in these. This is obvious on the gene expression level for SP-EPNs but 
does not translate significantly to the protein level, including the NF2 expression. In SP-MPE 
tumors, chr 9 and chr 18 have a marginal trend following the CNV status. However, as for 
all other tumors, the vast majority of proteins did not seem to reflect the CNV state in the 
corresponding subgroup. 
Despite that we see a few examples of genes and proteins that follow the global direction 
of the recurrent structural aberrations, the majority do not. This alludes to the fact that the 
recurrent structural aberrations do not drive the tumor phenotype alone. Therefore, we 
continued by matching our subgroup-specific signature proteins, which by definition 
includes all significantly over- or underexpressed proteins, to their corresponding chr locus 
to evaluate whether a proportion of them might be explained by CNV patterns (Figure 19). 
The majority of signature proteins seemed rather randomly distributed across the genome. 
The SE tumors in all compartments were characterized mostly by negative protein fold 
changes compared to all other tumors. Overall, these findings support the hypothesis that 
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no recurrent structural event (for example, SNPs) is the oncogenic driver but rather 
epigenetic mechanisms because chromosome gains and losses do not translate significantly 
to the proteome. 
 
Figure 19: Distribution of signature proteins per subgroup on chromosomes. Illustration of signature 
proteins, as determined by a differential expression (DE) analysis, at their genomic locus per subgroup. 
Proteins with a higher (blue) or lower (red) fold change compared to all other subgroups are highlighted. The 
blue or red bars are relative to the total number of signature proteins per respective subgroup, as indicated 
in brackets below subgroup titles. 
The main characteristic of EPNs are recurrent structural aberrations. However, genome 
sequencing efforts have largely failed to identify significantly recurrent mutated genes and 
oncogenic drivers as a result. Here, we could show that the majority of these structural 
gains or losses have a limited impact on the global proteome phenotype. This might be 
explained by buffering mechanisms that could manifest as alterations in the protein 
synthesis rate or turnover to compensate for the structural gains or losses. 
4.3.3.4. ST-EPN-RELA cell surface-proteome sub-classification 
Plasma membrane and secreted proteins have a crucial role in a vast number of 
physiological processes300. This includes growth factor receptors and G-protein-coupled 
receptors (GPCRs) for signal transfer from external stimuli or adhesion proteins defining 
cell shape and motility. Other proteins are involved in the transport of nutrients, salts, or 
other molecules. They are involved in cell-cell communication and segregation of different 
tissues, for example. On the other hand, malfunctions in these protein classes are often 
involved in the acquisition of cancer hallmark traits during tumorigenesis. This can manifest 
as surface proteome changes that allow a cell to invade surrounding tissue, evade the 
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immune system response, or gain independence of survival signals. However, 
transmembrane proteins, especially GPCRs (>25%) and ion channels (>10%), represent the 
group of proteins that is most frequently targeted by drugs. Simultaneously, about 60% of 
all FDA-approved drugs target transmembrane proteins demonstrating their importance as 
potential therapeutic targets369,370. Here, we followed up on our previous observation of 
sub-subgroups in ST-EPN-RELA (2) and PF-EPN-A (3) tumors on the proteome level (see also 
chapter 4.3.1). Based on preliminary results, we hypothesized that ECM-related proteins 
might account for the sub-subgrouping, potentially resulting in different levels of 
aggressiveness and overall outcome. Therefore, we continued by performing a surface 
proteome enrichment for ST-EPN-RELA tumor samples (n= 16). Briefly, this was achieved 
by oxidizing carbohydrates of the resuspended cell-debris pellet, comprising plasma 
membrane fragments, and subsequent biotinylation of the cell-surface proteins. The 
labeled cell-surface proteins were captured using protease-resistant neutravidin-agarose 
beads. Reduction, alkylation, and digestion of proteins were performed on-beads, followed 
by peptide elution in an aqueous buffer and C18-based desalting to achieve LC-MS 
injection-ready samples. 
Upon enrichment, we identified an average of 800 to 1000 plasma membrane proteins per 
sample. An average of about 80% of the total intensities per sample were attributed to 
plasma membrane or secreted proteins (Figure 20A). Focusing solely on surface proteins, 
we could identify two different clusters corresponding to our previous observation (Figure 
20B). Two samples were manually assigned as a third cluster and disregarded in the 
following analysis, as they were not clearly associated with either cluster. Next, we firstly 
performed a differential expression analysis (Figure 20C) and secondly, a GSEA of the 
significantly regulated proteins (Figure 20D). In cluster one we found an increased 
expression of collagen degradation & synthesis, ECM degradation, ECM organization, 
complement cascade regulation proteins, MET activating PTK2 signaling, and promoting 
cell motility. The second cluster exhibited an enrichment of proteins involved in 
transmission across chemical synapses, cellular response to stress, the VEGFA pathway, 
Rho GTPase signaling, and cell-cell communication. This shows a broad involvement of 
ECM-related proteins and processes, as well as signaling processes in the sub-subgrouping 
of ST-EPN-RELA. 
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Figure 20: ST-EPN-RELA cell surface-proteome sub-classification. A) Illustration of surface-proteome 
enrichment results. Differentially colored bars represent the fraction of the total intensities originating from 
the different cellular regions. B) umap analysis showing at least two sub-subgroups of ST-EPN-RELA tumors 
based on the surface-proteome profiles. C) Differential expression (DE) analysis using Limma moderated t-
statistics for the comparison of the surface proteome in ST-EPN-RELA cluster 1 against ST-EPN-RELA cluster 
2. Proteins are significant at a threshold of -log10 p-value < 0.05 (Benjamini-Hochberg adjusted), and an 
absolute log2 fold change of >1 are highlighted. D) Gene set enrichment analysis (GSEA) of differentially 
regulated proteins comparing cluster 1 and cluster 2. E-G) Boxplot illustration of ANXA1 (E), FPR1 (F), and 
EMILIN1 (G) protein expression across all EPN subgroups. 
Next, we investigated the up- and downregulated proteins in the comparison of both sub-
clusters. Since the majority of these proteins were not identified in the global tumor 
proteome, we could not always compare to the protein’s overall expression. We highlight 
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a few interesting candidates per sub-cluster. For example, SPP1 (Osteopontin) was 
significantly enriched in cluster 2, and its mRNA expression levels in glioma have previously 
been reported to rank among the top 10 of all cancer cell lines371. Its increased expression 
in lower-grade gliomas was associated with poor survival. This is in line with the aggressive 
phenotype of ST-EPN-RELA and PF-EPN-A, which both show a higher expression of SPP1 
compared to any other subgroup in our global proteome data. Other proteins enriched in 
cluster 2 similarly link to poor survival (EZR, ezrin)372 or cancer cell invasion and 
aggressiveness (ANXA1, a Ca(2+)-binding protein)373 (Figure 20E). The latter correlates to 
hypoxia conditions and is highly expressed in various types of malignant tumors, including 
all EPN subgroups besides PF-SE and healthy tissue. It likely acts via secretion and autocrine 
signaling to promote aggressiveness and survival. The knockdown of ANXA1 has been 
shown to mitigate this aggressive phenotype in NSCLC cells373. While ANXA1 cannot be 
directly addressed as a potential therapeutic target, the inhibition of its receptor, FPR1, has 
been demonstrated to decrease tumor growth and metastasis formation in breast 
cancer374. This is particularly interesting as we see FPR1 exclusively expressed in ST-EPN-
RELA and PF-EPN-A tumors in our global proteome data (Figure 20F). The inhibition of FPR1 
can be efficiently achieved by the immunosuppressive drug Cyclosporin A (CsA), presenting 
an interesting follow-up experiment. 
On the other hand, we also found several potentially interesting proteins enriched in cluster 
1. This is, for example, the choline-specific glycerophosphodiesterase (ENPP6) that is often 
highly expressed in developing oligodendrocytes375, or the elastic microfibril interface 
located protein (EMILIN1)376 with a crucial role in the tissue microenvironment. It has been 
shown that lower levels of EMILIN1 facilitate tumor cell trafficking and metastasis, thus 
implicating its protective role in tumor growth and spread (Figure 20G). Here, we observed 
that it is expressed through most tumors, but exhibits a significantly high variability in PF-
EPN-A, PF-EPN-B, and ST-EPN-RELA. Interestingly, the highest expression occurred in some 
of the ST-EPN-RELA tumors. Lastly, we also found an enrichment of OLFML3 (not detected 
in global proteome), a secreted scaffold protein with an essential role in early development. 
It has previously been proposed as a novel therapeutic target for glioblastoma377, and its 
depletion can reduce the intratumoral microglia density with overall survival benefits378. 
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In summary, utilizing a surface proteome enrichment in ST-EPN-RELA tumors confirmed a 
sub-subgroup driving impact of ECM-related proteins. We found a number of potentially 
interesting proteins that vary within ST-EPN-RELA tumors and show implications with 
aggressive phenotypes. Most interesting among them is ANXA1 and its receptor FPR1, 
which can be targeted with selective inhibitors to diminish the poor prognosis for ST-EPN-
RELA and PF-EPN-A tumors. 
4.3.4. Exosome cargo characterization in ST-EPN-RELA 
Vesicular trafficking has previously been associated with overall EPN biology379. Their cargo 
is typically a mixture of proteins, lipids, metabolites, and nucleic acids. Importantly, 
extracellular vesicles (EVs) can cross the blood-brain-barrier (BBB) and are reported in all 
biological fluids, such as blood or cerebrospinal fluid (CSF)167,380. Thus, they present an 
easily accessible and non-invasive source for biomarker identification to advance 
diagnostics and prognostics or provide insight into the tumor-specific biology. This could be 
especially relevant for ST-EPN-RELA and PF-EPN-A tumors that exhibit the worst prognosis 
and overall survival while lacking a promising therapeutic target. Here, we continued with 
the optimization of EV isolation from ST-EPN-RELA and PF-EPN-A cell culture supernatant 
and subsequent characterization of the EPN-related EV protein cargo. This was done in 
collaboration with Dr. Kendra Maaß, Mieke Roosen, Dr. Marcel Kool, and Dr. Kristian 
Pajtler. 
Briefly, extracellular vesicles are comprised of two main classes, namely exosomes and 
ectosomes380. The latter are generated directly by pinching off a part of the plasma 
membrane and constitute microvesicles, for example. They have an average diameter of 
500 nm. On the other hand, exosomes derive from the endosomal pathway and have an 
average diameter of 100 nm. Through the formation of early- and late endosomes, they 
eventually generate so-called, multivesicular bodies (MVPs). They are able to either fuse 
with the lysosome or autophagosome for degradation or with the plasma membrane to 
release the contained exosomes into the extracellular space. Almost all cells in a biological 
system release EVs as part of their physiological behavior. The removal of unnecessary 
constituents from a cell to maintain and regulate homeostasis was thought to be their 
primary function. However, context-dependent and mechanism-driven accumulation of EV 
cargo, especially in exosomes, adds to the growing evidence that they are involved in 
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intercellular communication381,382. Numerous studies have linked EVs and exosomes in 
particular to CNS-related diseases, repression of the immune response, cancer progression 
(proliferation, angiogenesis, and tumor spreading), and other implications383–387. Further, it 
has been shown that the cargo of exosomes can alter the biological response of a target 
cell in both the close surrounding (paracrine) or distantly located areas (endocrine)381. 
Here, we utilized all available EPN patient-derived cell lines, representing ST-EPN-RELA and 
PF-EPN-A tumors. Hereinafter they are referred to as BT165 & EP1NS for ST-EPN-RELA and 
BT214 & EPD210 for PF-EPN-A. We performed a global proteome profiling of each cell line 
together with a characterization of the proteomic cargo of isolated microvesicles and 
exosomes. The data obtained from different cell lines per tumor were combined for the 
majority of analyses. The isolation was performed from cells supernatant by successive 
ultracentrifugation and retrieval of fractions for microvesicles (10.000 x g pellet) and 
exosomes (100.000 x g pellet). The initial optimizations steps, including serum depletion, 
different coatings for the ultracentrifugation tubes, alternative precipitation methods, and 
additional purification using a size exclusion column, are not outlined in detail. The final 
procedure is explained in the corresponding method section. The isolation quality control 
was performed by our collaborators using immunogold electron microscopy, Qubit protein 
quantification, and nanoparticle tracking analysis (NTA). The latter showed a peak 
concentration of particle diameter in range with exosomes, whereas the microvesicle 
fraction likely presents a rather mixed population of vesicles (data not shown). 
Furthermore, EVs were specifically gold-labeled using α-CD63 antibodies to allow their 
visualization in a transmission electron microscope (TEM) using CD63 as a selective 
exosome marker (data not shown). 
CD63 and CD81 are considered hallmarks of exosomes and significantly enriched compared 
to microvesicles and global cell line profiles in our proteome data (Figure 21A)380. Another 
common marker for exosomes, namely CD24, could not be identified despite its known high 
expression in EPN tumors. This was due to its overall short sequence with only a single 
tryptic peptide and our two peptide per protein filter threshold during data analysis. The 
proportion of identified protein intensities that were annotated according to the GO: 
cellular component term for extracellular exosomes (ID: GO:0070062) did not show 
enrichment for the exosome fractions (Figure 21B). This was even the case compared to 
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the full cell lysates. The loose specificity of exosome annotation databases is a known 
problem in the field and highlights the necessity of accurate vesicle isolation and quality 
control workflows. Besides the enrichment of CD63 and CD81, several endoplasmic 
reticulum (ER)-resident (luminal) proteins were found in the dataset, resulting from the 
trans-Golgi network and ER contribution in the biogenesis of exosomes and their cargo382. 
On top of our optimized sample preparation, the above results indicate a reliable 
enrichment of the exosome fraction according to current guidelines of the international 
society of extracellular vesicles388. Using our proteome data, we found an excellent 
separation of both vesicle types, all cell lines, and the respective tumor subtype (Figure 
21C). 
 
Figure 21: Ependymoma (EPN) extracellular vesicle (EV) cargo characterization in ST-EPN-RELA and PF-EPN-
A cell lines. A) Intensity-based absolute quantification (iBAQ) rank distribution for ST-EPN-RELA (EP1NS and 
BT165) and PF-EPN-A (EPD210 and BT214) cell lines, and isolated exosomes and microvesicle fractions of 
both. Exosome markers CD63 and CD81, ST-EPN-RELA markers NES and L1CAM, as well as some interesting 
candidates (STEAP3, ACOT7, and LAMA2), are highlighted in the panel. B) Illustration of the proportion of 
identified protein intensities (brown) that correspond to the gene ontology (GO)- cellular component (CC) of 
extracellular exosomes. C) t-distributed stochastic neighbor embedding (t-SNE) analysis of EPN isolated 
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extracellular vesicles (exosomes and microvesicle) and cell lines (ST-EPN-RELA and PF-EPN-A). Dr. Kendra 
Maaß and Mieke Roosen performed the isolation and quality control of extracellular vesicles. 
Next, we systematically compared vesicle and cell line data to our extended annotation 
(based on gene expression and extended by proteomics) of subgroup-specific signature 
proteins. We chose this targeted strategy to circumvent a lacking control cell line, such as 
astrocytes, which will be added in future experiments to allow a more comprehensive 
analysis of differentially regulated proteins and pathway enrichment analysis (e.g., GO and 
GSEA). Until then, we utilized our global proteome data as a guideline. In total, we could 
identify and quantify 53 out of 69 (PF-EPN-A) and 166 out of 224 (ST-EPN-RELA) signature 
proteins. Among them, 6 (1) (PF-EPN-A) and 24 (12) (ST-EPN-RELA) were also significantly 
enriched in exosomes (microvesicles) compared to their cell line of origin (Supplementary 
Figure 9A to 9G). Only by comparing vesicle fractions across tumor subgroups we identified 
ACOT7, NES, and L1CAM to be enriched in ST-EPN-RELA exosomes (Figure 21A and 
Supplementary Figure 10A to 10C). Especially L1CAM and NES represent the tumor biology 
in the vesicle cargo as they were previously identified as ST-EPN-RELA biomarkers 
(Supplementary Figure 10B to 10C). The potential role of ACOT7, a cytosolic acyl coenzyme 
A thioester hydrolase, is less evident in an EPN-related context, but it has been suggested 
as crucial for the physiological brain function389. 
Another observation was the metalloreductase (STEAP3) upregulation in ST-EPN-RELA 
exosomes compared to both, its cell line of origin and PF-EPN-A exosomes (Figure 21A and 
Supplementary Figure 11A). It is known as a potential effector of the p53 pathway 
interfacing apoptosis and cell cycle progression390. Further, it is indirectly involved in 
facilitating the secretion of proteins. Interestingly, high expression levels of STEAP3 were 
previously shown in malignant gliomas, inversely correlating with prognosis and overall 
poor survival rates391,392. In glioma cells, a knockdown of STEAP3 (RNA knockdown) could 
attenuate aggressive phenotypes, such as cell proliferation and invasion391. This was in line 
with the expression levels of STEAP3 in ST-EPN-RELA exosomes, but neither in the 
corresponding cell lines nor in the tumor proteome profiles, showing a minus 3.5-fold 
change compared to all other subgroups (Figure 21A and Supplementary Figure 11A). This 
observation might qualify for future follow-up experiments. 
Similarly, we identified significant enrichment of LAMA2 and FARP1 (Figure 21A and 
Supplementary Figure 11B and 11C) in PF-EPN-A exosomes by comparing the respective 
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vesicle fractions across tumors or against its cell line of origin (Supplementary Figure 9A to 
9G)393. FARP1 shows localization to the plasma membrane and implications in cell 
proliferation through MAPK signaling394, which was enriched in the tumor GSEA of PF-EPN-
A compared to all other subgroups. Glioma initiating cell- (GIC) and oligodendrocyte 
progenitor cell differentiation were associated with laminin subunit alpha-2 (LAMA2), 
which has a role in mediating the attachment, migration, and organization of cells into 
tissues during development395. 
In summary, together with our collaborators, we established and optimized an efficient 
exosome isolation protocol. Using our global proteome data as a guideline, we could 
pinpoint several interesting proteins that exhibit selective enrichment in tumor-specific 
exosomes. Some of which reflect the known tumor biology, for example, L1CAM. Others, 
such as STEAP3 or ACOT7, might be of interest for further follow-up studies. In functional 
assays, our collaborators already generated preliminary results (not part of this thesis) that 
indicate increased proliferation and migration in ST-EPN-RELA cell lines, endothelial cells, 
and microglial cells upon exposure to ST-EPN-RELA vesicles. Finally, we are anticipating to 
extend the current experimental setup to include astrocytes as a control cell line, 
supernatant from tumor tissue, and exosomes from patient-derived serum samples. This 
will enable a more comprehensive analysis independent of previous signature proteins. 
4.3.5. Perspective view on multi-omics data integration 
In the previous chapters, we utilized each -omics layer separately or performed two-
dimensional correlation analyses in order to pinpoint common or different features. This 
approach becomes increasingly challenging with the number and depth of complementary 
data layers. Identifying complex relations within and across multiple levels and several 
thousands of data points will require computational methods for the unsupervised 
integration and examination of these heterogeneous datasets. In this rapidly growing field, 
only a few approaches are currently available and still require a specialist for its realization 
in practice. One of these methods, namely MOFA, was developed by a collaborating group 
for the detection of technical and biological variation in comprehensive multi-omics 
data135. Here, we provide a preliminary perspective of this type of data analysis using the 
top 1% of most variable CpG probes (4260 CpGs) in the methylome data and the 20% most 
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variable features in the transcriptome (3890 transcripts) and proteome data (1745 
proteins) (Figure 22A to 22C). 
 
Figure 22: Multi-omics factor analysis (MOFA) achieves higher resolved subgrouping. A-C) t-distributed 
stochastic neighbor embedding (t-SNE) analysis of ependymoma (EPN) methylation patterns (n= 515, top 1% 
of CpG probes with the highest standard deviation) (A), the transcriptome gene expression (n= 135, top 20% 
of most variable features), and the proteome profiles (n= 103, top 20% of most variable features). D) Multi-
omics factor analysis (MOFA) reveals low dimensional factors and their relevance per omics-layer. E) 
Exemplary, an illustration of genes/proteins that load onto factor 1 and 11 per EPN subgroup, highlighting the 
separation of PF-EPN-A from all others and in additional two sub-subgroups. F) t-SNE analysis of combined 
MOFA results, as factors 1 to 15, reveals a more detailed separation. The methylome and transcriptome data 
were provided by our collaborators from Pajtler et al., 2015. Dr. Mathias Kalxdorf performed the MOFA 
analysis. 
In brief, similar to a principal component analysis (PCA), MOFA performs a dimensionality 
reduction to infer interpretable factors that describe sources of variation across all data 
layers. These factors may capture discrete or shared variation within and across the 
different multi-omics datasets (Figure 22D). The MOFA model explains ~60% of the 
variation in the methylome data and ~50% in both transcriptome and proteome data. Next, 
we can highlight whether a specific subgroup of tumors is described by one or multiple of 
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these factors, which can be further annotated using GSEA. For example, genes and proteins 
loading on factor 1 are contributing to the separation of PF-EPN-A and ST-EPN-RELA tumors 
from all others (Figure 22E). Furthermore, the sub-subgrouping of PF-EPN-A tumors is 
driven by genes and proteins that contribute to factor 11 (Figure 22E). The unsupervised 
identification and integration of all fifteen MOFA-determined factors results in a more 
detailed separation of the EPN tumors (Figure 22F). Neither of the individual -omics layers 
could identify all substructures independently. The methylome data were insufficient to 
separate PF-EPN-B and PF-SE, for example. Further subgrouping of SP-MPE, SP-EPN-RELA, 
PF-EPN-A, and SP-EPN tumors could only be detected in the integrated MOFA approach 
(Figure 22F). GSEA and GO annotation analysis for individual factors or between tumor 
subgroups (data not shown) recapitulate, for example, that PF-EPN-A and ST-EPN-RELA sub-
subgroups are largely driven by ECM degradation, ECM organization, and ECM structural 
constituents. The heterogeneity of PF-EPN-B has been described previously264. For the 
majority of other EPN subgroups we had insufficient numbers of samples on either the 
transcriptome or proteome level. 
In general, the MOFA analyses perfectly recapitulates and extends the molecular 
classification of EPNs in an unsupervised fashion. This type of analysis will be especially 
useful in disease entities with unknown substructures or for the identification of sub-
subgroups that were previously not evident from the individual layers. 
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5. Discussion 
The large-scale study of protein expression has not yet been implemented into clinical 
routine129,137. Reasons for this are comprised of logistical, ethical, and technical challenges, 
as outlined in chapter 1.2.3. In this thesis, we approached the technical aspect to ease the 
introduction of an automated and thus reproducible sample preparation pipeline for a 
variety of different and quantity-limited, clinical specimen. This was achieved by optimizing 
and transferring the single-pot, solid-phase-enhanced sample preparation (SP3) protocol 
onto a liquid handling platform for generic, reproducible, and parallelized proteomic 
sample preparation, while propagating all its benefits into the workflow. The pipeline 
resolves several bottlenecks that previously hindered the implementation of proteomics to 
complement other NGS profiling methods, which are likewise not yet fully integrated into 
routine clinical application1,27. The resulting end-to-end automated workflow (autoSP3) 
enables systematic proteome profiling for such routine applications, constituting an 
important step towards its implementation in a clinical or research environment. 
5.1. Large-scale proteome profiling enabled by autoSP3 
Proteomic sample preparation still largely depends on a number of consecutive manual 
handling and pipetting steps. This includes the lysis of a specimen, the reduction and 
alkylation of extracted proteins, the subsequent removal of contaminating buffers or salts, 
and the proteolytic digestion of proteins to peptides. Initially, we evaluated and optimized 
a series of steps and parameters of the manual SP3 protocol to achieve its maximal 
performance while aiming for high scalability for subsequent automation of the procedure. 
The sample lysis and protein extraction comprise the first essential step that is required for 
almost all types of samples (e.g., fresh-frozen tissue or FFPE tissue). Here, we tried to 
achieve a one-for-all solution to handle any type of sample, which has not been achieved 
by any other method. In addition, we aimed for a scalable solution that seamlessly 
integrates with a 96-well format to avoid a limiting factor early on within our workflow. 
Here, we failed to omit a mechanical sample disruption to aid the extraction of proteins for 
two reasons: I) the amount of extracted protein from tissue material was neither linear nor 
reproducible (Figure 1B), and II) the lack of a proper DNA and RNA shearing turned out to 
be incompatible with the subsequent SP3 procedure. This manifested as protein binding 
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interferences and reduced peptide recoveries as a result (Supplementary Figure 1B). At the 
same time, enzymatic cleavage of nucleic acids led to reduced protein extraction 
efficiencies, because of the accompanying reduction of detergent concentrations to allow 
enzyme activity. This would result in a reduced sensitivity of the workflow, which is a 
significant drawback, especially for quantity-limited samples, and could dramatically 
increase the overall costs of the workflow. 
The highest protein yield and nucleic acid sheering efficiency was achieved using 4% SDS, 
as the main buffer constituent, in combination with AFA-based ultrasonication (Figure 1C 
and 1D). Thus far, we demonstrated proof-of-concept for the multiplexed (Figure 2D and 
2E) and highly efficient lysis of cells, fresh-frozen tissue, and a manually de-paraffinized 
cohort of 51 lung ADC FFPE tissue samples in the presence of 1 or 4% SDS. Despite the good 
performance, we see the additional potential to improve the current processing settings 
further. For example, we aim to optimize sonication frequencies and amplitudes in 
combination with cycle times, cycle length, and lower sample volumes in order to minimize 
the time needed per sample and maximize the sensitivity for low-input applications. While 
it currently takes about one hour to process 96 cell- or tissue samples, we can likely reduce 
this to about 20 minutes. This will enhance the overall throughput and improve the 
accompanying turn-around times per sample, which will be important when performing 
this in a clinical environment. Further, we collected preliminary data to show a full 
integration of AFA-based processing of FFPE tissue without requiring the manual de-
paraffinization. Interestingly, this was recently demonstrated in combination with SP3 in an 
application note by Lisa Schweizer et al., 2020, in collaboration with Covaris330. This is an 
essential step because the WHO classification of tumors and histology primarily rely on 
FFPE tissue, which is therefore routinely collected in biobanks over decades 
already159,168,396. Thus, this presents an immense resource of samples for retrospective 
proteome profiling, requiring a suitable method to enhance their accessibility. In addition, 
we aim to process body fluids (e.g., CSF and blood plasma/serum) to showcase that autoSP3 
presents the first method for the preparation of all sample types and low-quantities 
Undoubtfully, this marks a significant step towards standardized and routine proteomics 
applications. 
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In this thesis, the seamless integration of all steps into an end-to-end automated workflow, 
comprising multiplexed AFA-based ultrasonication and automated SP3 (autoSP3), was 
achieved. Peptides resulting from cells, fresh-frozen tissue, or FFPE material could be 
subjected to LC-MS without any further clean-up. Importantly, the SP3 method does not 
exhibit a bias towards hydrophobic peptides as the binding happens on the protein level, 
and digested peptides are released into the aqueous buffer irrelevant of their 
hydrophobicity (Figure 3C). Recently, Tanveer Batth et al., 2019, has proposed protein 
aggregation as an alternative binding mechanism of SP3397. The authors claim that insoluble 
proteins preferentially precipitate on microparticles (e.g., SP3 beads) irrespective of their 
surface chemistry. While this is already extensively discussed within the original SP3 
publications and its patent application, we could observe apparent differences in the 
numbers of identified peptides when using different bead types and surface chemistries 
(Supplementary Figure 2F). At the same time, the authors claim that unmodified beads 
show similar performance, but do not show their data. Further, we find it highly unlikely 
that polar interactions can be easily reversed by changing to an aqueous buffer 
composition. We aim to show this in additional experiments. However, most importantly, 
SP3 (autoSP3) is capable of removing the most frequently used buffer components during 
sample lysis and protein extraction, adding to the high flexibility and efficiency of protein 
extraction from a variety of sample types (e.g., SDS facilitates FFPE processing159,168). This 
generally includes SDS or other non-ionic detergents, such as Triton X-100 or NP-40, and 
the anionic detergent sodium deoxycholate, which aid in extraction and solubilization of 
proteins including transmembrane proteins. Further, Urea-based buffers can be processed, 
and they recently gained popularity by leading to an increase in protein yields in specific 
applications398–400. Other acid-labile surfactants, such as RapiGest SF401 or ProteaseMax 
SF402, are typically less potent for protein extraction and require, for example, precipitation 
and centrifugation or spin filter columns (e.g., FASP) for sample clean-up after its hydrolysis. 
The automation of such processes is less straightforward, requiring more sophisticated and 
expensive equipment on top of a liquid handler. Altogether, the procedure could alleviate 
many shortcomings that are associated with classical sample preparation protocols and 
manual handling, by benefiting from all the valuable features of SP3 and the nature of 
automation. Altogether, uniquely positioning autoSP3 as a building block for routine 
(clinical) proteomics. 
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Next, we demonstrated the excellent protein quantification reproducibility achieved with 
the autoSP3 procedure with a series of 60 HeLa samples, resulting in a median CV [%] of 
16.3% over a period of one month. In addition, we achieved a median CV [%] values below 
15% when including the entire sample preparation process from sample lysis and protein 
extraction to LC-MS injection-ready peptides (Figure 15C). The resulting advantage is that 
samples can be processed and measured over extended periods, for example, during 
longitudinal sample collection or time series, without introducing sample preparation 
variability. This is particularly important in a realistic clinical environment with ongoing 
patient enrolment and sample collection in irregular intervals. Indeed, the ADC cohort 
could showcase an almost perfect grouping of replicate tissue slices, based on their 
proteome composition and despite randomization, demonstrating consistency and 
robustness of the procedure. Furthermore, we demonstrated the high sensitivity of 
autoSP3, a key attribute for clinical workflows, by processing minute amounts of sample 
and quantifying consistent numbers of proteins, such as roughly 500 proteins from as little 
as 100 HeLa cells (Figure 9B). Especially here, a robust and reproducible sample processing 
is important to avoid any unnecessary technical variability that has the potential to mask 
the biological differences of interest. This asset will open up great opportunities for new 
applications in the routine analysis of rare cell types or overall quantity-limited sample 
material. For example, the sensitivity of autoSP3 might enable the analysis of small biopsies 
that were previously inaccessible for proteomics applications. On the other hand, the size 
of a biopsy could potentially be reduced to improve the tumor cell content or resolution 
and specificity of the analysis as a result. Here, we also see the potential to further improve 
the sensitivity of our workflow by reducing overall processing volumes. So far, this was 
hindered by the available 96-well magnet, which requires a certain digestion volume in 
order to cover the protein-binding SP3 beads. This could be combined with an upgrade of 
our current Bravo system to a Bravo 96ST pipetting head that allows reproducible transfer 
of 0.3 to 70 volumes μL (as compared to ~ 5 μL minimal volume). 
The final autoSP3 workflow takes about 3.5 hours for the processing of 96 samples 
simultaneously. This includes all steps from cell- or tissue lysis (~one hour for 
ultrasonication prior to anticipated optimization) to proteolytic digestion (2.5 hours for 
autoSP3), and peptide recovery (~7 minutes). The continuous and parallel operation of the 
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Covaris LE220R-plus ultrasonicator and the Bravo platform for autoSP3 permits the 
processing of up to three plates, corresponding to ~300 samples, by a single operator and 
within a working day. The hands-on time is kept minimal at the same time. High-throughput 
sample processing contributes to rapid turn-around times that are required for clinical 
decision making. For example, the NSCLC international guidelines for genetic analysis 
recommend a turn-around of less than ten days403. In other disease entities or clinical 
scenarios more or even less turn-around may be required or tolerable. The capacity of our 
autoSP3 setup could already comfortably accommodate very large-scale proteomic studies, 
and resulting peptide samples may feed into several mass spectrometers, which are 
currently the remaining limiting factor. On top, we see the additional potential to improve 
our current setup. The protein reduction and alkylation, for example, is performed at 95°C, 
which requires one hour (out of 2.5 hours) of autoSP3 for heating and cooling. Here, an 
increased throughput can be easily achieved by either optimizing the reduction and 
alkylation conditions at lower temperatures or using a more efficient temperature device. 
The use of a plate hotel or larger deck-space has the additional potential to increase the 
workflow capacity to further minimize the hands-on time between individual runs, for 
example. AutoSP3 could be further improved by preventing evaporation (remains unsolved 
so far) during the proteolytic digestion to integrate this step on-deck and avoid manual 
interference. Lastly, the LE220R-plus ultrasonicator is fully compatible with a robotic arm 
that could facilitate the sample plate transfer between platforms to minimize the need for 
operator intervention. The implementation of the steps mentioned above has the potential 
to transform the current protocol in a complete hands-free pipeline that could continuously 
process many hundreds of samples per day in a robust and reproducible manner. 
AutoSP3 has been implemented on a Bravo liquid handling system, which is widely available 
to many genomics or biochemistry laboratories. The established workflows (Protocol A, B, 
C, and D described in chapter 4.2.1.) are provided in an online repository for the facile 
adoption of the method. In addition, we have recently generated methods that allow 
different starting volumes for samples (up to 25 μL) or additional clean-up of peptides. The 
latter is achieved by binding peptides to the beads at a higher than 95% organic buffer 
composition. This part of the initial SP3 protocol for peptide purification149 has recently 
been established by others on an Eppendorf liquid handling system404. While this is not 
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needed for global protein expression profiling, it can be useful for clean-up of PTM-
modified peptides, for example. To further improve the ease of implementation and usage 
of autoSP3, we are currently working on a user-interface integrated into the Bravo Vworks 
software. This is done in collaboration with Dr. Mauro Cremonini (Agilent Technologies). 
Another potential extension of autoSP3 for top-down proteomics, comprises its use for 
intact protein purification and subsequent MS analysis, as recently shown329. 
Because of the benefits over previous methods, the SP3 protocol has broad appeal in the 
field of proteomics. This includes efforts in automation, as recently shown on various 
platforms, such as a KingFisher liquid handling system with subsequent phosphopeptides 
enrichment405. Furthermore, a recent pre-print study shows the application of autoSP3 on 
a Hamilton Robotics Microlab STARlet liquid handling system for the fast and low-cost 
detection of SARS-CoV-2 peptides from clinical samples406. The study showcases a short 
turn-around time, high sample throughput, and cost-efficiency. In this case, the automation 
additionally reduced the risk of infection during sample preparation and marks an 
informative example for a clinical application of autoSP3. 
5.2. The added value of proteome profiling 
The proteome composition is a fundamental part of any biological system and crucial for 
understanding (patho)physiological conditions or functions. Nevertheless, it remains 
mostly unused in a clinical routine, as outlined throughout this thesis. Therefore, after 
technically establishing the autoSP3 workflow304, we applied it to process two different 
clinical cohorts, namely FFPE lung ADC slices and fresh-frozen ependymoma (EPN) brain 
tumor tissue, in order to demonstrate the added value of global proteome profiling. 
Further, we highlight the novelty of a number of observations that other NGS methods are 
inherently blind to or that cannot be predicted from gene expression alone. The profiling 
of the proteome composition of a disease cohort has the potential to unravel unknown 
functional consequences or clinically relevant targets or biomarkers. 
5.2.1. Molecular characterization of lung adenocarcinoma (ADC) growth patterns 
In this thesis, we showcase the application of autoSP3 to a cohort of 51 ADC FFPE samples 
for the molecular characterization of tumor growth patterns. In particular, we could 
demonstrate the ability of FFPE processing with quantity-limited material. In addition, as 
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expected from pathology, we observed that lepidic samples show a decreased expression 
of proteins associated with cellular invasion. In comparison to previous microarray gene 
expression profiling217, we identified 167 proteins (compared to 13 genes) with statistically 
significant differential abundance in lepidic samples compared to all other growth patterns. 
This shows that the differential proteome composition cannot be predicted from mere 
gene expression changes alone. A follow-up for a potential implication of any of the 167 
differentially regulated proteins (lepidic vs. all others), for their use as a therapeutic target 
or as a biomarker, might be of interest for further follow-up studies. 
However, the high variability in tumor cellularity of the provided ADC samples restricts a 
more detailed analysis. In the future, we aim to first extend our current workflow to allow 
the automated de-paraffinization and protein extraction of FFPE samples in combination 
with sample processing in overall smaller volumes. This will aid the handling of even less 
starting material. Here, we aim to reach the level of microdissection to collect and process 
highly concise tumor areas with maximal tumor cell content. This will enable us to perform 
a more comprehensive analysis of the proteome composition of the different growth 
patterns and at a higher spatial resolution across the obtained specimen. 
5.2.2. Proteome profiles extent ependymoma (EPN) molecular classification 
Furthermore, we utilized a cohort of EPN brain tumors with extensive molecular 
characterization available on various levels73. While this built the basis for classification into 
nine distinct molecular subgroups, the majority of them still lack insight into their functional 
differences, and the oncogenic driving mechanisms remain unknown (see also chapter 1 
and chapter 4.3). Here, we aimed to illustrate the potential of proteome profiling on top of 
or complementary to other molecular layers. 
Starting from small fresh-frozen tissue (<6 mg wet weight), we could quantitatively profile 
8248 proteins from 103 tumors that were unevenly distributed over all nine molecular 
subgroups and the healthy reference tissue. Interestingly, we could achieve a similar 
separation of the known molecular subgroups based on the tumors’ proteome composition 
(Figure 12A-C and Figure 12F). However, this annotation is still based on the prior 
knowledge of the anatomical region and DNA-methylome profiles. Relying on the proteome 
composition alone would be insufficient to achieve the same grouping without previous 
knowledge of subgroup-specific protein expression patterns or individual biomarkers. The 
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methylome and transcriptome result in a clearer separation (average silhouette score= 
0.58) compared to the proteome (silhouette score= 0.43). On the other hand, the proteome 
composition revealed a sub-subgrouping for ST-EPN-RELA and PF-EPN-A, showing a first 
hint of its added value. In addition, we performed an unsupervised MOFA as a perspective 
view for scenarios in which molecular subgroups are not yet defined. Methylome, 
transcriptome, and proteome data together result in a perfect recapitulation of the 
expected subgroups and further achieve a more detailed sub-subgrouping on top (Figure 
22F). This specifically highlights the advantage of complementary -omics profiling rather 
than focusing on individual layers. Multi-omics analysis has been a challenging task due to 
technical and especially bioinformatical reasons135,169. In recent years, however, various 
groups have invested massive efforts in multi-omics data analysis169. While this is still 
limited to skilled data scientists, the trend is going towards user-friendly solutions that will 
find rapid adoption in the field. 
In this thesis, EPN subgroups were known already and the primary purpose was the 
supervised identification of functional differences, biomarkers, or even potential 
therapeutic targets. The uneven distribution of samples per subgroup presented a distinct 
challenge for the subsequent bioinformatic analysis, including differential expression 
comparisons. However, this characteristic is a realistic scenario of a disease cohort, in which 
the sample collection itself can be a limiting factor for rare subtypes. Additionally, in a 
routine clinical application for molecular profiling analysis, the underlying subtype would 
be unknown at the time of sample collection. Thus, we inevitably have to deal with 
inhomogeneous numbers of samples per subgroup. The highest number of samples was 
available for PF-EPN-A (n= 24) and the lowest for SP-SE (n= 3). Here, we handled this uneven 
representation of distinct subgroups by utilizing the Limma R/Bioconductor software 
package for statistical analysis. Benefitting from the large number of samples, Limma 
performs an analysis of protein quantification value distribution across the entire dataset 
as an integrated whole rather than focusing on individual comparisons between sample- or 
group pairs. This allows a more accurate comparison for even small numbers of samples 
within a subgroup (e.g., SP-SE) against the remaining dataset as a whole (all others). At this 
stage, the subgroup annotation remains a prerequisite before performing any comparison. 
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Next, we focused on subgroup-specific proteins that could serve as a biomarker when no 
prior knowledge on sub-grouping is available. On top, these proteins have the potential to 
elucidate oncogenic driving mechanisms within a specific tumor subgroup. Here, CXorf67 
marks a perfect example, showing exclusive expression in PF-EPN-A tumors265,272. While its 
expression already marks a hallmark for PF-EPN-A tumors, the precise mechanism of 
CXorf67-mediated inhibition of the PRC2 function was previously unknown. The functional 
domain of CXorf67 was pinpointed to the C-terminal region, being responsible for binding 
to the majority of PRC2 components and the inhibition of its methyltransferase activity. We 
could additionally show the influence of PRC2 inhibition and the associated 
hypomethylation and de-repression of its targets at the transcriptome and proteome level 
compared to all other EPN subgroups. Surprisingly, we only found 12 and 15 PRC2 targets 
that were significantly regulated either on transcriptome and proteome level or solely on 
the proteome level (Figure 13I). Among them, several proteins, such as NCAM1407 or 
GPM6B408, have previously been associated with brain tumors. Further functional 
implications of the de-regulation of PRC2 targets remain to be elucidated. 
Interestingly, we found that both ST-EPN-RELA and PF-EPN-A show differential expression 
of ECM proteins between transcriptome and proteome level and all other subgroups while 
also being associated with higher disease aggressiveness and exhibiting the worst overall 
prognosis73. Furthermore, the proteome composition of both revealed an additional sub-
subgrouping that is driven by ECM-related proteins (supported by DE analysis and MOFA). 
To follow-up on this observation, we performed a cell-surface proteome enrichment of ST-
EPN-RELA tumors. Here, we could find several interesting proteins, with FPR1 linked to 
ANXA1 being the most promising potential target373,374. The inhibition of FPR1 has 
previously resulted in a decrease of tumor growth and metastasis formation374. This is 
particularly interesting as we observed an almost exclusive expression of FPR1 in both 
subgroups, which urgently call for new treatment plans due to their worst prognosis and 
poor outcome. Using cell culture experiments, a relevant implication remains to be 
elucidated, such as IC50 experiments upon treatment with an FPR1 inhibitor (e.g., 
Cyclosporin A374 or Cyclosporin H409). 
Unfortunately, patient-derived cell lines for follow-up experiments are only available for 
ST-EPN-RELA (2x) and PF-EPN-A (2x). They are rather difficult to handle (e.g., long cell 
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doubling times) and require specialized, expensive cell culture media. Thus, following up 
on several observations made throughout this thesis takes rather long and is limited to 
targets identified in ST-EPN-RELA and PF-EPN-A. Therefore, other subgroup-specific 
findings cannot be validated yet. However, a more in-depth analysis of the subgroup-
specific proteins is still ongoing to derive functional insight into their specific biology. Many 
of these proteins have previously not been annotated as an EPN subgroup signature on the 
basis of other -omics layers. Importantly, we could showcase a few examples of signature 
proteins, such as L1CAM and NES (Figure 21A), that are enriched within isolated 
extracellular vesicles, reflecting the tumor-specific biology367. This marks the possibility of 
subgroup-specific biomarker profiling in a low-invasive manner through blood or CSF 
sampling. In a clinical environment, this profiling approach could find facile adoption. 
Altogether, profiling of the EPN cohorts’ proteome composition helped to unravel many 
previously unknown signature proteins, which were not evident based on the other NGS 
approaches. Further, as expected, many previously annotated signature genes did not 
translate to signature proteins and its resulting phenotype. This might influence their 
importance for the biological interpretation and their functional consequences between 
different subgroups. A more thorough analysis of the entire dataset is needed and currently 
ongoing. This already highlights the importance of advanced bioinformatic tools and 
workflows to support these complex analyses in a systematic approach. Currently, this a 
limiting factor for a clinical routine as the sheer amount of data and its complexity make it 
increasingly challenging to find meaningful interpretation. This becomes especially 
important when turn-around times need to be achieved. 
5.3. Re-evaluation of the status quo: clinical proteomics 
The quantitative profiling of thousands of proteins across hundreds of samples remains 
challenging. Yet, massive efforts in the proteomic field towards standardization, 
simplification, and automation, such as the autoSP3 workflow, are rapidly moving towards 
its feasibility148,151,161,304,330,410. In combination with new-generation mass spectrometers, 
their sequencing speed, sensitivity, and robustness, and cost-effectiveness of workflows, it 
is already possible to perform such large-scale profiling experiments in acceptable turn-
around times113,116. Complementary to other -omics levels, this ability of molecular 
(proteome) profiling and characterization will build the path to patient-oriented systems 
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medicine (precision medicine), as described in chapter 1. The anticipated aim of molecular 
profiling could be a disease (sub)classification, the identification or screening of (predictive) 
biomarkers, or the functional insight into the (patho)physiology, such as disease 
progression or relapse1,2,27. However, many limitations yet remain to be solved for 
successful clinical integration. This relates to ethical, legal, logistical, but most importantly, 
bioinformatic bottlenecks. 
Nowadays, the generation of comprehensive data, such as in-depth proteome profiles or 
even multi-omics data, for the molecular characterization of an individual is becoming 
feasible from minute amounts of available sample material and at affordable costs117. 
While this can obviously provide a deeper understanding of an individual’s molecular make-
up and disease phenotype, it is not trivial to extract and interpret the biological and/or 
clinically relevant results. In the literature, several great examples have emerged that 
illustrate the utility of proteomics and/or multi-omics data to generate new medical 
knowledge or identify clinically actionable targets131,137,139,144,406. However, these types of 
analyses typically require a significant expenditure of time spent by a specialist to 
understand and interpret the data. This becomes even more challenging with multiple -
omics layers and additional clinical or health record information about an individual. Here, 
an increasing number of tools and integrative solutions, such as MOFA, RGCCA, MCIA, 
iCLUSTER, and others, are becoming available to support the interpretation of complex 
multi-level data169. In an ideal scenario, easy-to-use or automated software tools are key 
to rapidly extract useful information, allowing fast and straightforward interpretation for a 
patient’s benefit. In foresight, sophisticated software solutions utilizing machine learning 
algorithms might be useful to identify traits or trends in complex datasets that are not easily 
observed by manual investigation. Other accompanying bottlenecks are the logistics of data 
handling and storage. It is not surprising that research groups and especially companies 
(e.g., Biognosys, Roche Diagnostics, OmicEra Diagnostic) recognize this gap between 
immense amounts of data and their meaningful interpretation for a clinical utility. Several 
initiatives (SMART-CARE, CLINSPECT-M, DIASyM, and MSTARS) that were recently funded 
by the federal ministry of education and research (BMBF, Germany), are envisaging to 
tackle such remaining bottlenecks. 
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Another crucial factor for a routine application of personalized molecular profiling is the 
ethical point of view. Of course, this has been and is extensively discussed in the field and 
will need the development of clear regulatory systems1,26. For example, what and how are 
the results presented to an individual. What if risk genes or protein expression for specific 
diseases are detected pre-symptomatically. Individual genes or proteins might reveal an 
increased predisposition of developing a specific disease. How does a physician deal with 
incidental observations? In some commercially available genetic testing, for example, 
offered by Dante Labs (L'Aquila, Italy)411 genetic counseling with a specialist is already 
recommended (e.g., by DNAfeed Inc. (San Diego, USA))412, but not mandatory in order to 
provide proper education about potential findings and their implications. For a routine 
integration of molecular profiling, this individualized counseling will require financing and 
time of specialists, such as physicians and potentially even psychologists. Consensus 
agreements need to be established in order to protect the patient’s rights and molecular 
data while simultaneously maintaining the benefits of molecular profiling. Here, the health 
insurance and portability and accountability act (HIPAA)413 or the general data protection 
regulations (GDPR)414 in the United States or European Union, respectively, define such 
standard measures for the protection of physical, network, and process security (e.g., data 
protection= HIPAA or GDPR compliant). On the other hand, this compliance often 
introduces additional bottlenecks, such as the high maintenance costs and paperwork, and 
the limited ability for physicians or researchers to perform retrospective (e.g., biobanked 
tissue) or prospective evaluation of patient samples and resulting data415. Informed 
consent with strict regulations but potentially also the possibility for individualized 
considerations are key for routine implementation. This can only be achieved by joint 
agreements between all participating parties ranging from insurance companies and health 
care providers to scientists, bioinformaticians, and medical doctors, to the individual 
patient. 
Altogether, the advantages of complementary -omics profiling, including proteomics, 
clearly position it as the key to personalized medicine. Unambiguously, the sheer 
complexity of such data requires a systems medicine approach for the extraction and 
interpretation of meaningful results and decision-making guidance in a clinical 
environment. Beyond a better understanding of biological systems and (patho)physiology 
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itself, an improved patient stratification and classification, the identification of biomarkers, 
or new therapeutic targets are among the anticipated aims. In addition, molecular 
characterization might lead to better therapy decisions, such as avoiding or de-escalating a 
specific therapy approach for individuals. In 2013 and 2015, the interest in systems 
medicine has triggered the foundation of the “e:Med” consortium416 as well as the 
“European Association of Systems Medicine e.V.” (EASyM)417. Both essentially aim to make 
personalized and systems medicine available to everyone by tackling the major questions 
and bottlenecks: I) getting together all responsible and relevant fields of expertise, 
including clinicians, researchers, medical and patient organization, funders, ethic and 
privacy authorities, and patients. II) Establishing a hands-on training and education 
framework. III) Developing guidelines for data handling, from storage to analysis and 
interpretation. IV) Promoting and supporting the implementation of systems medicine “big 
data” in routine applications. V) Evolving sophisticated computer-based solutions (e.g., 
machine learning and artificial intelligence) for the analysis of complex (multi-omics) data. 
Since its inception, the e:Med research and funding concept has resulted in 1410 systems 
medicine oriented publications (as of 03.06.2020)416. With this, we think that the technical 
framework for large-scale systems medicine data generation can already be actionable. The 
logistical, ethical, and mainly bioinformatic solutions for a routine implementation are 
lagging behind. However, these limitations will be tackled and solved in the coming years, 
while standardization and performance of multi-omics and especially proteomics pipelines 
will continue to become more sensitive, more reproducible, and easy-to-use. 
The future of medicine with personalized -omics profiling and decision-making is at a 
tipping point from bench to bedside. 
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9. Supplementary Figures 
 
Supplementary Figure 1: Optimization of cell lysis and protein extraction conditions tailored for single-pot 
solid-phase-enhancer sample preparation (SP3). A) Lysis of 5000, 50.000, and 500.000 cells facilitated by 2% 
SDS (blue) and 4% SDS (red), and quantification of extracted protein mass. Five randomly selected cell lines 
were used (A375, RPMI-7951, UACC-62, ISTMEL-1, and HeLa). B) Mechanical disruption-free lysis using 2% 
SDS (blue), 4% SDS (red), or RIPA (green) in combination with SP3 to process varying amounts of protein input 
(25 μg, 50 μg, 100 μg, 150 μg, and 200 μg). The relative [%] recovery and the absolute [μg] recovery after SP3 
processing are shown for each condition. C) Agarose gels to highlight nucleic acid content of a HeLa lysate 
after mechanical disruption-free processing in different buffer compositions and with and without Benzonase 
treatment. For the Benzonase treatment, buffer compositions were adapted for enzyme compatibility. D) A) 
Lysis of 5000, 50.000, and 500.000 cells facilitated by 0.1% RapiGest (RG) (blue), 0.1% SDS (red), 0.1% SDS 
with 1% Triton X-100 (red), and quantification of extracted protein mass. Five randomly selected cell lines 
were used (A375, RPMI-7951, UACC-62, ISTMEL-1, and HeLa). A375, RPMI-7951, UACC-62, and ISTMEL-1 cells 
were cultured, counted, and pelleted by Dr. Gertjan Kramer.  
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Supplementary Figure 2: Optimization of protein binding conditions in single-pot solid-phase-enhancer 
sample preparation (SP3). A) SDS-page of HeLa input and the SP3 unbound (red) and bead-bound (blue) 
fraction of proteins using three different acidification concentrations with TFA (1%, 0.5%, and 0.2%). B) 
Agarose gels to confirm DNA extraction from mouse kidney tissue. C) Agarose gels to illustrate the DNA 
(mouse kidney) sonication efficiency for the Bioruptor Pico and a probe sonication using different numbers 
of cycles or sonication times. D) SDS-page of HeLa input and the SP3 unbound (red) and bead-bound (blue) 
fraction of proteins using four different concentrations of spike-in DNA (mouse kidney) (0.5 μg, 1 μg, 2 μg, 
and 5 μg). E-F) Number of identified and quantified proteins (E) and peptides (F) with different protein input 
amounts (50 μg (light blue) to 250 μg (dark blue)) and different paramagnetic bead types (ReSyn Amine, 
classic carboxyl SP3 beads, ReSyn HILIC). G) SDS-page of constant HeLa input and the SP3 unbound (red) and 
bead-bound (blue) fraction of proteins using five different concentrations of SP3 beads (400 μg, 300 μg, 200 
μg, 100 μg, 50 μg). H) SDS-page of varying HeLa input (30 μg, 20 μg, 10 μg, 5 μg, 2 μg) and the SP3 unbound 
(red) and bead-bound (blue) fraction of proteins using a constant amount of 200 μg SP3 beads.  
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Supplementary Figure 3: Comparison of single-pot solid-phase-enhancer sample preparation (SP3) to in-
solution digest and filter-aided sample preparation (FASP). A) Venn-diagram of identified HeLa peptides in 
all three methods. B) Boxplot of molecular weight distribution obtained from all three methods compared to 
the whole Uniprot human proteome. C) Boxplot of hydrophobicity GRAVY score distribution obtained from 
all three methods compared to the whole Uniprot human proteome. D) Gene ontology enrichment of cellular 
compartments for the in-solution digest (blue) and SP3 processed samples (orange), showing an almost 
identical distribution of protein origins. 
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Supplementary Figure 4: Peptide library generation and matching-between-runs. A) Comparison of HeLa 
runs with and without prior high-pH fractionation and concatenation. B) Comparison of high-pH performance 
with eight fractions per run and with ammonium formate (dark blue) or ammonium hydroxide (light blue) 
buffer. The number of peptide spectrum matches (upper panel) and identified and quantified proteins (lower 
panel) are illustrated. C) Separation performance of high-pH runs for ammonium formate (dark blue) or 
ammonium hydroxide (light blue), shown by the number of fractions in which a peptide sequence can be 
found. D) Peptide and protein numbers achieved within different libraries using either 1-hour or 2-hours 
gradients and with different numbers of high-pH fractions (8, 16, 24, 32). E) Comparison of identified and 
quantified proteins with either matching-between runs (black) or by MS2 (grey) using a Top-2 or Top-20 
method. F) Comparison of numbers of identified peptides with either matching-between runs (black) or by 
MS2 (grey) using a Top-2 or Top-20 method. G) Comparison of the coefficient of variation (CV) [%] distribution 
using a Top-2 or Top-20 method and binned according to the average protein abundance (A (lowest), B, C, 
and D (highest)). 
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Supplementary Figure 5: Correlation of protein abundance and reproducible quantification. A) Four protein 
abundance bins (A, B, C, and D) were defined and cumulative frequency distributions [%] of the calculated 
CVs of quantified proteins (including match-between-runs) within each bin are plotted. The corresponding 
average CV values per group are shown. The table summarizes the percentage of quantified proteins 
observed with a CV higher or lower than 10%, 30%, and 50% for each abundance bin. B) Same as in A, the 
data are plotted without the use of match-between-runs. C) log2 LFQ intensities of selected individual 
proteins and the sum of all proteins within a sample are plotted across all 60 measurements. C) Illustration 
of variation of manually selected housekeeping proteins across the entire protein abundance range and 
across all 60 raw files. Modified from Mueller et al., Mol. Syst. Biol., 2020.  
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Supplementary Figure 6: Differential expression analysis and gene-set enrichment of papillary sub-
subgroups and lepidic or papillary against all others. A) t-distributed stochastic neighbor embedding (t-SNE) 
analysis of the proteome data corrected via a linear regression model. B) Differential expression analysis 
between subclusters papillary_1 and papillary_2 (see A) using Limma moderated t-statistics. Proteins passing 
significance thresholds of -log10 p-value < 0.05 (Benjamini-Hochberg adjusted) and an absolute log2 fold 
change >1 are highlighted in orange. C) The number of differentially expressed proteins in the papillary 
subcluster comparison. D) Gene set enrichment analysis of p-value ranked proteins for papillary_1 versus 
papillary_2. Gene sets with an adjusted -log10 p-value < 0.05 were considered significant and are highlighted 
in dark color. E) STRING network analysis of the 167 significant proteins (-log10 p-value < 0.05 and an absolute 
log2 fold change >1) in lepidic versus all other samples. F) Gene set enrichment analysis of p-value ranked 
proteins for lepidic versus all other samples. G) Gene set enrichment analysis of p-value ranked proteins for 
papillary versus all other samples. In both GSEA analyses, gene sets with an adjusted -log10 p-value < 0.05 
were considered significant and are highlighted in dark color. Modified from Mueller et al., Mol. Syst. Biol., 
2020.  
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Supplementary Figure 7: CXorf67-mediated inhibition of PRC2 complex. A) Schematic illustration of full-
length CXorf67 and the three deletion mutants: amino acids 1 to 150 (CX-N), II) amino acids 151 to 300 (CX-
M), and III) amino acids 301 to 503 (CX-X). B) Western blot confirming the selective expression of deletion 
mutants or full-length CXorf67. C) Western blot confirming the additional localization to the nucleus. D) 
Staining of transduced cell lines for the presence of Flag-tagged proteins (CXorf67, CX-N, CX-M, and CX-C) as 
well as H3K27me3 mark. E-F) Global expression of PRC2 target genes per subgroup on the transcriptome-
level (E) and proteome-level (F). The experiments illustrated in panel A to D were performed by Dr. Jens 
Huebner. The transcriptome data were provided by our collaborators from Pajtler et al., 2015. Panel A-D were 
modified from Huebner et al., Neurooncology., 2019. 
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Supplementary Figure 8: Determination of top 10 signature proteins per ependymoma (EPN) subgroup. A) 
t-distributed stochastic neighbor embedding (t-SNE) analysis of the top 10 signature proteins determined by 
a differential (DE) expression analysis. B) Heatmap illustration of the top 10 signature proteins per EPN 
subgroup. LFQ expression values [log2] are shown as a ratio to the mean expression in all other tumors. C-E) 
Boxplot illustration of QPRT (C), GPR50 (D), and CYB5R1 (E) protein expression across all EPN subgroups in 
the global tumor proteome. 
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Supplementary Figure 9: Determining differentially abundant proteins between ST-EPN-RELA and PF-EPN-
A cell lines and their extracellular vesicle isolates. A-G) Differential expression (DE) analysis using Limma 
moderated t-statistics for the comparison of ST-EPN-RELA and PF-EPN-A cell lines, their extracellular vesicles 
(exosomes and microvesicles), and between the subgroup-specific vesicle fractions. Proteins are significant 
at a threshold of -log10 p-value < 0.05 (Benjamini-Hochberg adjusted), and an absolute log2 fold change of >1 
are highlighted. 
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Supplementary Figure 10: Candidate proteins and their expression in extracellular vesicles and the global 
tumor proteome. A-C) Boxplot illustration of ACOT7 (A), NES (B), and L1CAM (C) protein expression across 
their cell lines (blue) and extracellular vesicles (exosomes (red) and microvesicle (green)), and across all EPN 
subgroups in the global tumor proteome. 
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Supplementary Figure 11: Candidate proteins and their expression in extracellular vesicles and the global 
tumor proteome. A-C) Boxplot illustration of STEAP3 (A), LAMA2 (B), and FAPR1 (C) protein expression across 
their cell lines (blue) and extracellular vesicles (exosomes (red) and microvesicle (green)), and across all EPN 
subgroups in the global tumor proteome. 
 
